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SUMMARY 
Collagen is ubiquitous in the human body being the main component of connective tissues such 
as cartilage, bone, tendon, and ligaments. Disorders of connective tissues often originate from 
genetic defects in collagen genes or genes encoding collagen modifying enzymes. Collagen 
encompasses a superfamily of glycoproteins carrying extensive post-translational modifications. 
Defective post-translational modifications of collagen lead to severe developmental disorders 
with mild to lethal outcomes emphasizing the importance of these modifications. The oxidative 
modification of proline and lysine residues is well described and important for the functionality 
of collagens. Oxidatively modified lysine residues are further modified with glycan molecules, a 
process called collagen glycosylation. Eight decades ago, the existence of Glucose-Galactose-
Hydroxylysine collagen glycans were discovered and subsequently found to be conserved in 
structure from sponge to human. The GLT25D1 and D2 galactosyltransferases that initiate these 
glycans were first characterized and reported only recently. The second enzyme catalyzing the 
elongating reaction, i.e. the transfer of glucose to galactosylhydroxylysine has yet to be identified, 
which is an aim of the present work. Application of a conventional purification approach followed 
by protein identification by tandem mass spectrometry repeatedly identified the putative 
glycosyltransferase UGGT2. Recombinantly expressed UGGT2 did not, however, possess a 
collagen glucosyltransferase activity. Biochemical approaches to identify the glucosylating 
enzyme did not provide clear answers whereas a bioinformatics approach revealed the enzyme 
GTDC1 that should be considered a strong candidate for the collagen glucosyltransferase.  
Association of heritable developmental disorders with defects in collagen modifying enzymes 
suggests that defects in the glycosylating enzymes may be found in patients with connective tissue 
disorders. Screening human patient cells from several untyped connective tissue disorders did 
not reveal defects in collagen glycosylating activities. Abnormalities of collagen in many human 
diseases make collagen a central molecule in medical research. Apart from medical interest, there 
is a large demand for, and limited supply of recombinant collagen for biotechnological 
applications in tissue engineering, tissue remodeling after transplantation, and wound healing. 
The inability of the human hydroxylating and glycosylating enzymes to efficiently modify large 
amounts of collagen has hampered the biotechnological production of collagen. With the 
identification of two collagen modifying enzymes from Acanthamoeba polyphaga mimivirus which 
possess enzymatic activity in bacteria, a system for the production of high yield recombinant 
collagen was established. The coexpression of the two mimiviral hydroxylases with human 
collagen in bacteria enabled efficient proline and lysine hydroxylation of collagen close to 
physiological levels without the need to supplement with cofactors. The high yield from bacterial 
expression combined with a high degree of prolyl and lysyl hydroxylation provides the framework 
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for the large-scale production of post-translationally modified recombinant collagens for human 
applications. 
Conclusively, the work conducted in this thesis provides new insights in the biology of collagen 
glycosylation and describes a new system for the production of physiological collagen for 
biotechnological applications. 
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ZUSAMMENFASSUNG 
Kollagen ist der Hauptbestandteil der extrazellulären Matrix und allgegenwärtig im menschlichen 
Körper. Bindegewebe wie Knorpel, Knochen, Sehnen und Bänder erhalten ihre Form und 
Festigkeit hauptsächlich durch ihren Kollagengehalt. Eine der häufigsten Ursachen von 
vererbbaren Bindegewebskrankheiten sind genetische Defekte, welche zu Kollagenmangel oder 
zu fehlerhaften Kollagenstrukturen und schlussendlich zu schwerwiegenden 
Entwicklungsstörungen führen. Oftmals wurden Defekte nicht nur in den Genen von Kollagen 
gefunden, sondern auch in Genen Kollagen modifizierender Enzyme. Der Krankheitsschweregrad, 
ausgelöst durch die fehlerhaften Modifikationen, variiert von leicht bis tödlich und verdeutlicht 
die Wichtigkeit der Kollagenmodifikationen. Die oxidativen Modifikationen von Prolin- und 
Lysinresten sind sehr wichtig für die Funktionalität von Kollagen und bereits beschrieben. 
Oxidativ modifiziertes Lysin wird mit Galaktose und Glukose glykosiliert und bildet somit die 
Kollagen spezifische Glykanstruktur. Obwohl die Kollagenglykosilierung schon vor acht 
Jahrzehnten erstmals beschrieben wurde und die Struktur von Hydroxylysin gebundener 
Galaktose-Glukose-Dimeren im gesamten Tierreich konserviert ist, wurde erst vor sechs Jahren 
das erste der für die Glykosilierung verantwortlichen Enzyme entdeckt, die 
Kollagengalaktosyltransferase. In der vorliegenden Arbeit wurde die Identifikation des zweiten 
Enzyms, der Kollagenglukosyltransferase, mittels herkömmlicher Proteinaufreinigung und 
anschliessender Proteinidentifizierung durch Massenspektrometrie angestrebt. Die 
vermeintliche Glykosyltransferase UGGT2 wurde wiederholt identifiziert, konnte aber nach 
spezifischen Aktivitätstests nicht als Kollagenglukosyltransferase bestätigt werden. Da die 
biochemischen Ansätze keine klaren Resultate bezüglich der Identifizierung der 
Kollagenglukosyltransferase ergaben, wurde versucht das Enzym mittels bioinformatischen 
Methoden zu identifizieren. Daraus resultierte das Enzym GTDC1 als möglicher Kandidat, welches 
unbedingt auf seine Aktivität als Kollagenglukosyltransferase getestet werden sollte. 
Die häufig diagnostizierten Kollagenfehlbildungen und -mangelerscheinungen in 
Bindegewebskrankheiten werden oftmals mit Defekten in den Kollagen modifizierenden 
Enzymen assoziiert. Bis dato wurde kein Fall beschrieben, bei welchem spezifisch die 
Glykosyltransferasen betroffen sind. Sämtliche von uns analysierten Zellen aus Patienten mit 
unbekannten Bindegewebskrankheiten verfügten über vollständig funktionale 
Glykosyltransferasen. Kollagenabnormalitäten in unterschiedlichen humanen Krankheiten 
machen Kollagen zu einem zentralen Molekül der medizinischen Forschung. Nebst dem 
medizinischen Interesse an Kollagen, besteht auch eine Nachfrage an rekombinant hergestelltem 
Kollagen für biotechnologische Anwendungen im Rahmen der Gewebeherstellung und -
modellierung nach Transplantationen oder in der Wundheilung. Die Herstellung von 
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physiologischem Kollagen war bis anhin erschwert, weil die menschlichen Hydroxylasen in auf 
grosse Mengen ausgerichteten Expressionssystemen nicht aktiv sind. Mit der Entdeckung von 
zwei Acanthamoeba polyphaga Mimivirus Kollagenhydroxylasen, welche in Bakterien aktiv sind, 
haben wir ein Expressionssystem für die Herstellung von grossen Mengen an rekombinantem 
hydroxyliertem Kollagen geschaffen. Die Coexpression dieser zwei viralen Hydroxylasen mit 
humanem Kollagen in Bakterien ergab eine effiziente Hydroxylierung von Prolin- und Lysinresten 
annährend den physiologischen Werten. Die grossen Mengen Kollagen aus bakterieller 
Expression und der hohe Grad an Hydroxylierung schaffen die Rahmenbedingungen für eine gross 
angelegte Produktion von rekombinantem Kollagen für biotechnologische Anwendungen. 
Die Resultate der vorliegenden Dissertation liefern neue Erkenntnisse für die Beschreibung der 
Kollagenglykosilierung und dokumentieren ein neues System für die Produktion von 
physiologischem Kollagen für biotechnologische Anwendungen. 
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LIST OF ABBREVIATIONS 
ADAMTS A disintegrin and metalloproteinase with thrombospondin motifs 2 
BMP-1 Bone morphogenetic protein 1 
CAZy Carbohydrate active enzymes 
COL1A1 Alpha-1-chain of collagen type I 
ColGalT Collagen galactosyltransferase 
ColGlcT Collagen glucosyltransferase 
ConA Concanavalin A 
CRTAP Cartilage-associated protein 
Cys Cysteine 
DEAE Diethylaminoethanol 
DXD Aspartic acid – any amino acid – aspartic acid 
ECM Extracellular matrix 
EDS Ehlers-Danlos syndrome 
ER Endoplasmatic reticulum 
FCS Fetal calf serum 
Gal Galactose 
Glc Glucose 
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GT Glycosyltransferase 
GTDC1 Glycosyltransferase-like domain-containing protein 1 
Hyl Hydroxylysine 
Hyp Hydroxyproline 
LH Lysyl hydroxylase 
LOX Lysyl oxidase 
NaCl Sodium chloride 
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PBS Phosphate buffered saline 
PLOD Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 
Pro Proline 
P3H Prolyl 3-hydroxylase 
P4H Prolyl 4-hydroxylase 
PPIB Peptidyl prolyl cis-trans isomerase B 
PTM Post-translational modification 
Ser Serine 
TBS Tris buffered saline 
UGGT UDP-glucose:glycoprotein glucosyltransferase 
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INTRODUCTION 
Collagen is the most abundant structural protein in vertebrates. One of the critical factors for the 
structural and biochemical functions of collagen is post-translational modification (PTM). Since 
molecular research on collagen biosynthesis started in the 1930s, PTMs and their contribution to 
collagen architecture were extensively studied. Hydroxylation of proline plays a significant role in 
collagen folding and stability by enhancing the collagen triple helix thermal stability [1]. Lysine 
hydroxylation is evidentially important for proper crosslink formation between collagen fibers [2, 
3]. However, little is known about collagen glycosylation. Even though the structure of collagen 
glycosylation is conserved in the animal kingdom from sponge [4] to human [5], the function of 
collagen glycosylation remains elusive. The genes coding for the collagen core 
glycosyltransferases have been discovered only in the past years [6]. The genes coding for the 
elongating glycosyltransferases have not been identified to date. 
Defects in several collagen modifying enzymes lead to developmental disorders and fragility of 
connective tissue and bones with various severity. Until now, defects in conjunction with collagen 
glycosylation have not been described. Pathologic high levels of modification derived from over 
hydroxylation and over glycosylation result in mineralization defects in bones [7, 8]. However, the 
cause of the over modification does not come from defective glycosylating enzymes but rather 
from kinetic folding differences of defective collagen chains leading to prolonged enzymatic 
activity. High levels of PTMs do not infer a pathological sign per se because the degree of 
modification is highly diverse among tissues and collagen types. The molecular mechanism 
regulating type, amount, and position of the PTM is not known. Until now, 23 genes encoding 
various collagen modifying enzymes exist in human [9]. However, the functional contribution of 
the modifications among different cell types and tissues is not fully described for all modifications. 
In particular the function and various extent of collagen glycosylation remains to be studied. 
COLLAGEN STRUCTURE AND BIOSYNTHESIS 
Among the genomes of vertebrates (and higher invertebrates) are 28 distinct collagen types 
encoded by at least 45 genes. The collagen types are classified predominantly according to domain 
structure and their suprastructural organization [10]. Some collagens form fibrils with a 
characteristic periodicity of the forming units giving a striated pattern. They are grouped as fibril-
forming collagens. Other collagens associate with collagen fibrils and are grouped as fibril-
associated collagens with interrupted triple helices (FACIT). Further groups are network-forming 
collagens, transmembrane collagens and molecules with collagenous domains. For simplicity, this 
chapter covers only the biosynthesis of the most abundant collagen fibrillar type I collagen. 
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Composition of fibrillar type collagen 
Collagen is a large trimeric protein. Its subunits comprise three α-helical strands coiling together 
into a right handed triple helical suprastructure. The three α-helical strands can either be identical 
or different forming homotrimeric or heterotrimeric structures, respectively. The prerequisite for 
its characteristic structure is encoded in the collagen sequence. Every collagen amino acid 
sequence contains a collagenous motif with a glycine (Gly) residue at every third position. Repeats 
of the Gly-Xaa-Yaa motif form the characteristic domains of collagen molecules. The high 
abundance of Gly is necessary since only the small hydrogen side group of Gly fits in the center 
pocket of the triple helix. Every other amino acid than Gly has a bulkier side group, hence, any 
mutation occurring at the Gly position will likely have dramatic consequences. Gly substitutions 
have been identified in Osteogenesis imperfecta (OI) patients and Ehlers-Danlos syndrome (EDS) 
patients resulting in structural abnormality of the collagen helix or defective triple helix formation 
(see below) [11, 12]. 
The side chains of the remaining Xaa and Yaa amino acid positions protrude towards the outside 
of the triple helix. This arrangement allows the accommodation of any amino acid but often 
proline (Pro) or hydroxyproline (Hyp) are found. The amino acid composition of the α1-chain of 
human collagen type I contains 26.7% Gly residues and 19% Pro residues of which about 45% are 
hydroxylated [13]. The presence of large amounts of Pro and Hyp together with the recurrent Gly 
give rise to an alpha helical conformation. The steric repulsion of the pyrrolidine rings from Pro 
residues results in larger axial distance between each amino acid compared to normal alpha-
helices. Consequently, the helix structure is a stretched polyproline helix with restricted mobility 
due to the pyrrolidine rings. These rigid pyrrolidine rings have stabilizing effects since they limit 
rotation around the peptide N-C bond. Three polyproline α-helices provide the subunits for the 
triple helical procollagen chain. The triple helical collagenous domain of every procollagen is 
flanked by non-collagenous N-and C-terminal domains. In fibrillar collagen types these non-
collagenous domains are called propeptides and are cleaved off prior to fibril formation (Figure 1). 
In contrast, in network forming collagen types and FACIT collagen types the propeptides remain 
uncleaved and significantly contribute to the assembly of the collagen supramolecular structure 
[9]. 
Introduction 
 
 -11-  
 
Triple helix assembly and fibrillogenesis 
Collagen molecules are assembled from three monomeric pro-α-chains. Each α-chain gets 
synthesized into the rough endoplasmatic reticulum (ER) where it gets hydroxylated and 
glycosylated prior to folding and assembly into the procollagen triple helix. The extent of 
modification depends on the helix forming kinetic, which is in turn affected by the polypeptide 
primary structure. In general, fibrillar collagen types carry fewer modification compared to 
network forming types. The chain selection requires high specificity prior to trimerization and 
triple helix formation in order to avoid unfavorable α-chain trimers or multimeric aggregates with 
short misaligned triple helical patches. For example, pro-α1(I) chains can form homotrimers or 
heterotrimers with pro-α2(I) chains, but pro-α2(I) chains cannot form homotrimers, as shown in 
insect cells [14]. Consequently, the trimerization event is not only essential for the initial 
encounter of the triple helix but also prevents formation of misaligned triple helices [15]. Both the 
mechanism for correct α-chain selection and the mechanism determining the ratio of α1 and α2 
chains defining the collagen composition remain unknown. More is known on the molecular 
domain responsible for chain selection and triple helix initiation. Upon alignment of the 
appropriate pro-α-chains, trimerization is initiated through the non-collagenous domain at the C-
termini. The globular non-collagenous C-propeptides contain one N-glycan residue and eight 
cysteine (Cys) residues for α1(I) and seven for α2(I) [16]. The four carboxyl-terminal Cys residues 
are involved in intramolecular disulfide bonds while the other Cys residues at the N-terminal end 
Figure 1| Schematic representation of fibrillar type I collagen. The α1-chain of procollagen type I 
consists of a 1’014 amino acid (aa) long collagenous domain flanked by telopeptidyl regions, a N-
propeptide, and a globular C-propeptide. Upon collagen maturation the propeptides get cleaved off and 
the triple helical collagenous domain (COL domain) remains. Two procollagen α1(I) and one α2(I) chain 
assemble to a triple helical structure with glycine facing the center pocket. Figure adapted from (Nimni 
ME, Harkness RD: Molecular structure and functions of collagen. In Nimni ME (ed): Collagen. Vol 1. Boca 
Raton, CRC Press, 1988). 
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of the C-propeptide form intermolecular disulfide bonds [16, 17] Studies on procollagen III 
revealed that the non-collagenous C-propeptides align and recognize the three identical α-chains 
[18, 19]. After bringing the non-collagenous domains in close proximity by forming non-covalent 
interactions, disulfide linkages are built between the three non-collagenous domains. The newly 
formed C-terminal trimerization domain serves as a helix nucleation site and propagates triple 
helix formation in a zipper-like fashion from the C-terminus to the N-terminus. Studies from OI 
patients harboring distinct Gly to serine (Ser) mutations in the collagenous domain emphasize the 
C-to-N terminal triple helix formation. The clinical severity of these mutations concords with the 
distance of the Gly to Ser substitutions from the C-termini, as demonstrated by the lethality 
associated with mutations close to the C-termini and by the moderate diseases associated with 
mutations closer to the N-termini of the α-chain [20].  Also mutations in the trimerization domain 
of collagen type I (COL1A1) lead to OI with mild to severe phenotypes. Mostly, these mutations 
cause a slow assembly of the trimeric suprastructure and secretion of hypermodified collagen 
type I, or in more severe cases to early stop signals [21-24]. The variable severity of mutations 
suggests that the carboxyl-terminal propeptide is responsible for the correct interaction and 
selection of the three pro-α-chains. Similar findings have been reported for mutations in the 
carboxyl-terminal propeptide of collagen type III (COL3A1) and collagen type V (COL5A1 and 
COL5A2) that lead to Ehlers-Danlos Syndrome (EDS) [25-27]. 
Peptidyl prolyl cis-trans isomerases like CyPB and FKBP65 might also influence the kinetic of 
collagen folding [28]. These isomerases mainly locate to the C-terminus where collagen folding is 
initiated and facilitate triple helix formation. The C-nucleation domain contains four consecutive 
Gly-Pro-Hyp triplets, of which the pyrrolidines must be in trans configuration in order to be 
competent to initiate triple helix formation [29]. Additionally, several chaperones, such as GRP78, 
HSP-47, and FKBP65, are in contact with the collagen molecule (Figure 2) [30]. Collagen-bound 
HSP-47 might prevent the aggregation of procollagen in the ER and is not released until traveling 
to the cis-Golgi network where it dissociates due to lower pH and returns to the ER [30-32]. The 
newly formed triple helical procollagen molecules ready for secretion are large in size with a 
length of 300 – 400 nm. Since secretory vesicles are generally only 60 – 80 nm in diameter, 
collagen molecules either use a different secretory pathway or have to increase the vesicle size in 
order to accommodate the large procollagen fibers. The latter has recently been described as the 
mechanism how collagen molecules ensure their packaging and hence their secretion. The ER 
luminal procollagen molecules recruit the cytosolic ubiquitin ligase CUL3-KLHL12 possibly via the 
transmembrane protein TANGO1 to the ER exit site [33, 34]. CUL3-KLHL12 attaches a single 
ubiquitin to COPII, in particular SEC31 which is a component of COPII. COPII monoubiquitination 
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drives the assembly of large COPII coated secretion vesicles thereby providing space for the large 
procollagen molecules [35]. Upon efficient secretion the procollagen molecule gets cleaved at 
specific non-collagenous sites by extracellular proteases ADAMTS2 and BMP1/tolloid-like 
proteases releasing the N-propeptide and the globular C-propeptide, respectively. The remaining 
fibers then self-assemble into fibrils. In particular the cleavage of the C-propeptide is essential for 
the initiation of self-assembly and fribrillogenesis [36, 37]. BMP1 also cleaves the catalytically 
quiescent lysyl oxidase enzyme and produces an active mature form (LOX) [37]. LOX catalyzes the 
oxidative deamination of specific telopeptidyl lysines (Lys) and hydroxylysines (Hyl). The 
resulting aldehydic forms LysAld and HylAld initiate a series of condensation reactions to form 
covalent intermolecular cross-links with Lys or Hyl residues from adjacent fibers. Depending on 
the residues involved several pathways yield mature pyridinoline (Pyr), deoxypyridinoline 
(dPyr), pyrrole (Prl), and deoxypyrrole (dPrl) cross-links (Figure 3) [37]. 
Figure 2| Biosynthesis of fibril-forming collagen type I. Upon α-chain synthesis into the rough ER, 
the chains get hydroxylated (P4H, LH, P3H) and glycosylated (ColGalT, ColGlcT). Two α1(I) chains and 
one α2(I) chain trimerize and triple helix formation is initiated from the disulfide cross-linked (PDI) C-
terminus. The chaperone protected (SerpinH1, FKBP10) triple helical procollagen molecule passes the 
secretory pathway via enlarged monoubiquinated COPII vesicles. Extracellular proteases cleave off the 
N-propeptide (Adamts2) and non-collagenous C-propeptide (BMP1) and activate (BMP1) the cross-
linking enzyme lysyl oxidase (LOX). The released collagenous domain self-assembles into fibrils and 
maturates its cross-links to rigid covalent structures. The process of self-assembly is highly defined 
resulting in a characteristic striated pattern with repeating periodicity (D-period). 
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COLLAGEN PTMS AND THEIR DIVERSITY AT SINGLE LOCI 
The intracellular PTMs of collagen encompass five distinct enzymatic reactions which all take 
place in the ER, namely, 4-hydroxylation of Pro, 3-hydroxylation of Pro, 5-hydroxylation of Lys, 
galactosylation of Hyl, and glucosylation of galactosylhydroxylysine (Figure 4). Although these 
modifications were discovered eight decades ago and the structural and enzymatic basis of the 
modifications is largely solved, the regulation of the PTMs at a given locus is not defined. For 
example, a single Lys residue can either remain unmodified, be hydroxylated, be hydroxylated and 
galactosylated, or be hydroxylated, galactosylated, and glucosylated. Such variations at a single 
locus appear tissue specific but sometimes even vary within the same type of collagen. Profound 
knowledge of how PTM localization is regulated might shed light on the possible functional 
contribution of 3-Hyp or glycosylation since no function could be assigned which generally 
describes the necessity of these types of modification. Knowing the functional properties of PTMs 
Figure 3| LOX-mediated fibrillar type collagen cross-linking. Top panel shows the cross-linking sites 
with telopeptidyl aldehydes (open circles) t-Lysald and t-Hylald, and the helical Lys and Hyl residues 
(closed circles) hel-Lys and hel-Hyl, respectively. Red hexagon represent the carbohydrates Gal and Glc 
attached to the hel-Hyl involved in cross-links. The lower panel summarizes the initiation and 
maturation of cross-link pathways. The boxed compounds are non-reducible cross-links. Taken from 
[37]. 
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and their regulatory mechanism might provide new possibilities for therapeutic approaches for 
many hereditary diseases. Additionally, a complete picture of the PTM distribution along the 
individual collagen types is desirable for the production of collagen for biotechnological purposes. 
 
Proline hydroxylation 
Hydroxylation of Pro residues is the most abundant PTM in collagen. The Pro residues either get 
hydroxylated at the C4, which is most common, or at the C3 position giving 4-Hyp or 3-Hyp, 
respectively. In mammalian fibrillar collagen α-chains, about a quarter of the amino acids are 
prolyl residues with about half of them being 4-hydroxylated. 4-Hyp is mainly found at the Yaa 
position of the common Gly-Xaa-Yaa motif. Since the collagenous domain of type I fibrillar proteins 
encompass about 1’000 amino acids, it is common to present a single amino acid frequency as per 
1’000 amino acids. Mass spectrometric mapping of hydroxyproline in collagen type V revealed 
106 4-Hyp / 1’000 amino acids and 98 4-Hyp / 1’000 amino acids for bovine and recombinant 
human α1(V)-chain, respectively [39]. The sites of 86 Pro residues were found hydroxylated in 
both chains suggesting that the PTM at these sites is invariant and always 4-Hyp. 
The conversion of Pro to 3-Hyp is a rare but conserved modification of many collagens. The 3-Hyp 
content is variable among collagen types with an occurrence of one to two residues per α-chain in 
types I and II, between three to six residues in types V and XI and more than 10 residues in type 
Figure 4| Intracellular post-translational modifications of collagen. Upon polypeptide synthesis 
into the rough ER, the α-chain gets modified by prolyl 4-hydroxylase, prolyl 3-hydroxylase, and lysyl 
hydroxylase. The latter modification forms hydroxylysine which get O-glycosylated by 
galactosyltransferase and glucosyltransferase. The non-collagenous globular domain at the C-terminus 
get N-glycosylated and disulfide linked prior to assembly into triple helix and secretion to the 
extracellular space. Taken from [38]. 
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IV [40-42]. Unlike 4-Hyp, 3-Hyp is thought to be exclusively found in the Xaa-positioned Pro and 
restricted to Gly-3Hyp-4Hyp triplets. However, recent studies mapping Hyp based on mass 
spectrometric techniques unraveled new sites for Xaa position hydroxylation besides Gly-Hyp-
Hyp. Xaa-positioned Hyp has been identified in Gly-Hyp-Ala, Gly-Hyp-Val, and Gly-Hyp-Gln triplets 
[39, 43]. Due to the inability to distinguish 3-Hyp from 4-Hyp with conventional mass 
spectrometry, it is not clear whether the assigned Hyp is 3-hydroxylated or 4-hydroxylated. 
Hence, the principle that every Xaa-positioned Hyp is 3-hydroxylated and every Yaa-positioned 
Hyp is 4-hydroxylated is doubted. Since amino acid analysis of type II collagen reveals only one to 
two 3-Hyp residues per α-chain, the mass spectrometric identification of 14 Xaa-positioned Hyp 
residues per α-chain might indicate that also 4-Hyp exists at the Xaa position [43]. Xaa-positioned 
4-Hyp residues are thought to destabilize the triple helix in Gly-4Hyp-Pro triplets [44] but not in 
the context of triplets that lack Pro or Hyp at the Yaa position such as Gly-Hyp-Ala triplets [45]. 
Otherwise, the data from mass spectrometric Hyp mapping could be interpreted differently. 
Assuming that not every 3-Hyp site per α-chain is 100% hydroxylated, the one to two 3-Hyp per 
type II α-chain might be localized to variable sites within the chain. Such an interpretation would 
be in accordance with the amount of 3-Hyp per chain and the amount of possible 3-Hyp sites, 
however the regulating mechanism defining the localization is unknown. 
Lysine hydroxylation and glycosylation 
Lys is hydroxylated at the C5- (or epsilon) position forming Hyl. A distinct type of O-glycosylation 
characteristic for collagen is extending on these Hyl residues. First, a galactose (Gal) residue is 
linked via a β1-O glycosidic bond to the peptidyl 5-hydroxylysine forming the monosaccharide 
structure Gal-Hyl. Sometimes the monosaccharide is elongated with a single glucose (Glc) residue 
to form the disaccharide structure Glc-Gal-Hyl (Figure 5). 
 
Figure 5| Dissaccharide structure attached to Hyl of the collagen backbone. Gal (orange) is attached 
via β1-O glycosidic bond to the C5-hydroxy group of Hyl. Glc (blue) is then linked via α1-2 glycosidic 
bond to the galactosyl-hydroxylysine polypeptide chain. 
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In mammalian collagens the carbohydrate content of hexoses ranges from 0.4% in skin to about 
4% in cartilage and 12% in basement membrane [13]. This goes in hand with the predominant 
types of collagen found in these tissues, namely type I in skin, type II in cartilage, and type IV in 
basement membranes separating epithelial and endothelial tissues from underlining connective 
tissues (Figure 6). Dermal fibrillar type collagen carries fewer glycosylated residues than network 
forming basement membrane type IV collagen which has a general high degree of PTMs. In this 
context, the type of collagen presumably dictates the amount of modification needed to fulfill a 
given function in the respective tissue. However, whether the function of the modified collagen 
remains the same irrespective of the tissue where the collagen is expressed, remains to be 
investigated. As the amount and ratio of the disaccharide to the monosaccharide vary 
substantially between different collagen types, the two saccharides might have different functions 
from each other (Figure 6). Most of the interstitial collagen types have a molar ratio of 2:1 for 
Gal:Glc residues meaning as much disaccharides as monosaccharides. The basement membrane 
type IV collagens carry more disaccharides than monosaccharides on Hyl [46]. The overall amount 
of glycosylation in a single chain might depend on the helix folding kinetics but the mechanisms 
determining the localization and regulating the extent of glycosylation are not known. 
Unexplained is also the finding that the site of modifications in a given collagen type vary even 
though they are expressed in the same tissue. This suggests that the overall amount of modified 
residues might be more important than a specific site within the molecule. In the α1-chain of type 
V collagen the lysine residue 84 has been detected as Gal-Hyl form and Glc-Gal-Hyl form 
suggesting that glycosylation at this site is dynamic [39]. Comprehensive mapping of glycosylation 
Figure 6| Variability of collagen modification. The distribution of Lys hydroxylation and glycosylation 
vary significantly between different types of collagen. In general, classical fibrillar types (I,II,III) carry 
less modifications than network-forming mesh-like types (IV). Short chain fibrillar type V with retaining 
N-propeptides are also highly glycosylated. Taken from [46]. 
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sites in collagen type II supports the findings for dynamic glycosylation at specific sites [43]. The 
site mapping analysis also revealed that glycosylation not only depends on hydroxylation of Lys 
residues but also other factors such as steric hindrance from adjacent amino acids. Recently, the 
distribution of lysine hydroxylation and glycosylation at a single locus has been investigated 
(Figure 7). The results indicated that the variability does not only depend on the type of tissue but 
also on the species [47]. 
 
 
FUNCTIONS OF COLLAGEN PTMS 
The PTMs of collagen significantly contribute to collagen’s function providing the connective 
tissue with strength and shape. The importance of the PTMs can be exemplified by the disease 
scurvy, the old sailor’s illness, caused by vitamin C (ascorbate) deficiency. People deficient for 
ascorbate show symptoms such as easy bruising, fragile capillaries, poor wound healing, skin 
changes and bone pain. Ascorbate is an important cofactor for the Pro and Lys hydroxylase 
enzymes. Hydroxylation of Pro and Lys residues in procollagen α-chains is reduced upon 
ascorbate deficiency in the cells. The resulting defect in collagen biosynthesis leads to collagen 
malfunctioning and unstable collagen fibers as observed in scurvy [48].  
To date genetic defects in the human P4H complex leading to the absence of 4-Hyp have not been 
reported. The absence for P4H deficiencies in humans could be due to lethal consequences at early 
embryonic stages. Lacking 4-Hyp leads to failure of collagen type IV assembly and to impaired 
collagen secretion. Consequently, decreased deposition of collagen in the extracellular space 
results in dysfunctional basement membrane integrity. Supporting evidence comes from studies 
done in the nematode worm C. elegans. The P4H complex is essential for viability and 
Figure 7| Modification variability of a single locus among tissues and species. Distribution of Lys, 
Hyl, Gal–Hyl and Glc-Gal–Hyl at residue Lys87 of the α1-chain in bovine bone, bovine skin, rat-tail tendon, 
and mouse bone, determined by a semi quantitative mass spectrometric approach. Taken from [47]. 
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morphogenesis in C. elegans. RNA-interference studies revealed that disruption of the genes 
encoding the P4H complex resulted in embryonic lethality [49, 50]. A single study from a P4h1 
null mice which die at embryonic day 10 emphasizes the lethality of an absent P4H complex and 
thus suggesting defective architecture of basement membrane to be the main cause of death in 
these mice [51].  
4-hydroxyproline and helix thermal stability 
The contribution of 4-Hyp to thermal collagen stability is established [1], however the mechanism 
how 4-Hyp modification stabilizes the helical structure is not fully clear. Water-bridged hydrogen 
bonding between 4-Hyp residues and Gly residues are thought to be essential for the firm 
attachment of each adjacent α-chains [52]. On the contrary, the contribution of water-bridges to 
helix stability is in so far unlikely to be significant since the entropic cost to immobilize more than 
500 water molecules per triple helix is enormous in order to build and maintain the bridges [53]. 
Additionally, (Gly-Pro-Hyp)10 peptides maintain a stable triple helix even in anhydrous 
environments like methanol or propan-1,2-diol [54]. Later studies identified a stereo electronic 
effect by which the electron withdrawing oxygen from 4-Hyp pre-organizes the chain in a proper 
conformation for triple helix formation [53, 55, 56]. Studies using the more electronegative 
fluorine atom in a fluoro-proline (Flp) conjugation, which cannot participate in potential hydrogen 
bonding networks, substantiate the stereo electronic effect. Flp in the (Gly-Pro-Flp)10 peptides 
accomplish more stable helix formations than (Gly-Pro-Hyp)10 peptides [53].  
3-hydroxyproline and type specific functions 
With the identification of three 3-Hyp residues in collagen type V, each with approximately 234 
residues apart from each other, the theory of a highly determined distribution pattern of 3-Hyp 
residues among fibrillar type collagens arose [40]. The 234 residues distance resembles the D-
period length characteristic in fibrillar type collagens. Since this periodicity of 3-Hyp appearances 
has been detected mainly for collagen types V and XI which are minor components of type I and II 
fibrils, respectively, it is possible that 3-Hyp sites facilitate the staggered D-periodic alignment. 
Types V and XI might serve as a template for proper aligning and self-assembly of the major 
collagen types I and II via hydrogen bonding between adjacent 3-Hyp residues in a staggered 
array. The invariant 3-Hyp site at Pro981 which has been found in types I, II, and V might provide 
the counterpart for hydrogen bonds with 3-Hyp sites of adjacent chains. Hence, the D-periodicity 
of 3-Hyp residues could be proposed to possess a fundamental role in ordered self-assembly of 
the fibrillar type supramolecular structure [40]. In contrast, the non-fibrillar but network forming 
type IV collagen contains a high amount of 3-Hyp residues. Whether 3-Hyp plays a role in ordered 
assembly for this type as well is unknown. The large amount of 3-Hyp in type IV collagen might 
have a different function than in fibrillar types. The 3-hydroxy pyrrolidine ring from 3-Hyp is 
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exposed at the surface of the triple helix thereby contributing to epitopes that underlie immune 
responses against collagens. Sub endothelial type IV collagen bears the platelet-specific 
glycoprotein VI GPVI-binding site which might be 3-Hyp. Exposure of 3-Hyp due to a damage in 
the basement membrane initiates platelet aggregation and leads to blood coagulation upon injury 
[57]. That mechanism provides the link between blood coagulation and the extracellular matrix 
(ECM). 
5-hydroxylysine and fibril cross-linking 
Hyl basically accomplishes two distinct functions. On the one hand, the more distal Hyl in the N- 
and C-telopeptidyl regions of collagen can be oxidatively deaminated to produce reactive 
aldehydes. These aldehydes undergo a series of non-enzymatic condensation reactions with Lys 
or Hyl from adjacent procollagen fibers. Lys, Hyl, and their aldehydic forms are necessary for intra 
and intermolecular collagen cross-link formation (Figure 3) (reviewed in [37]). On the other hand, 
Hyl, particularly located in the helical domain, serves as acceptor site for carbohydrate 
attachments. Hydroxylation and subsequent glycosylation of Lys in the Gly-Xaa-Lys motif 
influences many biological functions, including fibrillogenesis [58], crosslinking [59, 60], and 
matrix mineralization [61]. 
Glycosylated hydroxylysine and modulating cell receptor binding  
Alterations of collagen glycosylation have often been reported in several bone and skeletal 
disorders thereby suggesting that collagen glycosylation might play a role in bone mineralization 
[61-63]. The glycan might regulate the distribution of bone mineral along the collagen fibril. 
However, the localization of the glycan to Hyl involved in crosslinking anticipates the functional 
involvement of the glycan in cross link formation. During cross link maturation the glycan might 
regulate the cross link species towards either divalent or trivalent cross links depending whether 
the involved glycan is in the mono- or disaccharide form [60]. Such a mechanism would also 
explain the variable extent of Hyl glycosylation. Other functions for collagen glycosylation might 
target the collagen remodeling process. The endocytic collagen receptor µPARAP/Endo180 
internalizes collagen for lysosomal degradation via its fibronectin II domain. Additionally, the 
receptor carries a lectin domain which has been shown to modulate the endocytic efficiency 
towards highly glycosylated type IV collagen [64]. However, the impact of the glycan is uncertain, 
since another endocytic receptor, the mannose receptor, does not share this property as the 
receptor internalizes glycosylated collagen independent of a functional lectin domain [64]. The 
potential for the glycan to serve as receptor is also described for interactions of cells with 
basement membranes. The high glycan content in type IV collagen could serve as interaction or 
binding receptor in order to recruit cells to the basement membrane. Glycosylated Hyl residues 
thereby modulate cell adhesion through integrin binding [65]. In contrast, the glycan might have 
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different functions in fibrillar type collagens than the basement membrane type IV collagen. In OI 
patients, highly glycosylated collagen fibrils show a slight increase in fibril diameter, however it 
is not clear whether the increased glycosylation or the absence of 3-Hyp due to defective 
enzymatic activity in these patients is responsible for the disturbance of the lateral fibril growth 
[66].  
In summary, several function for collagen glycosylation including control of matrix mineralization, 
crosslinking, collagen remodeling, collagen-cell interaction, and fibrillogenesis have been 
reported. Despite all the reported findings explaining the function of collagen glycosylation, the 
specific biological function of glycosylated hydroxylysine in relation to the extent and type of 
glycosylation at their molecular loci, is still not clearly defined. 
COLLAGEN MODIFYING ENZYMES 
The collagen Pro and Lys hydroxylating enzymes belong to the protein family of 2-oxoglutarate 
dioxygenases and require iron (FeII), O2, 2-oxoglutarate and ascorbate for their activity. Molecular 
oxygen is captured with iron (FeII) in the enzyme’s active pocket to hydroxylate Pro or Lys. One 
oxygen atom of O2 makes up the hydroxyl group on Pro or Lys, whereas the other atom is 
incorporated into succinate. Succinate and CO2 are produced in a coupled reaction by oxidative 
decarboxylation of 2-oxoglutarate (Figure 8). Upon oxidizing the iron FeII to FeIII, the enzyme 
becomes inert until ascorbate reduces the enzyme’s iron, restoring its active state. The availability 
of ascorbate in that reaction is significant, since a lack of ascorbate leads to reduced hydroxylation 
and unstable collagen fibers as observed in scurvy [67].  
Prolyl hydroxylases 
The mammalian enzyme prolyl 4-hydroxylase (P4H) is a α2β2 tetramer that catalyzes the 
formation of 4-Hyp. The α subunit P4Ha contains the substrate-binding domain and the catalytic 
active site. In humans, three genes code for isoforms of the α subunit, namely P4HA1, P4HA2, and 
P4HA3. The β subunit P4Hb functions independently as a protein disulfide isomerase (PDI) and is 
encoded by P4HB [68, 69]. P4Hb binds and retains the α subunit in the ER through the C-terminal 
ER-retention signal KDEL and maintains the α subunit in a soluble active form [70]. The 
hydroxylation reaction is only performed on individual collagen strands but not on triple helices 
[71] and P4H does not hydroxylate single Pro residues but recognizes the minimal Gly-Xaa-Pro 
motif [72]. 
Like P4H, the prolyl 3-hydroxylase (P3H) also belongs to the 2-oxoglutarate dioxygenase protein 
family and requires FeII, O2, 2-oxoglutarate and ascorbate as cofactors (Figure 8). In humans, three 
homologues sequences have been identified and designated as P3H1, P3H2 and P3H3 encoded by 
Introduction 
 
 -22-  
leprecan, MLAT4 and LEPREL2, respectively [73]. P3H1/Lepre1 was first described as a basement 
membrane-associated leucine- and proline-enriched proteoglycan [74] and shares 46 and 41% 
sequence identity to P3H2 and P3H3, respectively. Unlike the α2β2 tetrameric P4H complex, 
immune-purified P3H is able to hydroxylate procollagen substrates by itself [73]. Still, P3H forms 
a tight complex with cyclophilin B, a peptidyl prolyl cis-trans isomerase (CyPB) and with the 
chaperone cartilage-associated protein (CRTAP). The importance of CRTAP for prolyl 3-
hydroxylation becomes evident since defective CRTAP leads to decreased prolyl 3-hydroxylation 
[75]. Moreover, the absence of CRTAP and 3-Hyp results in over modified collagen fibrils with 
increased diameter implying changes in fibrillogenesis. The over modification is due to extended 
lysyl hydroxylase and P4H activity on the unfolded collagen chain. The proper 3-hydroxylation 
and positional rotation of the Pro residue at position 986 (Pro986) in α1(I) and α2(I) seems to be 
important for collagen folding. Mice lacking CRTAP or humans with CRTAP mutations show severe 
osteochondrodystrophy characterized by severe osteoporosis and higher mineral content of bone 
matrix [7, 75]. Deficiencies in CRTAP or P3H1 are associated with the clinical features of recessive 
OI type VII. 
Figure 8| Hydroxylation of the collagen peptide chain by prolyl 4-hydroxylase (P4H) and prolyl 
3-hydroxylase (P3H).  Upper panel: The mammalian P4H is an α2β2 tetrameric enzyme. The α-subunit 
contains the active site with tightly bound ferrous iron to two histidine (His412 and His483) and one 
aspartic acid (Asp414) residues. By decarboxylating 2-oxoglutarate to succinate, one oxygen atom of O2 
gets incorporated into succinate and the other is used to hydroxylate Pro at the C4-position (orange 
shaded O). Ascorbate reduces the oxidized ferric iron to ferrous iron, thereby restoring the enzymes 
active state. Bottom panel: The same mechanism is used by the P3H complex to hydroxylate Pro at the 
C3-position (orange shaded O). 
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Lysyl hydroxylases 
The collagen lysyl hydroxylases (LH) catalyze hydroxylation of Lys residues by a mechanism 
similar to that described for prolyl hydroxylases. The addition of a hydroxyl group at the C5-
position of a polypeptide-lysine results in the formation of Hyl accomplished by LH. LH enzymes 
form homodimers and are peripheral membrane proteins in the lumen of the ER [76, 77]. In 
humans, three isoforms exist, called the procollagen-lysine,2-oxoglutarate 5-dioxygenase 1 
(PLOD1), PLOD2 and PLOD3 encoding for LH1, LH2 and LH3, respectively [9, 78]. Alternative RNA 
splicing has been observed only for the PLOD2 gene, resulting in a shorter LH2a and a longer LH2b 
splicing variant with an extra exon [79]. LH1 and LH2 share 59% identity and LH3 has 57% 
identity with LH1. Phylogenetic analyses from mouse Lh cDNA proposed that the LH1 and LH2 
have been brought about by a duplication event, since they are more closely related to each other 
than to LH3 [80].  
The expression pattern of all three isoenzymes is rather widespread than tissue specific. All three 
or at least two isoenzymes have been found in the same tissues analyzed from human and mouse 
[79-82]. Conclusively, the isoenzymes might not only appear as tissue specific variants but could 
have substrate specificity in the same tissue. Different substrates could include the type of 
collagen or different acceptor sites on the same collagen α-chain. Certainly, the extent of 
hydroxylysine in collagen type I varies between bone and skin collagen in the telopeptidyl domain 
but does not vary in the collagenous triple helical domain [83]. That finding indicates the 
participation of two different isoenzymes in hydroxylating Lys residues on the same collagen type. 
Indeed, LH1 has been identified to be mainly responsible for Lys hydroxylation in the collagenous 
triple helical domain with Lys in the Yaa position of the Gly-Xaa-Yaa acceptor motif [84-86]. In 
contrast, LH2 specifically hydroxylates telopeptidyl Lys residues in the Xaa-Lys-Ala or Xaa-Lys-
Ser sequence [83, 87]. The specific substrate for the third isoenzyme LH3 is unknown. However, 
LH3 has been postulated to have triple enzymatic activity as in hydroxylation of Lys, 
galactosylation of Hyl and glucosylation of Gal-Hyl [88]. LH3 is a classical lysine hydroxylase with 
a Fe- dioxygenase domain at the C-terminus. A possible galactosyltransferase activity residing in 
the N-terminus could never be confirmed unlike the glucosyltransferase activity, which has been 
shown repeatedly [89, 90]. The contribution of PLOD3 to collagen glucosylation appears to be on 
a low level compared to collagen galactosyltransferase and it is questionable whether it is of 
sufficient biological relevance [91]. 
Glycosyltransferases 
Even though glycosylation of collagen was identified in 1935 [92] and the structures of the 
glycosides have been described since 1966 [5, 93] some of the glycosylating enzymes were 
discovered only in the past two decades. However, the publication of PLOD3 being an enzyme with 
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triple catalytical function namely Lys hydroxylation and subsequent galactosylation and 
glucosylation led to a lack of interest in continuing with the scientific investigation to identify the 
collagen glycosylating enzymes. Nevertheless, in 2009 the galactosyltransferase could be 
identified and annotated as GLT25D1 and GLT25D2 [6]. GLT25D1 is the prevailing isoform with a 
widespread expression pattern among human tissues unlike GLT25D2 which seems to be more 
restricted to the nervous system and the skeletal muscle. GLT25D1 is a soluble endoplasmic 
reticulum localized protein predefined by the C-terminal RDEL ER-retention signal sequence and 
verified by immunofluorescence staining [94]. Experiments with lysates from semi-purified 
glycosyltrasnferases reveal that the collagen glycosylating enzymes depend on divalent metal 
ions, preferentially Mn2+, and a nucleotide activated hexose donor to fulfill their catalytic activity 
[5]. The specific collagen glucosyltransferase (ColGlcT, EC 2.4.1.66) has not been cloned to date. 
Viral collagen modifying enzymes 
The characteristic Gly-Xaa-Yaa collagen and collagen-like structure has long been thought to be 
restricted to metazoans and some prokaryotes [95, 96]. Little is known about the prokaryotic 
collagen-like proteins and none of them have been characterized for post-translational 
modifications necessary for collagen integrity. The description of an aquatic giant virus belonging 
to Mimiviridae [97] has shown that collagen-like genes are also contemporary in the viral 
kingdom. Acanthamoeba polyphaga mimivirus expresses seven collagen genes [98, 99]. In 
addition to collagen genes, these viruses harbor genes encoding P4H [100] and LH enzymes [101]. 
Indeed, the Acanthamoeba polyphaga mimivirus LH L230 efficiently hydroxylates mimiviral and 
human collagen-like peptides [101].  
Since the virus contains genes on its own for hydroxylation of collagen-like proteins the question 
arose whether they also glycosylate collagen. Virus mediated glycosylation is a very rare feature 
for viruses and not long known. First evidence suggesting viruses might code for their own 
glycosylating genes was described in the Paramecium bursaria chlorella virus [102, 103]. 
Recently, analysis of the reported viral genome of Acanthamoeba polyphaga mimivirus revealed 
that mimivirus contains at least eleven open reading frames coding for possible glycosylating 
enzymes [97]. Together with the identification of sugar biosynthetic pathways for UDP-L-
rhamnose [104], UDP-GlcNAc [105] and unusual amino sugar viosamine [106], it is suggested that 
Acanthamoeba polyphaga mimivirus also encodes its own glycosylation machinery. By now, only 
one mimiviral glycosyltransferase has been cloned and characterized, the bifunctional collagen 
LH and core glucosyltransferase L230 [101]. Unlike human collagen glycosylation, the mimiviral 
collagen core glycosyltransferase adds a Glc residue to Hyl of the collagen backbone. In contrast 
to the human core Gal-Hyl monosaccharide which can be elongated to the Glc-Gal-Hyl 
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disaccharide structure, it is not known whether the mimiviral core Glc-Hyl structure can be 
elongated.  
Interestingly, the viral collagen modifying enzymes are soluble and active when expressed in E.coli 
[101]. In contrast, mammalian enzymes are not active in bacterial expression systems and the 
prolyl hydroxylases need co-expression of the partnering subunits, like the PDI, to be active in 
yeast or tobacco expression systems [107, 108]. The identification of these viral collagen 
modifying enzymes and their capability to be functionally expressed in bacteria is very interesting 
for biotechnological purposes thus opening new possibilities for the high yield production of 
recombinant hydroxylated collagen in bacterial expression systems.  
 
DEFECTS IN COLLAGEN MODIFYING ENZYMES 
Heritable disorders of connective tissues including skin, bone, cartilage, blood vessels and 
basement membranes are among the most common human genetic diseases. The diseases are 
classified according to clinical features and the pattern of inheritance into EDS, OI, 
Chondrodysplasias, Alport syndrome, Epidermolysis bullosa and the Marfan syndrome. The 
classification of these diseases cannot only be made by the link from genotype to phenotype. 
Defects in collagen type I can lead to OI or EDS. Even more, the same mutation can develop 
different phenotypes with respect to severity of the disease. For many of these diseases the 
molecular cause lays in mutations of different collagen types, collagen modifying enzymes or 
collagen interacting proteins. Until now, defects in eight collagen modifying enzymes have been 
identified in humans (Table 1). In this chapter the two most prominent diseases of collagen 
modifying enzymes EDS and OI will be described.  
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Table 1: Characteristics of collagen modifying enzymes and their association to human disorders. 
Gene Enzymatic function Diseases caused by gene mutation 
[Reference] 
Prolyl 4-hydroxylase and protein disulfide isomerase 
 
P4HA1 Hydroxylates Pro at the C4 position Embryonic lethal in mice [51] 
P4HA2 Hydroxylates Pro at the C4 position  
P4HA3 Hydroxylates Pro at the C4 position  
P4HB Protein disulfide isomerase Essential for viability in C.elegans [109] 
PDIA3 Protein disulfide isomerase  
PDIA4 Protein disulfide isomerase  
PDIA6 Protein disulfide isomerase  
Prolyl 3-hydroxylase and peptidyl prolyl cis-trans isomerase 
LEPRE1 Hydroxylates Pro at the C3 position OI type VIII [8, 110] 
P3H2 Hydroxylates Pro in Col. type IV High myopia [111] 
P3H3 Hydroxylates Pro at the C3 position  
CRTAP Cofactor for P3H1 (LEPRE1) OI type VII [75, 112] 
PPIB Peptidyl prolyl cis- trans isomerase OI type IX [113] 
FKBP10 Peptidyl prolyl cis- trans isomerase OI type XI [114] 
Lysyl hydroxylase 
 
PLOD1 Hydroxylates helical Lys EDS type VI [86] 
PLOD2a   
PLOD2b Hydroxylates telopeptidyl Lys Bruck syndrome 2 [115] 
PLOD3 Hydroxylates Lys in col. type IV, V   
Glycosyltransferase 
  
GLT25D1 Galactosylates Hyl  
GLT25D2 Galactosylates Hyl  
EC 2.4.1.66 Glucosylates Gal-Hyl  
Lysyl oxidase 
  
LOX Oxidatively deaminates Lys/ Hyl Lathyrism [116] 
Metalloproteinase 
  
ADAMTS-2 Cleaves the N-terminal propeptides EDS type VIIc [117] 
BMP-1 Cleaves the C-terminal propeptides OI type XII [118, 119] 
Tolloid-like 1 Cleaves the C-terminal propeptides  
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Osteogenesis imperfecta 
OI is a heritable bone dysplasia characterized by fragile bones, easy susceptibility to fractures and 
growth deficiency [120]. OI defines a heterogeneous group of diseases with variable severity and 
occurs in approximately 15’000 to 20’000 births [121]. Most cases affect mutations in collagen 
type I with autosomal dominant inheritance. Only 10% mutant gene expression is sufficient for 
disruption of normal collagen function [122]. Several rare cases have been identified with 
mutations in non-collagenous genes. But the function of all of these genes relates to collagen 
biosynthesis. Currently, the genetic classification of OI distinguishes between autosomal 
dominant and autosomal recessive inheritance but with a broad range of severity across both 
groups. The dominant types encompass the classical types caused by collagen type I mutations 
and the recessive types group defects of genes involved in collagen modification, folding and 
processing (Table 2).  
 
Table 2: Classification of Osteogenesis imperfecta. From [120, 121, 123]. 
OI Type Gene Defect Phenotype 
Dominant inheritance 
 Classical types 
 I COL1A1 null allele Mild, nondeforming 
 II COL1A1 or COL1A2 Perinatal lethal 
 III COL1A1 or COL1A2 Progressively deforming 
 IV COL1A1 or COL1A2 Moderately deforming 
 COL1-mutation negative 
 V IFITM5 Distinct histology 
Recessive inheritance 
 Mineralization defect 
 VI SERPINF1 Distinct histology 
 3-Hydroxylation defects 
 VII CRTAP Severe to lethal 
 VIII LEPRE1 Severe to lethal 
 IX PPIB Moderate to lethal 
 Chaperone defects 
 X SERPINH1 Severe 
 XI FKBP10 Progressive deforming, Bruck 
syndrome 1 
 C-Propeptide cleavage defect 
 XII BMP1 Severe, high bone mass case 
Unclassified Osteogenesis imperfecta-like 
 Zinc-finger transcription factor defect SP7 Moderate 
 Cation channel defect TMEM38B Moderate to severe 
 WNT signaling pathway defect WNT1 Moderate, progressively 
deforming 
 Bruck syndrome 2 PLOD2 Joint contractures 
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Autosomal dominant Osteogenesis imperfecta 
A general decrease in bone mineral density (osteopenia) and brittle bones are the characteristic 
clinical features of dominant OI. Beside bone fragility, many patients show signs of dental 
abnormalities, progressive hearing loss and blue sclera, which are caused by thinness of collagen 
layers [124]. About 90% of OI cases have heterozygous mutations in either of the collagen type I 
pro-α chains (COL1A1, COL1A2) [125]. Despite the high causative percentage for a single protein, 
OI patients show a large genotypic heterogeneity with respect to mutation sites. Unrelated 
patients rarely carry the same mutation in the same gene and even phenotypic variability has been 
reported for both, related or unrelated patients with the exact same collagen mutation [121, 126]. 
About 80% of collagen mutations are Gly substitutions and about 20% alter splicing sites [126]. 
The substitution of Gly with bulkier amino acids leads to assembly of collagen fibers that are 
branched or abnormally thick and short (Figure 9). Splice site mutations often lead to frameshifts 
that produce structurally abnormal but partially functional collagen resulting in a mild form of OI. 
General, mutations in the C-terminal domain are more severe, as these mutations prevent initial 
triple helix formation which results in a process called collagen suicide and the degradation of the 
Figure 9| Defective collagen biosynthesis. Mutations in one of the collagen pro-α(I) chains can lead to 
early stop in α-chain synthesis or disability to fold into the triple helix leading to chain degradation and 
subsequent procollagen suicide. Some mutations sill lead to partially functional but abnormal collagen 
secretion with branched fibers. (Source: Fauci et al., Harrison’s Principles of Internal Medicine, 17th 
Edition: http://www.accessmedicine.com) 
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whole collagen molecule (Figure 9). Recently, several degrading pathways have been proposed for 
defective collagen disassembly including ERAD proteasomal degradation of chains, an 
unidentified pathway for heterotrimeric structures and autophagy of supramolecular aggregates 
[121]. Some severe to lethal mutations are located to C-terminal regions important for binding of 
integrin, matrix metalloproteinases, fibronectin and cartilage oligomeric matrix protein (COMP) 
suggesting erroneous interactions with the extracellular matrix [126]. 
Autosomal recessive Osteogenesis imperfecta 
Other genetic causes, besides mutations in collagen, currently account for about 2 – 5% of OI cases. 
These non-collagenous genes are mainly inherited in an autosomal recessive pattern and 
encompass genes coding for collagen modifying enzymes, collagen chaperoning genes and genes 
involved in osteoblast maturation (Table 2). Among collagen modifying enzymes, the entire P3H 
complex is affected with mutations in CRTAP, LEPRE1 or PPIB which result in OI [75, 113, 127, 
128] (Figure 8). The three proteins assemble in a 1:1:1 ratio and catalyze the 3-hydroxylation of 
Pro986 in collagen α1(I) and Pro707 in α2(I). Mutations in CRTAP and LEPRE1 lead to over 
modification by LH and P4H enzymes [112]. A similar effect has been observed for collagen C-
terminal structural defects indicating for a delay in helix-formation [112]. The chaperoning 
function of CRTAP might be essential for normal chronological collagen folding but the mechanism 
is not known. Over-modification by hydroxylation and glycosylation has also been observed for 
PPIB-deficiencies [113]. CyPB (encoded by PPIB) is a peptidyl-prolyl cis-trans isomerase and 
isomerase activity is known to be rate-limiting for collagen folding since the conversion from cis-
prolines to trans configuration is necessary for proper triple helix formation [129]. CyPB is 
ubiquitously expressed and independent of CRTAP and P3H1 (encoded by LEPRE1) whereas 
CRTAP and P3H1 are mutually stabilizing in the P3H complex [130]. That explains the similar 
phenotypes of CRTAP- and LEPRE1-deficiencies. Besides the P3H complex, mutations in the LH 
gene PLOD2 also lead to skeletal conditions resembling OI. Patients with a homozygous frameshift 
mutation in the alternative exon of PLOD2 lack expression of telopeptidyl LH2 which results in 
impaired collagen cross link formation [131]. Yet again, different mutations for PLOD2 have been 
identified which do not give genotype – phenotype correlations. Brothers, having the same PLOD2 
mutations show dissimilar phenotypes diagnosed as mild OI for one brother and more severe and 
with a higher fracture history as a mild form of Bruck syndrome for the other [131]. Bruck 
syndrome is denoted by association with OI and congenital joint contractures [115]. 
Recently, mutations in another collagen modifying enzyme were found to result in an OI 
phenotype. BMP1, the bone morphogenetic protein 1, cleaves the C-terminal propeptide prior to 
fibril formation. BMP1-deficiency is characterized with a similar phenotype like for dominant 
collagen mutations in the C-propeptide showing impaired collagen secretion and multiple 
recurrent fractions except that patients with a BMP1 mutation have high bone mass [119]. The 
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interplay of bone production by osteoblasts and resorption by osteoclasts is used for therapeutic 
strategies (Figure 10). Treatment with bisphosphonates, analogues of pyrophosphates, reduces 
the life span and function of osteoclasts thereby slowing down the process of bone resorption 
[125]. Hence, the prolonged osteoblasts still produce mutated collagen but less of the ‘OI bone’ is 
resorbed. The arisen increase in bone thickness leads to reduction in fracture rate and bone pain 
[125]. Other therapies and OI management include calcium/vitamin D supplementation, 
orthopedic surgery and personal designed exercise programs. Currently, no cure for OI exists. 
 
 
 
Ehlers-Danlos syndrome 
With an incidence of 1:5’000, EDS is amongst the most common heritable connective tissue 
disorders (Ehlers-Danlos National Foundation, www.ednf.org). EDS is characterized by 
hyperextensibility of skin and hypermobility of joints. The generalized weakness and fragility of 
soft connective tissues often goes along with skeletal abnormalities, easy bruising, pronounced 
bleeding and premature rupture of membranes [132]. Several types of EDS have been classified 
based on clinical criteria, mode of inheritance and molecular and biochemical analysis (Table 3). 
Figure 10| Bone structure, modeling and remodeling. (a) Bone consists of a solid outer (cortical) 
layer and a porous trabecular network filling the cavity inside. (b) In OI, the cortical and trabecular 
bones are generally thinner. The trabeculae are also less dense and less interconnected. (c) and (d) The 
lateral growth of cortical bone occurs primarily through modeling: osteoblasts deposit new matrix at 
the outer surface, which is subsequently mineralized; osteoclasts resorb the inner surface. In OI, 
imbalance between bone deposition by osteoblasts and resorption by osteoclasts leads to thinner and 
more porous bones. Taken from [30]. 
 
Introduction 
 
 -31-  
Table 3: The expanded Villefranche classification of Ehlers-Danlos syndrome. Adapted from [132]. 
EDS type (Villefranche #) Clinical findings Inheritance Gene defects 
Classical (I, II) Skin and joint hypermobility 
atrophic scars, easy bruising 
AD 
AR 
COL5A1, COL5A2, 
COL1A1 
TNX-B 
Cardiac-valvular  AR COL1A2 
Hypermobility (III) Joint hypermobility, pain, 
dislocations  
AD Unknown, TNX-B 
Vascular (IV) Thin skin, arterial or uterine 
rupture, bruising, small joint 
hyperextensibility 
AD COL3A1 
Vascular-like  AD COL1A1 (R-to-C) 
Kyphoscoliosis (VI) Hypotonia, joint laxity, 
congenital scoliosis, ocular 
fragility 
AR PLOD1 
Musculocontractural   AR CHST14 
Progeroid  AR B4GALT7, B3GALT6 
Spondylocheirodysplastic  AR SLC39A13 
Brittle cornea syndrome  AR ZNF469, PRDM5 
Arthrochalasis (VIIa, b) Severe joint hypermobility, 
skin mild, scoliosis, bruising 
AD COL1A1, COL1A2 
Dermatosparaxis (VIIc) Severe skin fragility, cutis laxa, 
bruising 
AR ADAMTS2 
AD = autosomal dominant, AR = autosomal recessive 
 
The classical, hypermobility and vascular types are the most common, whereas the 
kyphoscoliosis, arthrochalasis and dermatosparaxis types constitute very rare cases [132]. 
Genetic defects affecting the biosynthesis or enzymatic modification of collagen types I, III and V 
are the major causes of EDS. Mutations in two of the three genes (COL5A1 and COL5A2) for type V 
collagen account for about 90% of classical EDS cases [133]. Heterozygous mutations that abolish 
one COL5A1 allele result in COL5A1 haploinsufficiency which yields to half the amount of normal 
collagen V production. The reduced incorporation of collagen V into collagen I molecules is central 
in classic EDS pathogenesis. Ultrastructural examination of skin biopsies show irregular loosely 
packed collagen fibrils which build up the fragile tissue susceptible for atrophic scars. 
Until now, homozygous or compound heterozygous mutations of two collagen modifying 
enzymes, PLOD1 and ADAMTS2, have been described leading to kyphoscoliotic type VI and 
dermatosparaxis type VIIc EDS, respectively (Table 1 and Table 3). Mutations in PLOD1 result in 
weaker collagen structures because Hyl cross-links are more stable than Lys cross-links. PLOD1 
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deficiency accompanied by reduced hydroxylation can be confirmed by analyzing the ratio of 
lysylpyridinoline (LP) to hydroxylysylpyridinoline (HP) in the urine. A LP/HP ratio of 6 is 
considered normal, whereas a LP/HP ratio of 1 is low and pathogenic. For a small group of patients 
with EDS type VI no PLOD1 mutations could be detected, indicating that mutations for other PLOD 
genes or even the glycosylating enzymes might be the causative agents for the similar phenotype. 
Recently, two types of EDS, the musculocontractual and progeroid types have been associated 
with defects in glycosylating enzymes. Both enzymes are involved in proteoglycan metabolism, 
one (CHST14) is a key sulfotransferase enzyme in the biosynthesis of dermatan sulfate, the other 
(B4GALT7) is involved in the biosynthesis of the glycosaminoglycan (GAG) core. GAG-chain 
deficiency leads to abnormal collagen fiber assembly [134].  These patients show additional 
symptoms, like craniofacial abnormalities, joint contractures, wrinkled palms, tapered fingers 
besides the typical EDS symptoms. 
Until now, no defects could be attributed to collagen glycosylation and the collagen glycosylation 
enzymes. The over modification by hydroxylation and glycosylation seen in OI types VII, VIII and 
IX and EDS type VI is an effect of the extended time span for the modifying enzyme’s activity and 
the increased substrate availability. Whether mutations in the glycosylating enzymes also 
contribute to connective tissue disorders is not known. siRNA experiments in the nematode 
C.elegans targeting the C.elegans homologue for GLT25D2 (D2045.9) show viable offspring 
attributed with slow growth, locomotion problems and sterile progeny.   
DISCOVERING NEW GLYCOSYLTRANSFERASES IN SILICO 
In this study we aimed to identify the gene coding for the human collagen glucosyltransferase. The 
identification of new glycosyltransferases can either be achieved by conventional protein 
purification methods such as ion exchange chromatography and affinity chromatography from 
cells, tissues or organisms, or by utilizing bioinformatic tools to limit candidate proteins according 
to their biochemical properties. This chapter introduces the possibilities of these bioinformatic 
tools about properties of glycosyltransferases and how they can be used to identify new 
glycosyltransferases.  
The CAZy database and properties of glycosyltransferases 
With the human genome sequencing consortium [135] the entire human genome is accessible and 
all human sequences are available to feed bioinformatic tools for extensive blast searches, 
comparisons and grouping of proteins. In the field of glycosylation the CAZy-database 
(Carbohydrate Active Enzymes) provides a growing tool of all carbohydrate interacting proteins 
across all domains of life [136]. The database describes structurally-related catalytic and 
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carbohydrate-binding modules of enzymes and groups them into major enzyme classes like 
glycoside hydrolases, glycosyltransferases, polysaccharide lyases, carbohydrate esterases and 
auxiliary activities. For glycosyltransferases the grouping in CAZy is structured in families based 
on amino acid sequence similarities of glycosyltransferases. In 2015, the database describes 97 
glycosyltransferase-families with more than 175’000 entries (www.cazy.org). Unlike for glycoside 
hydrolases which vary a lot in structural properties, most glycosyltransferases accommodate a 
denoted GT-fold characterized as variation of the Rossmann-like structure (Figure 11). The GT-
folds are used to identify and classify the glycosyltransferases into families. Most enzymes with a 
GT-A fold contain the conserved DxD – motif which is necessary for enzymatic function. One or 
both of the aspartates are involved in coordinating the metal ion, usually a bivalent cation Mg2+ or 
Mn2+, which contacts with the phosphate group of the bound nucleotide. Unlike the GT-A fold 
enzymes the GT-B fold enzymes lack the DxD – motif and the nucleotide transfer is metal 
independent. The mode of interaction with the sugar donor and the GT-B is complex and requires 
the motion of both Rossmann-like domains of the GT-B fold. For both the GT-A and GT-B fold the 
three-dimensional structure has been solved (Figure 12). In the last years a third group named GT-
C has been introduced which describes the superfamily of integral membrane 
glycosyltransferases. The GT-C enzymes lack the Rossmann-like fold and contain a modified DxD 
– motif that can be aligned to ExD, DxE, DDx or DEx.  
Figure 11| Topology diagram of the Rossmann-like nucleotide diphospho sugra fold adopted by 
the GT‐A proteins. Orange arrows indicate β‐strands (1–7) forming the main β‐sheet of the 
Rossmann‐like fold. Blue cylinders indicate the most conserved α‐helices. Magenta arrows indicate β‐
lip. Red line indicates the location of the S4 loop with DxD motif. Taken from [137]. 
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Another specific feature of GT’s is the utilization of an activated donor that can be a nucleoside 
monophospho sugar, nucleoside diphospho sugar or lipid phospho sugar. The majority of GT’s 
utilizes nucleotide activated monosaccharides as sugar donor. The transfer of the sugar donor to 
the acceptor site can either be via inversion or retention of the carbohydrate bond (Figure 13). 
With the expectation that the collagen glucosyltransferase is metal – dependent [46, 140] and 
transfers the α-D-glucose in a retaining mechanism only four GT-families containing human 
Figure 12| Structural properties of glycosyltransferases.  Glycosyltransferases accommodate a 
denoted GT-fold. Accordingly they can be grouped in clans based on the reaction mechanism being 
either inverting or retaining. Adapted from [137, 138]. Cristal structures are taken from [139]. 
Figure 13| Mechanism. Glycosyltransferases transfer the donor glycosyl group with either inversion 
or retention of the anomeric stereochemistry with respect to the C1 leaving group. Adapted from 
[139]. 
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sequences would remain to search for possible candidates, namely GT 8, 24, 27, and 64 (Figure 
14). The GT 8 family is large and contains 9 human sequences. GT 24 is very distinct and contains 
only 2. GT 27 and 64 contain 4 and 5 sequences, respectively. 
 
GT-A fold (and variants)  GT-B fold (and variants)  other folds 
Inverting  Inverting  Inverting 
2, 7, 12, 13, 14, 16, 17, 
21, 25, 29, 31, 40, 42, 43, 
49, 54, 67, 73, 74, 75, 82, 
84, 92 
 1, 9, 10, 11, 18, 19, 23, 
28, 30, 33, 37, 38, 41, 47, 
52, 56, 61, 63, 65, 68, 70, 
80, 90, 94 
 51, 66 
Unknown folds 
Inverting 
Retaining  Retaining 
 
22, 26, 39, 48, 50, 53, 57, 
58, 59, 76, 83, 85, 87 6, 8, 15, 24, 27, 32, 34, 
44, 45, 55, 60, 62, 64, 69, 
71, 77, 78, 81, 88 
 
3, 4, 5, 20, 35, 72, 79, 93 
  Retaining 
89 
 
The knowledge from the in silico analysis is also very useful to analyze the output from mass 
spectrometric reads. Besides the annotated proteins, sequences of unknown or uncharacterized 
protein hits can be screened for signaling domains to enter the ER and the Golgi apparatus or for 
the ER-retention signal sequence KDEL since many soluble glycosyltransferases are ER resident 
as it is expected for the collagen glycosyltransferases [94]. 
In the end, the combination of the conventional purification protocol with the in silico analysis 
provides a powerful strategy to identify new glycosyltransferases. The identification of the 
collagen glucosyltransferase would not only unravel the last unknown piece of the human collagen 
modifying enzyme puzzle but would also allow to characterize the impact of the collagen glycan 
with respect to its functional role. What is the contribution of the collagen glycan in biosynthesis, 
assembly, secretion or in the extracellular matrix? Is the glycan important for signaling or collagen 
remodeling? This is also an important issue for biotechnological applications of industrially- 
produced collagen. What is the glycan’s and enzyme’s function and relevance in connective tissue 
disorder diseases or congenital disorders of glycosylation (CDG)? Would a CDG affect collagen 
biosynthesis and how? 
Figure 14| Classification of CAZy glycosyltransferase families in structural superfamilies. GT-
families in red comprise human sequences, GT-families in bold have at least one member with a solved 
3D-structure. Taken from [141]. 
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Abstract 
Glycosylation is a ubiquitous modification of lipids and proteins. Despite the essential 
contribution of glycoconjugates to the viability of all living organisms, diseases of glycosylation in 
humans have only been identified over the last decades. The recent development of next-
generation DNA sequencing techniques has accelerated the pace of discovery of novel 
glycosylation defects. The description of multiple mutations across glycosylation pathways has 
revealed a tremendous diversity of functional impairments bus also pointed to phenotypic 
similarities emphasizing the interconnected flow of substrates underlying glycan assembly. The 
current list of 100 known glycosylation disorders provides an overview on the significance of 
glycosylation in human development and physiology. 
 
 
Highlights 
 Congenital disorders of glycosylation underline the functional significance of glycosylation in 
human development and physiology. 
 The recent application of next-generation sequencing techniques widely expanded the 
discovery of glycosylation gene defects. 
 The extreme clinical variability associated with glycosylation disorders implies that such 
diseases are currently underdiagnosed. 
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Introduction 
Glycosylation is by far the most complex form of protein [1, 2] and lipid modification [3, 4] in all 
domains of life. The tremendous diversity of glycoconjugate structures resulting from intricate 
biosynthetic pathways is a major factor hampering the assignment of functions to glycans chains. 
Much has been learnt from the study of disrupted glycosylation genes in model organisms, thereby 
establishing numerous essential contributions of glycans in regulating cell and organ functions 
[5]. The study of human diseases of glycosylation brings additional insights by providing a more 
differentiated view on glycan functions. Indeed, most human mutations are hypomorphic, thus 
causing partial loss of glycosylation reactions that lead to variable clinical manifestations.  
Diseases of glycosylation are also referred to as congenital disorders of glycosylation (CDG). Given 
the heterogeneity of glycans, the clinical scope of CDG is considerable, ranging from nearly normal 
phenotypes to severe multi-organ dysfunctions causing infantile lethality. CDG are rare diseases. 
The prevalence among CDG types is very different from one type to another, but is largely 
unknown. The difficulty in identifying patients is another reason behind the rarity of CDG. 
Unspecific symptoms and the lack of simple laboratory tests make the recognition of CDG cases 
extremely challenging. The identification of CDG has long relied on the detection of under-
glycosylated serum transferrin by isoelectric focusing [6]. While easy to perform and requiring 
only few microliters of blood, this test exclusively reveals alterations of N-glycosylation. Similar 
blood tests have unfortunately not been established to reliably diagnose defects in other classes 
of glycosylation. The simplicity of the serum transferrin test also explains why disorders of N-
glycosylation account for the majority of known CDG. 
Recent developments in genome-wide DNA sequencing technology enable the identification of 
mutations without previous guessing for candidate genes. As in other fields of biology, next-
generation sequencing approaches have increased the pace of discovery for new types of CDG [7]. 
The barrier of 100 genes defects impairing glycosylation has just been passed. These defects 
encompass nearly all glycosylation pathways and affect different molecular processes from 
substrate biosynthesis up to protein trafficking [8, 9]. The recent application of unbiased 
strategies such as exome and whole-genome sequencing have further revealed CDG-causing 
mutations in genes previously not associated to glycosylation, thereby expanding our view on 
these complex pathways.  
CDG have originally been classified in two groups. So-called CDG type-I included defects of lipid-
linked oligosaccharide assembly up to their transfer to asparagine residues on nascent proteins, 
whereas CDG type-II included defects of N-glycans trimming and elongation as well as defects in 
any other class of glycosylation [10]. Because several defects affect multiple glycosylation 
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pathways, the artificial distinction between CDG type-I and -II has been replaced by a flat 
nomenclature simply associating implied genes with the suffix CDG [11]. Functionally, defects can 
also be grouped based on their contribution to glycosylation reactions (Figure 1). Accordingly, 
the present review discusses glycosylation disorders through five functional categories, featuring 
1) genes encoding glycosyltransferase enzymes, 2) genes involved in donor substrate 
biosynthesis, 3) genes mediating the translocation of donor substrates, 4) genes regulating 
glycosyltransferase localization, and 5) genes affecting the homeostasis of secretory organelles. 
Glycosyltransferases  
The human genome includes close to 200 glycosyltransferase genes [12]. The majority of these 
glycosyltransferases are transmembrane proteins anchored in the ER and Golgi membranes [13]. 
Defects of ER glycosyltransferases involved in the assembly of the oligosaccharide 
GlcNAc2Man9Glc3 (Figure 2) lead to defects of N-glycosylation resulting in glycoproteins lacking 
whole N-glycan chains. Depending on the glycoproteins affected, non-occupancy of N-
glycosylation sites can impair protein folding, secretion and stability. At the level of the organism, 
such defects lead to multiple organ dysfunctions. Neurological symptoms are frequent, featuring 
psychomotor retardation, ataxia, and hypotonia. Liver and cardiac dysfunctions are also 
frequently observed as well as endocrine disorders, which mainly affect the sexual maturation of 
female patients [14]. 
The functional impairments associated with some glycosyltransferase deficiencies reflect the 
functional relevance of the involved glycoproteins. For example, O-mannosylation [15] is an 
essential modification of -dystroglycan ensuring proper interactions between the dystroglycan 
complex and proteins of the extracellular matrix [16]. Such interactions are essential for the 
integrity of muscular fibers, for the migration of neurons in the cortex, and for the retinal 
architecture [17]. Accordingly, the main manifestations of O-mannosylation disorders are 
muscular degeneration, brain abnormality, and blindness. Clinically, these disorders belong to the 
congenital muscular dystrophies and are known as Walker-Warburg syndrome, Muscle-Eye-Brain 
disease, Fukuyama-type congenital muscular dystrophy, and Limb-girdle muscular dystrophy. 
The most severe cases are usually associated with mutations in the core mannosyltransferase 
genes POMT1 [18] and POMT2 [19] and in the 1-2 GlcNAc-transferase gene POMGNT1 [20] 
(Figure 2), but other gene defects also account for severe cases of Walker-Warburg syndrome and 
Muscle-Eye-Brain disease. To date, defects in 12 genes are known to cause congenital muscular 
dystrophies, although the functions of some of these genes are still unclear. For example, the FKTN 
and FKRP genes encode putative glycosyltransferases involved in O-mannosylation, but their 
exact substrate specificity and activity remain unknown [21].     
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Another form of O-linked glycosylation is characterized by the addition of fucose (Fuc) to serine 
and threonine in the context of the epidermal growth factor (EGF)-like domains and 
thrombospondin-1 (TSP1) domains. Typical acceptor proteins are members of the Notch family 
including the ligands Jagged and Delta-like, which are signaling proteins involved in 
morphogenetic processes [22]. Complete deficiency of core O-fucosyltransferases POFUT1 and 
POFUT2 has not been described yet, but heterozygous mutations in the POFUT1 gene have been 
identified in cases of Dowling-Degos disease, an autosomal dominant pigmentation disorder [23]. 
Furthermore, mutations in the downstream acting glycosyltransferases, i.e. the 1-3 GlcNAc-
transferase LFNG and the 1-3 Glc-transferase B3GALTL (Figure 2), have been associated with 
disorders of vertebral segmentation [24] and to multiple developmental defects known as Peters-
Plus syndrome [25], respectively. 
In general, defects of core glycosyltransferases are more severe than defects of terminal 
glycosylation. Nevertheless, the severity of the disease and the scope of organ involvements are 
also influenced by the functional redundancy inherent to specific glycosyltransferase reactions in 
the biosynthesis of classes of glycosylation. For example, mucin-type O-glycosylation is initiated 
by a large family of polypeptide GalNAc-transferases [26]. The partial redundancy in this enzyme 
family prevents a major loss of this type of glycans in humans, which explains why familial tumoral 
calcinosis is the only known disease of mucin-type O-glycosylation [27]. Mutations in the 
polypeptide GalNAc-transferase GALNT3 gene impair the glycosylation of the hormone FGF23, 
which requires O-GalNAc glycans for its intracellualr trafficking in the Golgi apparatus [28]. Loss 
of FGF23 secretion leads to hyperphosphatemia and tissue calcification, which are the cardinal 
symptoms of tumoral calcinosis.   
Donor substrates  
Despite the hundreds of glycosyltransferases expressed in human cells, only eleven building 
blocks are used as donor substrates for the assembly of all human glycans. These substrates 
include nine nucleotide-activated sugars and two dolichol-phosphate (P) linked sugars (Figure 
3A). Donor substrates are biosynthesized in the cytosol and in the nucleus for CMP-sialic acid (Sia) 
through multiple steps including interconversion between monosaccharide isomers. Donor 
substrates are used across classes of glycosylation, meaning that defects in the formation of 
individual nucleotide-activated sugars have a broad impact on glycan structures and lead to 
severe multiorgan disorders. However, clinical severity for a given gene defect widely varies 
based on the level of residual activity enabled by individual mutations. For example, about 100 
mutations have been described for the phosphomannomutase PMM2 gene [29], which represents 
by far the most frequent form of CDG. Mutations completely abrogating PMM2 activity lead to 
embryonic lethality [30] whereas point mutations of minimal impact on the enzymatic activity 
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will only cause mild intellectual disabilities. PMM2 activity mediates the conversion of mannose 
(Man)-6-P to Man-1-P, which is an early step in the biosynthesis of GDP-Man (Figure 3B). GDP-
Man is further converted to dolichol-P-Man by an enzymatic complex encoded by the DPM1, DPM2, 
and DPM3 genes. Dolichol-P-Man is a substrate used in N-glycosylation, O-mannosylation, and for 
the biosynthesis of the glycosylphosphatidylinositol (GPI) anchors. Accordingly, decreased 
dolichol-P-Man availability causes of range of diseases sharing features of classical N-
glycosylation disorders, but also of congenital muscular dystrophies for O-mannosylation defects.   
Sometimes, exome sequencing of untyped CDG cases reveals mutations in genes that were 
previously associated with diseases unrelated to glycosylation. For example, 
phosphoglucomutase deficiency resulting from mutations in the PGM1 gene causes glycogen 
storage disease XIV, characterized by accumulation of glycogen in muscles because of reduced 
formation of Glc-6-P from Glc-1-P occurring during breakdown of glycogen [31]. The reverse 
reaction catalyzed by PGM1, i.e. the formation of Glc-1-P from Glc-6-P is also important for the 
subsequent formation of UDP-Gal utilized for glycan formation (Figure 3B). Indeed, mutations in 
PGM1 have been identified as causing CDG with multiple clinical involvements such as growth 
retardation, cleft palate, muscular and cardiac disorders, and liver dysfunction among other 
manifestations [32].   
The study of glycosylation diseases occasionally points to unexpected findings relative to the 
biological importance of donor substrate biosynthesis. The GNE gene encodes the bifunctional 
enzyme UDP-GlcNAc 2-epimerase/ManNAc kinase, which catalyzes a rate-limiting step in the 
biosynthesis of Sia [33]. The disruption of the Gne gene in mice is embryonic lethal [34], but 
decreased GNE activity in human beings is mainly associated with adult-onset, progressive limb-
girdle muscle weakness with a remarkable sparing of quadriceps muscles [35]. This rather mild 
disease suggests that Sia can be efficiently salvaged in humans to bypass any defect of 
biosynthesis.     
Because the biosynthetic pathways of most donor substrates are interconnected, it is tempting to 
circumvent specific defects by increasing the supply of alternative carbohydrates that can be 
converted to the missing substrate. Unfortunately, such an approach has only been successful to 
treat the deficiency of Man-P isomerase (MPI), which catalyzes the interconversion of fructose-6-
P and Man-6-P (Figure 3B). MPI deficiency is mainly a hepatic-intestinal disease and thus lacks 
the neurological involvement often found in CDG [36]. The decreased formation of Man-6-P 
accompanying MPI deficiency can be efficiently compensated by dietary Man supplementation, 
thereby alleviating disease symptoms [37]. Similarly, dietary supplementation with Gal has 
recently been shown to normalize serum transferrin glycosylation in patients affected of 
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phosphoglucomutase 1 (PGM1) deficiency [32], suggesting that Gal supplementation may 
allievate some of the defects associated with the disease. 
Localization of donor substrates 
Nucleotide-activated sugars are synthesized in the cytosol and nucleus, but need to be transported 
to the lumen of the ER and Golgi apparatus for glycosylation reactions. Dedicated antiporters 
mediate the coupled translocation of nucleotide-activated sugars into the organelles and the 
return of corresponding nucleotide-monophosphates into the cytosol (Figure 1). Most 
antiporters are specific for a given nucleotide-activated sugar, although multi-specific 
transporters have also been described. For example, SLC35D1 transports UDP-GlcA and UDP-
GalNAc into the ER in exchange of UMP returning to the cytosol. These two nucleotide-activated 
sugars are involved in the biosynthesis of chondroitin sulfate, a main product of proteoglycans 
secreted by chondrocytes. Mutations in the SLC35D1 gene cause a skeletal disease called 
Schneckenbecken dysplasia, characterized by severe bone abnormalites leading to neonatal 
lethality [38]. It is likely that other classes of glycosylation are affected by the decreased transport 
of UDP-GlcA and UDP-GalNAc, but the extent of such alterations has not been addressed yet. 
Additional defects of nucleotide-activated sugar transport have been associated with diseases, of 
which the symptoms reflect the importance of the implied carbohydrate for specific cellular 
functions. Mutations in the SLC35C1 gene encoding a Golgi GDP-Fuc transporter impairs terminal 
fucosylation, which yields epitopes such as ABO and Lewis blood group antigens [39]. Some of 
these fucosylated epitopes function as ligands for selectins [40] and thereby participate to 
leukocyte adhesion and extravasation reactions [41]. Accordingly, the shortage of GDP-Fuc in the 
Golgi caused by defective transport impairs leukocyte trafficking and leads to increased bacterial 
infections. In addition, affected patients present with short stature, intellectual disability, and mild 
facial dysmorphism. Hematologic defects and susceptibility to infections could be reverted by oral 
supplementation with Fuc [42]. By comparison, mutations in the CMP-Sia transporter gene 
SLC35A1 were found in a patient with intellectual impairment, seizures, ataxia, thrombocytopenia, 
renal and cardiac disorders [43]. A general conclusion about the role of sialylation cannot be 
drawn from these two cases, but the symptoms confirm the importance of Sia for leukocyte and 
platelet functions.     
Dolichol-linked substrates do not use dedicated transporters to reach the ER lumen but proteins 
have been described that facilitate the translocation of these substrates across membranes. The 
first of these proteins is called MPDU1 and is required for making dolichol-P-Man and dolichol-P-
Glc available to ER mannosyltransferases and glucosyltransferases [44]. These enzymes mediate 
the elongation of the dolichol-PP-oligosaccharide substrate for N-glycosylation and participate in 
O-mannosylation and GPI anchor biosynthesis. The mechanism of MPDU1 action is still unknown, 
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but mutations in the MPDU1 gene lead to a form of CDG featuring symptoms typical of N-
glycosylation disorders, including psychomotor disability, hypotonia, and seizures [45, 46]. 
Similar symptoms were also observed in patients harboring mutations in the RFT1 gene [47], 
which encodes a protein involved in the translocation of the precursor dolichol-PP-linked 
GlcNAc2Man5 from the cytosolic into the luminal side of the ER membrane [48] (Figure 2). 
Defective RFT1 activity results in the accumulation of dolichol-PP-GlcNAc2Man5, which remains 
unavailable for further extension by luminally-oriented ER mannosyl- and glucosyltransferases.        
Localization of glycosyltransferases 
A precise localization of glycosyltransferases is also required for proper glycan maturation in the 
Golgi apparatus. Some glycosyltransferases concentrate in the cisternae of the cis-Golgi, whereas 
other accumulate in the trans-Golgi. The mechanisms underlying the distribution of 
glycosyltransferases are not completely understood, but proteins regulating vesicle transports 
are involved in the process. The Conserved Oligomeric Golgi (COG) complex orchestrates the 
recycling of medial- and cis-Golgi resident proteins by acting as a tether to connect COPI vesicles 
with cis-Golgi membranes [49]. COG defects lead to abnormal glycosylation [50] because of 
missorting of glycosylation enzymes and sugar transporters [51]. Whereas multiple classes of 
glycosylation are impaired, COG-related disorders are usually identified by detection of 
underglycosylated serum transferrin just like defects of N-glycosylation. 
To date, mutations in seven out of eight COG subunit genes have been described. The most severe 
diseases are observed for COG6, COG7 and COG8 mutations, associated with severe neurological 
impairment, liver dysfunction, and infantile lethality [52-55]. The identification of milder cases of 
COG6 and COG7 deficiency harboring different mutations [56, 57] however shows that the 
severity of the disease does not simply relate to the subunit affected but rather to the capability 
of forming a fully functional COG complex. Besides the severe diseases observed for COG6 and 
COG7 defects, moderate clinical manifestations have been associated with mutations in COG1 [58, 
59], COG2 [60], COG4 [61, 62], and COG5 [63-65]. 
COG subunits build a complex of two lobes, including COG1 to COG4 in lobe A and COG5 to COG8 
in lobe B (Figure 4). In general, defects in lobe A lead to milder disease than defects in lobe B. 
Lobe A appears to be important for overall Golgi architecture, playing a role in Golgi organization 
and cis-Golgi sorting [66]. Alterations in lobe A lead to accumulation of late glycosylation enzymes 
in COG complex vesicles, thereby preventing interaction with their substrate. Lobe B rather 
mediates vesicular sorting of trans-Golgi enzymes through functional interactions with the 
tethering and fusion machinery of trans-Golgi cisternae [67, 68]. Accordingly, 
glycosyltransferases from early Golgi cisternae, such as the 1-2 GlcNAc-transferase MGAT1, are 
more affected by a defect in lobe A [66]. By contrast, Gal-transferases and Sia-transferases residing 
Introduction – Publication 
 
 -52-  
in trans-Golgi cisternae are more influenced by lobe B alterations [67]. Furthermore, lobe B 
deficiency mainly results in altered steady state levels of these enzymes due to their translocation 
to the ER and subsequent proteasomal degradation [65]. 
Whereas COG defects demonstrate the importance of glycosyltransferase localization for 
glycosylation, the characterization of another disease called Tn syndrome has pointed to the 
importance of chaperones in supporting folding and trafficking of specific glycosyltransferases. 
The Tn syndrome is a clonal defect of core 1 1-3 Gal-transferase activity limited to a subset of 
hematopoietic cells. The presentation of bare O-linked GalNAc (the Tn antigen) on erythrocytes 
leads to the binding of naturally-occurring anti-Tn antibodies and hence to agglutination and 
hemolysis [69]. Tn antigen presentation on leukocytes and platelets may cause mild leukopenia 
and thrombocytopenia. Although core 1 1-3 Gal-transferase activity is decreased in Tn 
syndrome, no mutations have been found yet in the corresponding C1GALT1 gene. Rather, 
mutations in the COSMC gene encoding an ER-localized chaperone required for C1GALT1 folding 
have been identified as causing Tn syndrome [70]. C1GALT1 is the only glycosyltransferase known 
to undergo chaperone-assisted folding, but the example shows that proper glycosylation also 
relies on specific proteins such as COSMC that regulate the trafficking of glycosyltransferases from 
the ER to the Golgi. 
Organelle milieu  
Glycosyltransferases require co-factors, such as the metal ion Mn2+, and a range of environmental 
conditions to catalyze glycosylation reactions. The recent application of unbiased genetic 
approaches, such as homozygosity mapping and exome sequencing, has pointed to novel genes, 
which affect glycosylation by regulating the acidification and ionic constituents of the secretory 
pathway. 
The ATP6V0A2 gene encodes a subunit of an H+-ATPase proton pump localized in the Golgi 
apparatus [71], which likely regulates pH in Golgi cisternae. Defective ATP6V0A2 action yields 
structural alterations of Golgi architecture but also causes accumulation of abnormal intracellular 
vesicles [72]. These changes affect multiple classes of glycosylation as shown by the abnormal N-
glycosylation and mucin type O-glycosylation of blood serum proteins. Clinically, mutations in 
ATP6V0A2 lead to multiple abnormalities including growth delay and psychomotor disability, but 
also to skin wrinkling and connective tissue alterations referred to as cutis laxa [73]. Skin and 
skeletal phenotypes are likely related to alterations of extracellular matrix secretion as indicated 
by changes of TGF- signaling observed in affected fibroblasts [71]. 
Homozygosity mapping and exome sequencing also revealed mutations in the TMEM165 gene as 
causing a glycosylation disorder with broad clinical involvement. The five patients identified to 
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date present with growth and developmental delay, hypotonia, skeletal abnormalities, and 
hepatomegaly [74]. TMEM165 is a transmembrane protein localized in the Golgi membrane but 
also found in the plasma membrane, late endosomes and lysosomes. The function of TMEM165 is 
unclear but appears to be related to transport of calcium [75], which is normally found in high 
concentrations in the Golgi apparatus [76]. It is unclear whether TMEM165 dysfunctions also 
affect Mn2+ import mediated by the SPCA1 Ca2+ pump [77], which would explain the broad 
glycosylation defect observed in TMEM165 patients. 
Exome sequencing will continue to unravel genes of previously unknown or unclear function as 
cause of CDG. This growing catalog of gene defects will broaden our knowledge on the factors 
regulating glycosylation, but it will also bring forward new questions regarding the underlying 
mechanisms of such regulatory pathways. The recent characterization of TMEM165 is a good 
example outlining the difficult path following the description of mutations in a new gene. This 
work shows that biochemical and cell biological investigations are always required to understand 
the biological impact of genetic alterations. 
Concluding remarks 
This brief review of CDG illustrates the diversity of glycan functions by outlining the widespread 
consequences of alterations at specific points along biosynthetic pathways. While fascinating, the 
complexity of CDG and the broad range of disease severity within a CDG type, renders CDG 
diagnosis challenging. This suggests that CDG is probably underdiagnosed. Accordingly, the 
application of unbiased sequencing approaches will certainly reveal further gene defects as cause 
of CDG, but also unravel glycosylation defects in mild disorders such as non-syndromic intellectual 
disability [78]. Looking back at the evolving CDG landscape of the last decades, it has become clear 
that the description of these diseases has greatly increased the awareness of the biomedical 
community for the significance of glycosylation in human development and physiology. 
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Figure legends 
Figure 1. Gycosylation reaction. Schematic representation of the key players required for 
glycosylation reactions occurring in the Golgi apparatus. The biosynthesis of nucleotide-activated 
sugars (NDP-sugar) takes place in the cytosol whereas glycosyltransferase enzymes are localized 
on the luminal side of the endomembranes of the secretory pathway. Transporter systems are 
required for the import of nucleotide-activated sugars into the Golgi apparatus and for 
maintaining optimal ionic conditions in the organelle, thereby regulating pH, Mn2+ import and P 
export. 
 
Figure 2. Biosynthesis of core structures for N-glycosylation, O-mannosylation, and O-
fucosylation. N-glycosylation begins at the ER membrane by the stepwise assembly of dolichol-
PP-GlcNAc2Man9Glc3, which is transferred to the selected Asn residues of nascent glycoproteins 
by the oligosaccharyltransferase complex (OST).  O-Mannosylated and O-fucosylated glycans are 
shaped by the sequential addition of different monosaccharides based on the acceptor specificity 
of glycosyltransferases. 
 
Figure 3. A, List of donor substrates utilized in human cells for glycosylation reactions. B, 
Biosynthesis pathways of UDP-Gal, UDP-Glc, dolichol-P-Glc (DolP-Glc), GDP-Man, and DolP-Man. 
The positions of known gene defects are marked with the corresponding gene symbols.   
 
Figure 4. COG organization with display of lobe contributions to organelle architecture and 
protein trafficking. Both lobes interact with COPI tether proteins (Golgin84, p115) and several 
SNARE proteins (STX5, STX6, Sly1, GS27, SNAP29). Lobe A and B mediate vesicular retrograde 
transport of cis (MGAT1, MAN2A1, ST3GAL5) and medial (B4GALT1, ST3GAL1, ST6GAL1) Golgi 
enzymes, respectively. 
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RESULTS 
IDENTIFICATION OF COLGLCT – 3 BASIC APPROACHES  
After the identification of the ColGalT in our lab [1], we applied a similar approach to identify the 
second collagen glycosylating enzyme, the ColGlcT. First we performed a conventional 
purification protocol to specifically enrich the ColGlcT activity from human fibroblast cells. As an 
alternative enzyme source we partially purified the ColGlcT from chicken embryo. The enriched 
ColGlcT active fraction was then subjected to mass spectrometry for protein identification. In a 
second approach, we targeted the collagen lysyl hydroxylase LH3 in order to copurify the 
associated ColGlcT. As third procedure we searched the glycosyltransferase containing CAZy 
database for possible candidate genes, which were then subcloned and expressed with a 
baculovirus/insect cell expression system and tested for ColGlcT activity. 
The presentation of the experimental results obtained in this part is structured in four sections: 
1a) Preliminary results obtained from a human enzymatic source 
1b) Enrichment for procollagen glucosyltransferase activity reveals the putative 
glycosyltransferases UGGT2 (Manuscript Cabalzar et al, 2015) 
2) Affinity purification with PLOD3 
3) Candidate search from database – expression and activity 
 
1a) Preliminary results obtained from a human enzymatic source 
Human ColGlcT binds to anion exchange DEAE-Sepharose at pH 9.0  
In order to pre-fractionate the total cell lysate from human fibroblasts prior to protein 
chromatography we applied an ER-microsomal isolation protocol. Similar to ColGalT we expect 
ColGlcT to be an ER resident protein [2]. ER-microsomes were purified by ultracentrifugation of 
cleared total cell lysates after sonication to open the membrane. The ColGlcT activity was 
measured in the supernatant indicating that the enzyme could be a soluble ER luminal protein. By 
use of ion exchange chromatography the proteins were separated based on their charge and buffer 
system applied. To identify the active fractions specific for ColGlcT activity we used the standard 
glycosyltransferase assay with [14C]-labeled Glc on heat denatured collagen. Human ColGlcT binds 
to the anion exchange DEAE-sepharose beads and elutes with increasing salt gradient between 
170 to 220 mM NaCl (Figure 1). Anion exchange at pH 9.0 was the only type of ion exchange 
chromatography which allowed elution of ColGlcT. No binding was observed when applying anion 
exchange at pH 7.0 and 8.0 as well as cation exchange at pH 6.0 and 6.5 (data not shown). 
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Figure 1| Elution of human ColGlcT from anion exchange DEAE-sepharose. Cell lysate from human 
fibroblasts was ultracentrifuged and run over anion exchange DEAE-sepharose. The proteins elute over a 
gradient from 20 to 500 mM NaCl (A). The collected fractions were analyzed for collagen 
glucosyltransferase activity upon transfer of [14C]Glc to collagen (B,C). The highest activity levels for 
collagen glucosylation were measured in the elution fraction A13 at 180 mM NaCl. 
 
Identification of human collagen modifying proteins by LC-MS/MS 
Almost all human collagen modifying enzymes could be detected with mass spectrometric 
analysis. GLT25D1, LH1-3, P3H, P4Ha, P4Hb and PDIA6 were all identified in the flowthrough 
fraction after anion exchange DEAE chromatography (Table 1). LH3, P4Hb and PDIA3, 4 and 6 
were identified in the eluted fraction with ColGlcT activity. The most prominent 
glycosyltransferase identified was UDP-glucose:glycoprotein glucosyltransferase 1 (UGGT1). 
Candidate glycosyltransferases were searched by looking for homology to known 
glycosyltransferases and for specific structural features like ER-retention signal and DXD hexose 
binding motifs. None of the putative uncharacterized or unknown proteins could be attributed as 
a glycosyltransferase. Since the complexity of the eluted sample was very high we aimed for 
further chromatographic purification experiments. Yet, due to low activity levels, we changed the 
enzyme source from the human fibroblast cell culture to chicken embryo homogenates. 
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1b) Enrichment for procollagen glucosyltransferase activity reveals the 
putative glycosyltransferase UGGT2 (presented in the manuscript 
Cabalzar et al, 2015) 
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ABSTRACT 
 
 Collagen carries a specific type of glycosylation extending on hydroxylysine residues 
usually by a disaccharide structure hydroxylysine-β1-O-galactose-α1-2-glucose. The core β1-O 
galactosyltransferases GLT25D1 and GLT25D2 transfer UDP-galactose on hydroxylated lysine 
residues. The gene encoding the collagen glucosyltransferase enzyme elongating the 
monosaccharide with α-D-glucose is not known yet. Albeit, the reportedly multifunctional lysyl 
hydroxylase 3 encoded by plod3 has been found to glucosylate collagen but to a small extent which 
might not be of sufficient biological relevance and its sole contribution to collagen glucosylation 
remains questionable. We repeatedly identified the second UDP-glucose:glycoprotein 
glucosyltransferase homologue UGGT2 in enriched fractions for collagen glucosyltransferase 
activity. Similar to the collagen glycan structure, UGGT2 is conserved from sponge to human but 
no function has been assigned for UGGT2 yet. 
INTRODUCTION 
 
 Collagen, the most abundant protein in our body, encompasses a superfamily of 
glycoproteins mainly found in the extracellular matrix [1]. Collagen is the major component of 
skin, bone, cartilage, connective tissues, and basement membranes providing these tissues with 
high consistency and integrity. The key molecular feature to enable its function is their triple 
helical form and its aggregation into supramolecular structures. The triple helix formation 
originates from the amino acid composition of their three α-chains building up the triple helix. 
The characteristic amino acid repeats Gly-Xaa-Yaa allow a tight helical chain formation with the 
small amino acid glycine in the center. The Xaa and Yaa positions often represent proline residues, 
building a polyproline II like helix in each α-chain. The three polyproline II like helices based on 
the Gly-Xaa-Yaa repeats, are a prerequisite for triple helix formation [2]. Prior to triple helix 
formation, collagen undergoes a series of post-translational modifications which significantly 
contribute to collagen’s function providing the connective tissue with strength and shape. Among 
the genomes of vertebrates (and higher invertebrates) are 28 distinct collagen types encoded by 
at least 45 genes and 23 genes coding for collagen modifying enzymes [1, 3]. 
The most abundant modification is 4-hydroxylation of proline with about 100 4-hydroxyproline 
residues (4-Hyp) per 1000 amino acids and about half of the proline residues being hydroxylated 
in fibrillar type collagens [4]. Unlike 4-hydroxylation, 3-hydroxylation of proline is less abundant 
with an occurrence of one to two residues per α-chain in collagen types I and II, between three to 
six residues in types V and XI and more than 10 residues in type IV [5]. The amount of 3-
hydroxyproline (3-Hyp) varies not only among different collagen types but also within a certain 
type, e.g. in type IV collagen the variation goes from one to 20 per 1000 amino acids suggesting 
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tissue-/cell type-specific differences in modifying enzymes. Mass spectrometric mapping of 3-Hyp 
in fibrillar type collagens suggests a fundamental role for 3-Hyp in ordered self-assembly of the 
supramolecular structure, since the 3-Hyp residues were mapped with the characteristic D-
periodicity of collagen fibers [6]. In contrast, the 4-Hyp content varies within narrow limit in the 
same collagen type underlining its critical function for thermal helix stability. Besides the 
predominant hydroxylation of proline also lysine is hydroxylated forming hydroxylysine residues 
which can be glycosylated with galactose or galactose-glucose. Galactose (Gal) is linked by the 
core β-galactosyltransferases GLT25D1 and GLT25D2 via an O-glycosidic bond to peptidyl 5-
hydroxylysine (Hyl) forming the monosaccharide structure Gal-Hyl [7]. The monosaccharide can 
be elongated with a glucose (Glc) residue to form the disaccharide structure Glc-Gal-Hyl. The 
amount and ratio of the disaccharide to the monosaccharide and the free hydroxylysine structure 
are very variable between different collagen types [8]. The detection of both structures, Gal-Hyl 
and Glc-Gal-Hyl, at a single lysine residue suggests that glycosylation at this site is dynamic [9, 10]. 
The mechanism defining the extent of glycosylation is not known. Most of the collagen types carry 
more glycans of the disaccharide form than the monosaccharide. In mammalian collagen the 
carbohydrate content of hexoses ranges from 0.4% in skin to about 4% in cartilage and 12% in 
basement membrane [4]. The tissue dependent difference goes in hand with the predominant type 
of collagen found in these tissues. Dermal fibrillar type collagen carry fewer glycosylated residues 
than network forming basement membrane type IV collagen which have a general high degree of 
post-translational modifications [1, 11]. 
Alterations of collagen glycosylation have often been reported in several bone and skeletal 
disorders thereby suggesting that collagen glycosylation might play a role in bone mineralization 
[12-14]. The glycan might regulate the distribution of bone mineral along the collagen fibril. 
However, the localization of the glycan to Hyl involved in crosslinking anticipates the functional 
involvement of the glycan in cross link formation. During cross link maturation the glycan might 
regulate the cross link species towards either divalent or trivalent cross links depending whether 
the involved glycan is in the mono- or disaccharide form [15]. Such a mechanism would also 
explain the variable extent of Hyl glycosylation. Other functions for collagen glycosylation might 
target the collagen remodeling process. The endocytic collagen receptor µPARAP/Endo180 
internalizes collagen for lysosomal degradation via its fibronectin II domain. Additionally, the 
receptor carries a lectin domain which has been shown to modulate the endocytic efficiency 
towards highly glycosylated type IV collagen [16]. However, the impact of the glycan is uncertain, 
since another endocytic receptor, the mannose receptor, does not share this property as the 
receptor internalizes glycosylated collagen independent of a functional lectin domain [16]. The 
potential for the glycan to serve as receptor is also described for interactions of cells with 
basement membranes. The high glycan content in type IV collagen could serve as interaction or 
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binding receptor in order to recruit cells to the basement membrane. Glycosylated Hyl residues 
thereby modulate cell adhesion through integrin binding [17]. In contrast, the glycan might have 
different functions in fibrillar type collagens than the basement membrane type IV collagen. In OI 
patients, highly glycosylated collagen fibrils show a slight increase in fibril diameter, however it 
is not clear whether the increased glycosylation or the absence of 3-Hyp due to defective 
enzymatic activity in these patients is responsible for the disturbance of the lateral fibril growth 
[18]. In summary, several function for collagen glycosylation including control of matrix 
mineralization, crosslinking, collagen remodeling, collagen-cell interaction, and fibrillogenesis 
have been reported. Despite all the reported findings explaining the function of collagen 
glycosylation, the specific biological function of glycosylated hydroxylysine in relation to the 
extent and type of glycosylation at their molecular loci, is still not clearly defined. 
The importance of the post-translational modifications can be exemplified by the disease scurvy, 
the old sailor’s illness, resulting from a vitamin C (ascorbate) deficiency. People lacking ascorbate 
show symptoms like easy bruising, fragile capillaries, poor wound healing, skin changes and bone 
pain. Ascorbate is an important cofactor for the proline and lysine hydroxylase enzymes. 
Hydroxylation of proline and lysine residues in procollagen α-chains is reduced upon ascorbate 
deficiency in the cells. The resulting defect in collagen biosynthesis leads to collagen 
malfunctioning and unstable collagen fibers as observed in scurvy [19]. Many defects in the genes 
for collagen and its modifying enzymes have been identified leading to Ehlers-Danlos syndrome 
(EDS), Osteogenesis imperfecta (OI), and Bruck Syndrome (BS) [3, 20-22]. Among the collagen 
modifying enzymes are defects in the lysyl hydroxylase (LH) genes PLOD1 and PLOD2, the 
procollagen N- and C-propeptidases ADAMTS2 and BMP-1 respectively, and all components of the 
prolyl 3-hydroxylase complex, namely the peptidyl-prolyl cis-trans isomerase B PPIB, the 
cartilage-associated protein CRTAP, and the catalytic Fe- dioxygenase subunit LEPRE1. LH-
deficiency results in impaired collagen crosslink formation and consequent susceptibility to 
mechanical disruption of tissue, congenital scoliosis, joint laxity and bone fragility as observed in 
EDS type VI and BS. Defective ADAMTS2 also lead to autosomal recessive EDS with severe skin 
fragility, cutis laxa and easy bruising classified in type VIIc. PPIB, CRTAP, and LEPRE1 ensure 
proper 3-hydroxylation and positional rotation of proline986 in collagen type I. Missing 3-Hyp 
leads to delayed helix formation, following over modification by LH and prolyl 4-hydroxylase 
resulting in higher mineral content of bone matrix as in OI type VII. Up to now, there is no case 
reported with a genetic defect in the human prolyl 4-hydroxylase complex leading to the absence 
of 4-hydroxyproline. Unhydroxylated collagen leads to impaired secretion and its missing deposit 
in the extracellular space lead to failure of functional connective tissues and basement membrane 
integrity. RNA-interference studies in C.elegans revealed that disruption of the genes encoding for 
the prolyl 4-hydroxylase complex resulted in embryonic lethality [23-25]. Despite many diseases 
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have been described for defects in collagen modifying enzymes none has been attributed to a 
glycosylation defect. 
Recently, GLT25D1 and GLT25D2, the genes encoding the collagen galactosyltransferase have been 
identified [7]. The specific collagen glucosyltransferase (ColGlcT, EC 2.4.1.66) has not been cloned 
but one of the LH isoenzymes, procollagen-lysine 2-oxoglutarate 5-dioxygenase 3 (PLOD3), has 
also been shown to possess small amounts of that enzymatic activity [26]. PLOD3 has been 
postulated to have triple enzymatic activity as in hydroxylation of lysine, galactosylation of 
hydroxylysine and glucosylation of galactosylhydroxylsine. PLOD3 is a lysine hydroxylase with a 
Fe- dioxygenase domain at the C-terminus. A possible galactosyltransferase activity residing in 
the N-terminus could never be confirmed unlike the glucosyltransferase activity, which has been 
described repeatedly [27, 28]. The contribution of PLOD3 to collagen glucosylation appears to be 
on a low level compared to ColGalT and it is questionable whether it is of sufficient biological 
relevance [29]. The collagen glycan is conserved from sponge [30] to human [31] and also in Gallus 
gallus [32] despite the lack of the PLOD3 isoform in Gallus gallus indicating the existence of 
another enzyme for collagen glucosylation. 
We purified the ColGlcT activity from chicken embryo, which lack the PLOD3 isoform, by 
application of a conventional purification protocol. The active fractions were analyzed by tandem 
mass spectrometry and analyzed for glycosyltransferases. UDP-glucose:glycoprotein 
glucosyltransferase 2 (UGGT2) was repeatedly identified upon application of different 
purification protocols.  
MATERIALS AND METHODS 
 
Materials 
Chicken eggs were purchased from Brüterei Stöckli AG, Ohmstal, Switzerland. 
Preparation of gallus ColGlcT protein extract 
Protocols for enrichment of collagen glucosyltransferase were adapted from Myllyla et al., Risteli 
et al. and Schegg et al., [7, 33, 34]. 10 day old chicken embryos were homogenized in 225 mM 
mannitol, 75 mM sucrose, 50 μM dithiothreitol (DTT), and 50 mM Tris-HCl, pH 7.4, at 4 °C and 
centrifuged at 15,000 × g for 40 min. Supernatants were filtered and proteins were precipitated 
with 20% (NH4)2SO4 at 4 °C (35% saturation). After centrifugation the pellets were dissolved in 
buffer C1 (200 mM NaCl, 50 μM DTT, 0.05% CHAPS and 50 mM Tris-HCl, pH 7.4, at 4 °C) and 
dialyzed overnight against two times 5 liters 200 mM NaCl and 50 mM Tris-HOAc, pH 7.4, at 4 °C. 
The dialyzed fractions were pooled together and centrifuged and the supernatant was used as 
load for subsequent chromatographic protocols. 
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Chromatographic steps 
ConA-sepharose affinity chromatography 
ConA-sepharose beads (GE Healthcare) were equilibrated in buffer C1 supplemented with 1mM 
CaCl2 and 1 mM MnCl2. The gallus protein extract obtained by (NH4)2SO4 precipitation was also 
supplemented with 1 mM CaCl2 and 1 mM MnCl2 and incubated with the prewashed beads at 4 °C, 
rotating for 4 h. The bead-protein complex was centrifuged at 1’000 g for 5 min and washed once 
with supplemented buffer C1. Glycoproteins were eluted with buffer C1 containing 0.5 M α-D-
methyl-mannopyranoside (Sigma-Aldrich). 
Anion exchange chromatography 
The protein fraction containing ColGlcT activity eluted from ConA-sepharose chromatography 
was equilibrated with buffer A1 (50 mM diethanolamine, 20 mM NaCl, pH 9.0). The equilibrated 
load was applied to prewashed DEAE-sepharose FF 1ml anion exchange column (GE Healthcare) 
connected to an Äkta FPLC system (GE Healthcare) at a flow rate of 1 ml/min. The loaded column 
was washed with buffer A1 until the UV-detection level reached baseline again. Proteins were 
eluted with increasing concentration of buffer A2 (50 mM diethanolamine and 500 mM NaCl, pH 
9.0) up to 100% over 40 ml length.  
UDP-hexanolamine affinity chromatography 
Fractions containing ColGlcT-activity eluted from DEAE- anion exchange column were pooled, 
diluted with equal volume of buffer U1 (0.15 M NaCl, 10 mM MnCl2, 50 µM DTT, 50 mM Tris-HCl, 
pH 7.4) and applied on a UDP-hexanolamine-agarose column. The 2 ml bead resin was custom 
packed in a Benchmark Column 6.6mm/100mm 1xF 1xA (Omnifit) column and connected to an 
Äkta FPLC system (GE Healthcare). The loaded sample was run at 0.2 ml/min. After washing, the 
column was eluted with 3 column volumes of buffer U1 containing 5 mM uridine 5′-diphosphate 
disodium salt hydrate (UDP) (Sigma-Aldrich) and thereafter with 3 column volumes buffer U1 
containing 10 mM UDP. During elution 1 ml fractions were collected. The collected fractions were 
treated with 12.5 units alkaline phosphatase calf intestinal (New England Biolabs) /100 µl eluted 
fraction for 1 h at 37 °C prior to be used in glycosyltransferase assays. 
Gelatin-sepharose affinity chromatography 
Fractions containing ColGlcT-activity eluted from ConA-sepharose were pooled and applied on a 
gelatin-sepharose column. The 5 ml gelatin-sepharose resin (GE Healthcare) was custom packed 
in a C 16/40 column (GE Healthcare) and connected to an Äkta FPLC system (GE Healthcare). Prior 
to loading, the column was prewashed with 5 column volumes of buffer G1 (0.2 M NaCl, 0.05% 
CHAPS and 50 mM Tris-HOAc, pH 7.4 at 4 °C). After loading, the column was washed with high salt 
buffer G2 (1 M NaCl, 0.05% CHAPS and 50 mM Tris-HOAc, pH 7.4 at 4 °C) and proteins were eluted 
with low pH buffer G3 (0.2 M NaCl, 0.05% CHAPS and 50 mM Tris-HOAc, pH 5.0 at 4 °C) at a flow 
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rate of 0.2 ml/min. 1 ml fractions were collected for 20 min. Collected fractions were immediately 
neutralized with 1 M Tris-HCl pH 8.0. 
In a second independent experiment, we additionally added the GT donor substrate UDP to the 
protocol by supplementing 5 mM UDP (Sigma-Aldrich) to the buffers G1, G2 and G3. 
Glycosyltransferase assays 
Collagen glycosyltransferase assays were generally performed as described in Schegg et al. [7] 
using [C14] labelled UDP-Glc (20 μCi/ml) (PerkinElmer Life Sciences) and heat denatured collagen 
type I (250 μg, 10 min at 60 °C) as acceptor. Equal volumes from eluted protein fractions or from 
total cell lysates of baculoviral-overexpressed proteins (see cloning and expression of ColGlcT 
candidates) were used as enzyme sources. Assays were incubated at 37° for 3 h and stopped with 
5% TCA/ 5% phosphotungstic acid at 4 °C overnight. Precipitated proteins were filtered with 
Glass Microfibre filters (VWR) and 10 ml IRGA-Safe Plus scintillation fluid (Perkin-Elmer Life 
Sciences) was added. Radioactivity was measured in a Tri-Carb 2900TR scintillation counter 
(Perkin-Elmer Life Sciences). Data are shown in counts per minute [cpm] or converted to specific 
activity [pmol/min/mg total protein] where total protein concentration was determined by Pierce 
BCA protein assay according to instructor’s manual (Thermo Scientific). 
UGGT glycosyltransferase assays were performed according to Trombetta and Parodi [35]. Similar 
to the above described assay, also [14C] labelled UDP-Glc (20 μCi/ml) (Perkin-Elmer Life Sciences) 
and heat denatured acceptor substrates were used. Thyroglobulin, RNaseB and bovine collagen 
type I (all from Sigma-Aldrich) were heat denatured at 80 °C for 10 min and 200 – 250 µg was 
used per assay. Additionally, the assays contained 300 nM deoxynojirimycin (Sigma-Aldrich), 
inhibiting α-glucosidase activity. The assays were incubated at 37 °C for 30 min and stopped with 
5% TCA/ 5% phosphotungstic acid at 4 °C overnight. Radioactivity was measured as described 
above. 
Tandem mass spectrometry and data analysis 
Collected ColGlcT active fractions were subjected to both protocols for generating tryptic 
peptides, trypsin in-gel and in-solution digestion protocol. For in-gel digestion, proteins were 
separated by SDS-PAGE (4 - 12% precast gel, Invitrogen) and the gel lane was divided into 6 
regions. The gel pieces from each region were cut in small cubes and destained with 50% 
methanol in 100 mM ammonium bicarbonate pH 8.0 for 3 h at room temperature. After washing 
with ammonium bicarbonate, disulfides were reduced with 5 mM tris(carboxyethyl)phosphine 
hydrochloride (TCEP-HCl, Pierce) in ammonium bicarbonate buffer at 37 °C for 30 min. For 
alkylation of the cysteine residues, 20 mM iodoacetamide (Sigma-Aldrich) freshly prepared and 
solubilized in ammonium bicarbonate was added and incubated for 45 min at room temperature 
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in the dark. After complete removal of iodoacetamide solution the gel pieces were washed once 
with water and once with ammonium bicarbonate before dehydration in 80% acetonitrile and 
20% water. When the gel pieces turned opaque-white, the solution was removed and residual 
solvent was evaporated in a vacuum concentrator for 5 min. The shrinked gel pieces were covered 
with 100 ng trypsin in 20 µl Tris buffer (50 mM, pH 8.0) for 10 to 15 min at room temperature. 
The reswelled gel pieces were fully covered with Tris buffer and digested overnight at 37 °C. For 
peptide gel extraction, the samples were acidified with trifluoroacetic acid and acetonitrile to a 
final concentration of 0.1% and 5%, respectively. The samples were sonicated for 5 min in a 
sonicator water bath. The peptide solution was transferred to new tubes and the gel pieces were 
incubated with 50% acetonitrile and 0.1% TFA for 20 min at room temperature. After sonication, 
the peptide solution was combined with the aqueous solution in the new tube and evaporated in 
a vacuum concentrator until a residual volume of 5 µl. The samples were stored at -20 °C or 
immediately processed with C18 ZipTip (Millipore) according to the manufacturer’s protocol.  
For in-solution digestion, eluted fractions were directly processed according to Shevchenko et al. 
[36] following the method from waters (RapiGest SF surfactant protocol). Briefly, after diluting 
the sample in 100 mM ammonium bicarbonate, 0.1% (w/v) RapiGest (Waters) and 5 mM 
dithiothreitol (Sigma-Aldrich), the sample was heated for 30 min at 60 °C, cooled, and alkylated in 
15 mM iodoacetamide for 30 min in the dark. Proteins were digested with trypsin overnight at 37 
°C and acidified with trifluoroacetic acid to a final concentration of 0.5% prior to desalting using 
a C18 ZipTip (Millipore).  
Tryptic digests were subjected to reverse phase LC-MS/MS analysis using a custom packed 
150 × 0.075 mm Magic C18- AQ, 3 μm, 200 Å, column (Bischoff GmbH, Leonberg, Germany) and an 
Orbitrap Velos mass spectrometer (Thermo Scientific). The following 80 min LC gradient was 
applied: 0 min: 2% buffer B, 50 min: 30% B, 58 min: 50% B, 60 min: 97% B, 70 min: 2% B. Solvent 
composition of buffer A was 0.2% formic acid and 1% acetonitrile and buffer B contained 0.2% 
formic acid and 99.8% acetonitrile. Mass spectra were acquired in the m/z range 300 – 1’700 in 
the Orbitrap mass analyzer at a resolution of 30’000. Spectra were recorded in the collision 
induced dissociation mode acquiring 10 MS/MS spectra per MS scan with a minimal signal 
threshold of 2’000 counts. Peptides were identified and assigned using Matrix Science Mascot 
version 2.4.1. 
As an alternative sample preparation method, the eluted protein fractions were alkylated and 
digested using the Filter aided sample preparation (FASP) protocol from Wisniewski et al. [37]. 
This method is particularly suitable for studying entire proteomes and fractions containing 
biological membranes.  
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Cloning and protein expression 
The UniprotKB sequences for the ColGlcT candidate genes UGGT1 and UGGT2 were purchased 
from GenScript, New Jersey, NY. The obtained cDNA’s were subcloned into pFastBac1 or 
pFastBac1-Flag (N-terminal Flag-tag) baculovirus transfer vector (Invitrogen). The cDNA of 
UGGT2 was amplified by PCR with the following primers introducing BamHI and XhoI restriction 
sites, respectively, sense 5’-TATGGATCCATGGCGCCAGCGAAAGCCACG-3’ and antisense 5’-
TATCTCGAGTACACCAGTGCTAGAGTTCATCATG-3’. The PCR product was subcloned into 
pFastBac1 with BamHI/XhoI digestion (all restriction enzymes from New England Biolabs). 
The proteins were expressed using the baculovirus expression system (Invitrogen). Briefly, the 
subcloned pFastBac vectors were transformed into DH10Bac competent E.coli for recombinant 
bacmid DNA production. The recombinant bacmid DNA was transfected with cellfectin into Sf9 
cells to generate baculovirus. Baculovirus infected Sf9 cells were harvested after 3 days and lysed 
in TBS containing 0.5% Triton X-100 (Sigma-Aldrich). The lysates were used for expression 
verification by Western Blot and ColGlcT activity determination upon baculoviral passage 3. 
Western blotting 
Total cell lysates from baculoviral infected Sf9 cells were subjected to SDS-PAGE followed by 
transfer to nitrocellulose membrane (Highbound ECL, GE Healthcare) in semi-dry manner and 
Western Blot analysis using anti Flag antibody (Sigma-Aldrich). After transfer the membrane was 
blocked in 3% BSA (Sigma-Aldrich) for 1 h at room temperature. Primary antibody was diluted 
1:5’000 in PBS containing 0.5% Tween20 (Sigma-Aldrich) (PBS-T) containing 1% BSA and either 
incubated at room temperature for 1 h or at 4 °C o/n. The membrane was then washed 3x 10 min 
in PBS-T followed by incubation with secondary antibody, goat anti rabbit HRP (Sigma-Aldrich), 
diluted 1:10’000 in PBS-T/ 1% BSA at room temperature for 1 h. The blot was again washed 3x 
10 min with PBS-T. Subsequently it was developed with SuperSignal chemiluminescent substrate 
(Thermo Scientific). 
Flag-Tag protein purification 
Total cell lysates from baculoviral infected Sf9 cells were incubated with equilibrated ANTI-FLAG 
M2 affinity gel (Sigma-Aldrich) rotating for 1 h. The purification was performed according to the 
manufacturer’s protocol for the ANTI-FLAG M2 affinity gel. The gel bound FLAG fusion proteins 
were centrifuged at 1’000 g for 5 min and washed two times with TBS. The protein-bead complex 
was either directly analyzed by SDS-PAGE and Western blot or the FLAG proteins were eluted 
with 3X Flag peptide. 
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Methylation linkage analysis of glucose-galactose-hydroxylysine purified from sponge 
Glucose-galactose-hydroxylysine was purified according to Tenni et al. [38] and an aliquot was N-
acetylated in 70 l of 0.5 M methanolic HCl:pyridine:acetic anhydride (5:1:1, v:v:v) for 30 min at 
room temperature. The sample was dried by rotary evaporation and re-evaporated three times 
from 50 l methanol. Partially methylated alditol acetates were prepared from the N-acetylated 
sample and subjected to GC-MS analysis as described before [39]. 
RESULTS AND DISCUSSION 
 
Isolation of gallus glycoproteins with ConA and anion exchange chromatography 
Following the approach for the identification of ColGalT [7, 33], ColGlcT was purified in a similar 
way from chicken embryo. With the application of a two-step chromatographic protocol, we could 
specifically enrich the ColGlcT activity by 105-fold (Figure 1). After the initial protein fractionation 
with ammonium-sulfate, the active fraction was run over ConA-sepharose to isolate glycoproteins 
and followed by anion exchange chromatography. By screening the eluted fractions for collagen 
glucosyltransferse activity, the ColGlcT enzyme could be identified to be a glycoprotein and elute 
at 180 mM NaCl from the anion exchange column at pH 9. The fractions were further separated 
by SDS-PAGE and divided into gel regions according to molecular weight (Figure 2A). Earlier 
attempts to purify the ColGlcT suggested a molecular weight of 70 – 80 kDa [40]. In this region we 
found many ER-chaperones from the heat shock 70-kDa, heat shock cognate 71-kDa and heat 
shock 90-kDa families (Table 1). By looking at the whole proteome, we found 700 to 900 proteins 
per fraction and of these 437 proteins were identified in all 3 active fractions (Figure 2B). We 
identified LH1 and 2 and several glycosyltransferases, among them, UGGT1, UGGT2, glycogen 
[starch] synthase, glycogen debranching enzyme, beta 1-4 galactosyltransferase 1 and glycogenin. 
Of these only UGGT1 and LH1 were found to be enriched (Table 2). In general, we still identified 
181 proteins that were enriched over the purification process (Figure 2B and Table 2). 
No enrichment of gallus ColGlcT with affinity based chromatography 
With the application of affinity chromatography, ColGlcT was aimed to specifically enrich upon 
acceptor or donor interaction. Considering the latter, UDP-hexanolamine serves as donor 
competitor to UDP-hexoses in the active binding pocket of glycosyltransferases. The UDP-
hexanolamine-coupled agarose resin captures UDP-hexose glycosyltransferases but protein 
identification with mass spectrometry did not reveal any glycosyltransferases in the eluted 
fractions which goes in hand with the lack of proteins visible by SDS-PAGE (Figure 3B). Most of 
the proteins run over UDP-hexanolamine agarose did not bind, hence were found in the 
flowthrough fraction. But ColGlcT activity was measured only from the load fraction but neither 
from the flowtrough fraction than from the eluates (Figure 3C), suggesting that the ColGlcT still 
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remained bound. We eluted proteins with an excess of UDP competing for the active binding 
pocket and therefore not destroying the enzymes activity. However, the ColGlcT activity could not 
be detected when eluting with 5 mM UDP or with 10 mM UDP. Due to the high amount of UDP in 
the eluted fraction, we added CIP, an alkaline phosphatase, to eliminate the inhibiting capability 
of UDP in the ColGlcT enzymatic assay. By adding CIP to the assay, about 50% of the initial activity 
could be restored (Figure 3D).  
Affinity chromatography using gelatin-sepharose as the acceptor resin also failed to isolate the 
ColGlcT. Unlike the collagen modifying proteins P4H, LEPRE1, CRTAP, and PPIB, the ColGlcT 
enzyme did not bind to gelatin-sepharose (Figure 3A) [41]. ColGlcT activity was measured in the 
flowthrough fraction independent whether UDP as donor substrate was present in the 
chromatography or not (Data not shown).  
De novo identification of UGGT, glycogenin and PLOD1 in ColGlcT active fractions 
Mass spectrometric analysis of fraction B5 (Figure 1) with highest ColGlcT activity resulted in a 
similar proteome list (Table 3) like for earlier attempts (Table 1). Additionally, most of the 
proteins have been identified independent of the alkylation and trypsinizing method applied 
(Table 3). The glycosyltransferases UGGT and glycogenin are two glucosyltransferases which have 
been repeatedly identified in ColGlcT enriched fractions (see Tables 1-3). Among 
glycosyltransferases that have been identified only few times are KDELC1, POGLUT, XXYLT1, β1-
4GalT and glycogen debranching enzyme (Gbe). Repeated identification of the UDP-
glucose:glycoprotein glucosyltransferase (UGGT) in active fractions after ColGlcT protein 
purification provoked to have a closer look at this enzyme. UGGT is a well characterized 
glucosyltransferase which plays a major role in the quality control of N-glycoprotein folding in the 
ER [42]. Nevertheless, the ability of UGGT to transfer α-linked glucose on the Man7-9GlcNAc2 N-
glycan structure of improperly folded proteins makes UGGT a promising candidate to glucosylate 
collagen as well. The enzyme recognizes hydrophobic patches on acceptor substrates [43, 44], 
which we also thought could apply for the ColGlcT. Since collagen is glycosylated in the ER before 
helix formation, the hydrophobic amino acids that would be hidden in the collagen helix center 
are exposed and could be recognized by the ColGlcT as it is true for UGGT binding hydrophobic 
patches. 
Conserved α1-2 linkage of D-glucose to O-β-D-galactopyranosylhydroxylysine from sponge 
to human  
Collagen is highly abundant and widespread in the whole animal kingdom and the glycan 
composition has always been identified as Glc-Gal-Hyl or Gal-Hyl from sponge to human 
supposing conservation of the glycan’s structural properties. With the identification of UGGT, an 
α1-3 glucosyltransferase [45], we questioned the conservation of the glucose linkage to be 
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conserved. In human, the glycosidic linkage has been indirectly determined as α1-2 linkage of D-
glucose to O-β-D-galactopyranosylhydroxylysine in renal glomular basement membrane collagen 
by detecting activity of α-glucosidases towards the disaccharide structure and supported by 
periodate and methylation studies [31]. To confirm conservation, we purified the Glc-Gal-Hyl from 
sponge and analyzed the linkage with GC-MS of the methylated hexose fragments. Analysis 
revealed the expected D-glucose a1-2 D-galactose linkage (Figure 4). Due to the conserved 
structure, the modifying enzymes would be expected to be so as well. Blast searches revealed 
homologues proteins for GLT25D2, UGGT1 and UGGT2, and PLOD3 in human, the nematode 
C.elegans and the sponge A.queenslandica. However, no PLOD3 was found in G.gallus, despite the 
existence of the Glc-Gal-Hyl glycan. 
Recombinant human UGGT1 glucosylate denatured thyroglobulin but not collagen 
Two homologues are known for UGGT, UGGT1 and UGGT2. And UGGT1 exists in two isoforms, 
UGGT1-iso1 and UGGT1-iso2. UGGT1-iso2 lacks 24 amino acids at the N-terminus which is the 
only difference among the two UGGT1 isoforms. The UGGT proteins are very large with a 
molecular size of 177 kDa and 1555 amino acid residues. We cloned both isoforms into the 
baculovirus/insect cell expression system and tested them for ColGlcT activity. Expression of both 
isoforms was verified with anti-Flag Western blot and could also be visualized by coomassie blue 
protein staining of SDS-PAGE (Figure 5A and B). Both isoforms exhibit activity towards the 
denatured form of thyroglobulin but not towards denatured collagen (Figure 5C). Thyroglobulin 
served as control acceptor protein for UGGT1 activity. UGGT1 glucosylates high mannose glycans 
of UREA- or heat denatured thyroglobulin but not native thyroglobulin. The activity of UGGT1-
lysates towards heat denatured thyroglobulin is 3 times higher than the activity in mock-lysates 
including endogenous insect UGGT. To increase specificity, we purified UGGT1 from lysates with 
the Anti-FLAG M2 affinity gel (Figure 5D), but could not measure activity either directly with 
UGGT1 bound to the beads (Figure 5E) or when UGGT1 was eluted with 3X Flag peptide (data not 
shown). Both isoforms were also expressed without the Flag-Tag (Figure 5B) and activity on 
denatured thyroglobulin could be measured but not on denatured collagen (data not shown). 
No activity of human UGGT2 on denatured thyroglobulin, RNaseB and collagen 
The second homologue UGGT2 shares 55% identity with UGGT1 at the protein level. The highest 
degree of identity resides in the C-terminal 20% of these proteins, which is denoted as the 
glycosyltransferase domain. However, only UGGT1 displays the expected functional activity [35, 
46]. The function of UGGT2 is unknown and the identification of two homologues for UGGT 
throughout the entire animal kingdom from sponge to human suggests for highly conserved 
functions which could be distinct from each other [47]. Indeed, unlike for UGGT1, denatured 
thyroglobulin is not considered to be a substrate for UGGT2 [46]. Expression of UGGT2 with the 
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baculoviral/insect cell expression system neither revealed specific activity for denatured collagen 
nor for denatured thyroglobulin, but we also lacked an expression control (data not shown). To 
address protein expression, we introduced a Flag-Tag at the N-terminus of the enzyme (Figure 
6A). We detected very little to no protein expression at all with anti-Flag Western blot and also 
with commassie blue staining no band could be visualized when compared to control expression 
of UGGT1 (Figure 7B). Despite the high similarity of UGGT1 and UGGT2, we could not express full-
length UGGT2. Elimination of 220 amino acids at the more variable N-terminus of UGGT2 resulted 
in strong expression of a 150 kDa UGGT2-short form (Figure 6C). The short form of UGGT2 was 
not active on denatured collagen and also not on denatured thyroglobulin (Figure 6D). However, 
the successful expression of UGGT2 after the N-terminal elimination pointed towards a problem 
at the N-terminus for the full-length UGGT2 expression. Thereof, we designed another construct 
and eliminated only the signal sequence (S-pep) encoded by the first 25 amino acids (Figure 6A). 
The resulting construct was named cUGGT2. Both, cUGGT1 and cUGGT2 could be expressed 
(Figure 7D) and only cUGGT1 exhibited activity towards denatured thyroglobulin and RNaseB 
(Figure 7A and 7B). But both enzymes did not glucosylate denatured collagen (Figure 7C). 
Furthermore, cUGGT2 is not active on different pNP-sugar acceptors (Figure 7D). 
Purified gallus ColGlcT specifically glucosylates collagen but not thyroglobulin 
The fact that UGGT1 and glycogenin were constantly found in active fractions of ColGlcT activity 
assays does not only make them potential candidates but rather questions the specificity of the 
collagen-glucosyltransferase assay. To establish clarity we tested the purified gallus ColGlcT on 
different acceptor proteins. We found that purified gallus ColGlcT specifically glucosylates heat 
denatured collagen type I in contrast to heat denatured thyroglobulin or water control (Figure 
1C). More than three times less counts were measured when no acceptor protein (water control) 
was added to the assay. The residual activity could be attributed to glycogenin self-glucosylation. 
To address the contribution of UGGT1 in the assay, we tested the activity of the purified gallus 
ColGlcT sample on heat denatured thyroglobulin and native thyroglobulin. For both conditions we 
only measured the residual activity as described before, indicating that the activity on collagen is 
specific for ColGlcT. This result goes in hand with the lack of baculoviral expressed UGGT1 to 
glucosylate collagen (Figures 5 and 7).  
CONCLUSIONS 
 
Repeated identification of UGGT2 in enriched fractions for ColGlcT activity made UGGT2 a 
promising candidate as the ColGlcT. Additionally, the existence of two homologues for UGGT 
throughout the entire animal kingdom from sponge to human indicates highly conserved 
functions which could be distinct from each other. Supporting evidence derives from siRNA 
studies in C.elegans showing that UGGT2 is essential for viability but not UGGT1 or 
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Calnexin/Calreticulin [47]. Swapping the carboxy-terminal glycosyltransferase domain from 
UGGT2 to UGGT1 retained UGGT1 activity but not vice versa. Every other domain exchange 
towards the N-terminus destroys UGGT1 function [48]. The interchangeable carboxy-terminal 
glycosyltransferase domain presumes functional glycolytic activity for UGGT2, however the 
residues defining the acceptor and donor substrate might be located more towards the N-terminal 
region. Hence, even though UDP-glucose most likely is the donor substrate, we neither identified 
any glucosyltransferase activity towards different proteinacious acceptor substrates nor towards 
different pNP-sugar substrates. In particular, denatured collagen type I is not a substrate for 
UGGT2. The published results from a recent study by Takeda et al. confirmed our results that 
UGGT2 is not active on pNP-sugar acceptors but they detected very little activity on a 
proteinacious synthetic IL-8 acceptor and a biosynthetic compound comprised of a BODIPY-dye 
which was conjugated to Man9GlcNAc2 via Gly linker [49]. After 6h incubation only 6% of the 
BODIPY-dye compounds were glucosylated by UGGT2 compared to 38% for UGGT1. 
The inability of UGGT2 to glucosylate denatured glycosylated thyroglobulin as well as denatured 
collagen type I implies that UGGT2 does not accomplish the same function than UGGT1 and UGGT2 
does not glucosylate collagen. Whether UGGT2 uses UDP-glucose as donor substrate equally needs 
to be investigated than what is the specific acceptor substrate. Highly speculative but interesting 
might be the involvement of UGGT2 as a protein quality control regulator of proteins different 
than N-glycosylated [50-52]. 
Among other candidates identified by mass spectrometry, KDELC1 has been cloned and negatively 
tested for ColGlcT activity (unpublished data), POGLUT1 has been undoubtedly characterized as 
the protein O-glucosyltransferase RUMI [53], and XXYLT is the elongating xylosyltransferase 
adding xylose (Xyl) to Xyl-Glc-EGF repeats on the Notch protein [54]. 
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FIGURES AND TABLES 
 
Figure 1| Enrichment of ColGlcT activity from chicken embryo. After (NH4)2SO4 precipitation, 
proteins were subjected to two-step chromatography, namely ConA-sepharose and anion 
exchange DEAE-sepharose. (A) ColGlcT activity was determined after every step by measuring the 
[14C]-labelled glucose incorporation to denatured collagen. (B) The specific ColGlcT activity was 
calculated based on the amount of donor substrate and protein concentration in the sample. (C) 
The eluted fraction B5 was tested for different acceptor substrates with the highest activity for 
denatured collagen (dcollagen). (D) The ColGlcT activity could be enriched by 105-fold after 
purification from chicken embryo homogenate. Ld = load, SN = Supernatant, Ft = flowthrough, W 
= wash, E = elution, nThyro = native thyroglobulin, dThyro = denatured thyroglobulin. Mean ± 
SEM, n=2. Representative of 4 independent experiments. 
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Figure 2| Protein identification of ColGlcT active fractions. SDS-PAGE of chromatographed 
fractions after ConA, gelatin, and anion exchange chromatography. # indicates region cut out of 
the gel and used for peptide sample preparation for LC-MS/MS. (B) LC-MS/MS protein 
identification for indicated region. 
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Figure 3| No elution of ColGlcT from gelatin-sepharose or UDP-hexanolamine-agarose. Total 
cell lysates from chicken embryo homogenates or human fibroblasts have been prefractionated 
with anion exchange chromatography prior to run over (A) gelatin-sepharose or (B) UDP-
hexanolamine-agarose affinity chromatography, respectively. After gelatin-sepharose 
chromatography the ColGlcT activity was measured in the flowthrough (Ft) fraction indicating no 
binding. No ColGlcT activity could be measured after UDP-hexanolamine chromatography after 
elution with up to 10mM UDP. (C) SDS-PAGE of the eluted fraction E did not show any eluted 
proteins. (D) The inhibiting effect of UDP in the ColGlcT assay could be reduced by 50% when 
adding calf intestine phosphatase (CIP) to the reaction (#3). Doubling the amount of CIP does not 
reduce inhibition anyfurther (#6). Ld = load, Ft = flowthrough, W = wash, E = elution. Mean ± SEM, 
n=2. 
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Figure 4| Methylation linkage analysis of purified glucose-galactose-hydroxylysine from 
sponge. Partially methylated alditol acetates were prepared from glucose-galactose-
hydroxylysine and subjected to GC-MS analysis. Panel A shows the total ion chromatogram of the 
peaks corresponding to the terminal glucose and the 2-substituted galactose.  Panel B shows the 
annotated electron impact ionization mass spectrum of 3,4,6-trimethyl-1,2,5-acetyl-galactitol 
derived from the 2-substituted galactose eluting at 33 min. 
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Figure 5| Glucosyltransferase activity of Flag-UGGT1 on heat denatured thyroglobulin but 
not on collagen. (A, B) Flag-tagged UGGT1 isoform 1 and 2 were expressed using the 
baculoviral/insect-cell expression system. (C) Activity of total cell lysates was determined when 
incubated with heat denatured thyroglobulin, native thyroglobulin or heat denatured collagen for 
15 min or 180 min, respectively. (D) Flag-purification of F-UGGT1 and stained with anti-Flag 
antibody in western blot. (E) No activity could be measured of Flag-purified F-UGGT1 on 
denatured thyroglobulin. Mock = empty vector control. Ft = flowthrough. Beads = Enzyme-bound 
bead fraction. Mean ± SEM, n=3. 
Results - Manuscript 
 
 -89-  
 
Figure 6| F-UGGT2 constructs. Panel (A) represents the different UGGT constructs expressed in 
the baculoviral expression system. The Flag-tagged full-length UGGT2 (F-UGGT2) including the N-
terminal signal sequence (S-Pep) was only expressed weakly even though the bacuviral infections 
were good (B). An N-terminal truncated version F-UGGT2-short could be expressed but has no 
glucosylation activity compared to UGGT1 (C-D). The forth construct (cUGGT2) is characterized 
by the removal of only the 25 amino acid S-Pep and is described in Figure 7. 
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Figure 7| No activity of UGGT2 towards thyroglobulin, RNaseB and collagen. Baculoviral 
expressed cUGGT2 (c = without signal peptide) is not active on (A) denatured thyroglobulin, (B) 
denatured RNaseB and (C) denatured collagen. Mean ± SEM, n=3 (D) Expression of UGGT1 and 
UGGT2 without signal peptide (cUGGT1 and cUGGT2) visualized by anti-Flag western blot. (E) No 
activity of cUGGT2 on 5 different pNP-sugars. Mean ± SEM, n=2 
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2) Affinity purification with PLOD3 
Until now the collagen lysyl hydroxylase 3 (LH3) encoded by PLOD3 is considered to glucosylate 
the galactosyl-hydroxylysine residues from collagen [1, 2]. Compared to the ColGalT enzyme 
GLT25D1, the conversion rates for PLOD3 activity are low and its sole contribution to ColGlcT 
activity remains questionable. Since we found that overexpression of PLOD3 appears to have 
some little activity for collagen glucosylation (Figure 6A) the question arises whether PLOD3 itself 
is sufficient for the collagen glucosylation or whether PLOD3 is part of an enzymatic complex 
together with the ColGlcT which then glucosylates collagen. Other collagen modifying enzymes 
also act in protein complexes like the P3H complex [3, 4], suggesting that overexpression of one 
of the complex members could increase activity levels of the complex. Considering ColGlcT being 
part of the PLOD3 forming complex, we co-immunoprecipitated differentially-tagged PLOD3 from 
PLOD3 overexpressed cell lysates to identify the potential interacting partners of PLOD3. We used 
two different tagging strategies. On the one hand, we fused a human Fc-tag at the C-terminus of 
PLOD3 which was then immunoprecipitated with Protein A (Figure 8A). On the other hand, we 
cloned the tandem affinity purification TAP-tag at the N-terminus of PLOD3, ensuing the TAP-
PLOD3 construct which includes a two-step affinity purification protocol using IgG and 
streptavidin affinity resins (Figure 9A). Both strategies were applied independently and we 
searched the PLOD3 purified fractions after mass spectrometric protein identification for 
glycosyltransferases. 
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Figure 8|ColGlcT affinity purification with Fc-tagged LH3. A) Schematic representation of the C-terminal 
human Fc-tagged LH3 protein encoded by PLOD3 and its interacting partners shown in colored rounds. B) 
SDS-PAGE and anti-human IgG Western blot of the Fc-purified LH3 C) ColGlcT activity was determined after 
every purification step for the Fc-tagged LH3 (PLOD3-Fc*) and the untagged LH3 protein (PLOD3). The top 
panel shows the anti-human IgG Western blot for the corresponding fractions. Ft: flow through fraction, W: 
wash fraction, Elu: eluted fraction. D) SDS-PAGE of the eluted fractions for the untagged (-) and tagged (+) 
LH3 upon intensified washing steps. 
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Figure 9| ColGlcT affinity purification with TAP-tagged LH3. A) Schematic representation of the N-
terminal TAP-tagged LH3 protein encoded by PLOD3 and its interacting partners shown in colored rounds. 
B) SDS-PAGE and Streptavidin-POD Western blot of the TAP-purified LH3. TAP-PLOD3 indicates the 108 
kDa full construct and the TEV cleaved construct is at 92 kDa. C) ColGlcT activity was determined after every 
purification step. (+) indicates TAP-tagged LH3 input and (-) indicates untagged LH3 input. The top panel 
shows the Streptavidin-POD Western blot for the corresponding fractions. Ft: flow through fraction, W: 
wash fraction, B: protein-bead complex. 
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LC-MS/MS protein identification of the PLOD3 affinity purified fractions 
UDP-glucose:glycoprotein glucosyltransferase 2 (UGGT2) is the only glycosyltransferase that 
could be identified from PLOD3 affinity purified fractions (Table 2). Interestingly, UGGT2 has been 
found after application of both independent tagging strategies. By determining the specific 
ColGlcT activity after each purification step we measured activity in the purified fractions 
containing PLOD3 and UGGT2 (Figure 2B, C and 3B, C). However, the identification of UGGT2 could 
not be verified in a second experiment and considering the vast amount of proteins in the PLOD3 
affinity purified fraction, the identification of UGGT2 most possibly does not come from specific 
interaction with PLOD3. No glycosyltransferases were detected repeatedly with either of the 
tagged constructs. We found three ER chaperone proteins which could be identified multiple 
times, the 78-kDa glucose regulated protein (GRP78), luminal binding protein 4 (BIP4) and heat 
shock 70 kDa cognate (HSC-70) (Table 2). We did not further investigate their interaction with 
PLOD3 since we couldn’t detect a single band on SDS-PAGE, like for PLOD3, indicating not a strong 
binding. Most probably the chaperones are not specifically purified upon PLOD3 interaction but 
rather contaminating the sample due to their high abundance. In order to distinguish whether the 
activity we measured results from purified PLOD3 itself and to identify strong interacting partners 
we next repeated the experiment with more intensive washing steps to reach higher purity.  
 
Table 2| LC-MS/MS protein identification of the PLOD3 affinity purified fractions 
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Purified PLOD3 glucosylates heat denatured collagen 
Purification of Fc-tagged PLOD3 to higher purity increases the specific ColGlcT activity. Higher 
purity was achieved by introducing more washing steps from Protein A coupled magnetic 
Dynabeads. On SDS-PAGE only the purified PLOD3 protein could be detected and mass 
spectrometric analysis of the same fraction revealed no glycosyltransferase being present in that 
fraction (Figure 8D). According to Western blot analysis we could enrich PLOD3 in the purified 
fraction but when looking at the raw counts, the enzymatic activity of PLOD3 did not increase 
(Figure 8C). The acidic elution with pH 5 might kill some of the enzymes activity even though the 
eluted fraction is neutralized immediately. The higher enzymatic activity in the lysate could also 
indicate for a second enzyme contributing for ColGlcT activity. 
 
3) Candidate search from database – expression and activity 
Uncharacterized glycosyltransferases from CAZy families 8, 61 and 90 do not glucosylate 
collagen 
We searched the Carbohydrate Active enZYmes database (CAZy) for possible ColGlcT candidate 
genes according to families related to predicted α-glucosyltransferases and selected genes with 
uncharacterized functions (Figure 10). The CAZy-database comprises glycosyltransferases, which 
are grouped into families based on structural relations and homology of the catalytic modules. 
The glycosyltransferase families GT8, GT24 and GT90 encompass enzymes with retaining α-
glucosyltransferases. The GT8 is a large family including the human glycogenin-1 and -2, LARGE 
1 and 2, GLT8D1-4 and XXylT1. Unlike glycogenin and LARGE which are very well described 
Figure 10| Small selection of glycosyltransferases retrieved from the CAZy database. The CAZy GT-
families were selected based on the appearance of human sequences within the retaining GT-families. 
Members of the selected families that are not adequately described or characterized were chosen to clone 
into the baculovirus/expression system. 
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glucosyltransferases, only little is known about the GLT8D proteins. GLT8D3 and D4 are α-1,3 
xylosyltransferases elongating core-glucosylation on Notch EGF-repeats [5]. We cloned GLT8D1 
and D2 into our baculovirus expression system and tested for ColGlcT activity. Both enzymes do 
not glucosylate denatured collagen (Figure 11). When the enzymes activity was assayed on p-
Nitrophenyl-β-galactopyranoside (pNP-βGal), as an alternative acceptor substrate, we measured 
activity for GLT8D2 (Figure 11B). But, upon repeating experiments, we could not verify GLT8D2 
activity towards pNP-βGal. With the broad existence of collagen and its conserved PTM including 
glycosylation, the glycosylating enzymes are thought to be conserved as well among the animal 
kingdom. By blasting the GLT8D family members, we could not find any homologues proteins in 
the nematode Caenorhabditis elegans or the sponge Amphimedon queenslandica proteome, 
indicating that GLT8D1 or GLT8D2 are not the ColGlcT (Figures 14 and 15). 
 
 
Figure 11| ColGlcT activity of GLT8D1 and GLT8D2 on denatured collagen or pNP-galactose. The 
human cDNA from GLT8D1 and GLT8D2 was cloned into the baculovirus/expression system and ColGlcT 
activity was addressed either with (A) denatured bovine type I collagen or (B) pNP-alpha-Gal or pNP-beta-
Gal as acceptor substrates. In panel (A) GLT25D1 was used as an expression control with [14C]-Gal as donor 
substrate (orange). Blue indicates [14C]-Glc as donor substrate and grey indicates the control without 
acceptor substrate. n = 2, Mean ± maximum deviation from mean. 
 
Broader analysis of the human list from the CAZy-database revealed 343 glycosyltransferases 
(GT), glycoside hydrolases (GH) and carbohydrate-binding modules (CBM) (Figure 12). To narrow 
down the list, all well described glycosyltransferases were removed from the list. Enzymes 
involved in the N-glycosylation pathway like the Alg family members and the 
oligosaccharyltransferase subunits (OST) were eliminated resulting in a list of 81 mainly 
uncharacterized or unknown glycosytransferases. We performed extensive blast searches against 
the complete proteomes of the nematode C. elegans and the sponge A. queenslandica which both 
contain collagen proteins and its modifying enzymes. All proteins for which we couldn’t identify a 
homologue were removed from the list reducing it to 34 candidate proteins. Among the candidates 
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is the uncharacterized glycosyltransferase AER61 from the GT61 family. The GT61 family contains 
1,2-xylosyltransferases which are similar to glucosyltransferases. The two human proteins 
belonging to this family were both non-characterized. We cloned AER61 into the baculovirus 
Figure 12| List of 34 sequences from the human CAZy-database which contains unknown or 
uncharacterized glycosyltransferases with homologues in the C.elegans or A.queenslandica genomes.  
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expression system and analyzed for collagen glucosyltransferase. No ColGlcT activity was 
measured for AER61 (Figure 13A). By now, AER61 has been described as the ER- O-GlcNAc 
transferase (EOGT) [6]. 
 
 
Figure 13| ColGlcT activity for AER61, KDELC1, KDELC2, and PLOD3. (A) PLOD3 shows some ColGlcT 
activity towards denatured type I collagen. (B) mRNA expression of GLT6D1, UGGT1, and UGGT2 in human 
fibroblast cells. 
 
Another family found on the 34-list is the GT90 family which comprises three enzymes that are 
potential glucosyltransferases. One of them is the core glucosyltransferase protein O-β-
glucosyltransferase Rumi or POGLUT. POGLUT has been described firstly in Drosophila and has 
now been shown to also have xylosyltransferase activity [7]. The other two enzymes have 55% 
identity in the amino acid sequence and are named KDEL (Lys-Asp-Glu-Leu) containing 1 and 2 
(KDELC1 and KDELC2). No function has been assigned to both enzymes. We identified KDELC1 in 
the ColGlcT active fraction purified from chicken embryo extracts. We cloned both the KDELC1 
and KDELC2 into the baculovirus expression system and tested for collagen glucosyltransferase 
activity. No glucosyltransferase activity could be measured towards collagen (Figure 13A). 
Additionally, for neither KDELC1 nor KDELC2 a homologues protein exists in C. elegans or A. 
queenslandica (Figure 15). Human KDELC1 shares the highest similarity in the A. queenslandica 
proteome with POGLUT by 33% homology.  
GLT6D1 is an unknown member of the possibly α-glycosyltransferase group GT6. Besides the 
enzyme’s unknown function, GLT6D1 has been found to possess glucosyltransferase activity in an 
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assay including the substrate gelatin (non-published report). Gelatin features the ColGlcT 
acceptor site Gal-Hyl contemplating a possible collagen glucosyltransferase activity. However, 
blasting GLT6D1 did not reveal conservation of the gene throughout the animal kingdom. No 
homologue was identified in either C. elegans or A. queenslandica proteomes. Beyond that, GLT6D1 
mRNA is not expressed in human fibroblasts producing collagen indicating GLT6D1 is not the 
ColGlcT (Figure 13B). 
We expanded the bioinformatics approach and performed extensive blast searches of all known 
and predicted glycosyltransferases from the proteomes of Homo sapiens, the nematode 
Caenorhabditis elegans, the sponge Amphimedon queenslandica, the fruitfly Drosophila 
melanogaster, the pea aphid Acyrthosiphon pisum, the monarch butterfly Danaus plexippus, the 
bdelloid rotifer Adineta vaga and the yeast Saccharomyces cerevisiae (Figure 15). The GTs were 
grouped according to the CAZy families. Only the GT-families containing one or more gene entries 
for H. sapiens were considered and GT-families that do not contain at least a single gene for each 
species analysed, were removed from the list. Except for A. vaga and S. cerevisiae, because both of 
them lack collagen but also have the processing enzymes of the N-glycosylation pathway. By 
comparing the resulting list with the list of the 34 unknown or uncharacterized human GTs, we 
could exclude the above described candidate GTs GLT8D1, GLT8D2 and KDELC1 since they are 
not conserved among the animal kingdom (Figure 15). On the other hand, we were looking more 
detailed at GTDC1, B3GALTL, and UGGT2. All of them were not well characterized and have 
homologues in A. queenslandica. For the Glycosyltransferase-like domain-containing protein 1 
(GTDC1) we could not find a homologues protein in C. elegans. The closest similarity has been 
identified to the α-mannosyltransferase ALG2 which is also a GT4 enzyme. The GT31 enzyme beta-
Figure 14| Homology of selected glycosyltransferases in the animal kingdom. Blast searches of human 
glycosyltransferases against the indicated proteomes reveal that GLT6D1, GLT8D2, and KDELC1 are not so 
widespread among the animal kingdom than the known collagen modifying enzymes PLOD3 and ColGalT. 
POGLUT1 is characterized and described but appears in this list since it shares 33% homology to the 
unknown KDELC1. Besides the prominent abundance of the UGGT enzymes, GTDC1 appears to be the most 
conserved glycosyltransferase but has no homologue in the nematode and platelminthes. 
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Figure 15| Proteome analysis of CAZy glycosyltransferase families from sponge to human. The 
analysis was performed by Bernard Henrissat from the CAZy glycogenomics team. 
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1,3-glucosyltransferase (B3GALTL) has been identified once in ColGlcT active fractions purified 
from chicken embryo homogenates and is found in A. queenslandica and C. elegans  where it is 
named ZC250.2. We did not identify B3GALTL repeatedly and termed the enzyme unlikely to be 
the ColGlcT since it has been reported that B3GALTL glucosylates O-linked fucosylglycans on 
thrombospondin type 1 repeat domains [8]. 
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SCREENINGS OF UNTYPED CONNECTIVE TISSUE DISORDER CASES FOR 
GLYCOSYLATION DEFECTS 
Fibroblast cells from patients with unknown connective tissue disorders were screened for 
collagen glycosylation deficiencies. The patients showed characteristic clinical features affecting 
the skin and bone as observed in osteogenesis imperfecta and brittle bone disease patients. The 
collagen cross-links lysyl-pyridinoline (LP) and hydroxylysyl-pyridinoline (HP) ratio LP/HP were 
reduced in some of these patients indicating over modified collagen. Additional analysis 
performed at the Kinderspital Zürich revealed normal levels for LH and P4H activities. The finding 
of over modified collagens despite normal LH and P4H activities concluded a rate limiting step for 
modifying enzymes. Defects in the glycosylating enzymes could inhibit normal collagen triple helix 
formation thereby prolonging the hydroxylation event. Conceivably, defective collagen 
glycosylation could also hamper collagen secretion and proper processing. To identify whether 
collagen glycosylation is affected we tested the enzymatic activity by measuring the collagen 
glycan elongation using [14C]-labeled Glc and Gal. Collagen glycosyltransferase assays were 
generally performed as described in Schegg et al. [9] using UDP-[14C]Glc and UDP-[14C]Gal (20 
μCi/ml) (Perkin-Elmer Life Sciences) as donor and heat denatured collagen type I (250 μg, 10 min 
at 60 °C) as acceptor. All patient fibroblast cell lysates that were analyzed exhibit collagen 
glycosyltransferase activity (Figure 15 and 16). Some causes of disease were later identified as 
genetic defects of the P3H complex proteins CRTAP and P3H1. 
 
 
Figure 15| Enzymatic activity of untyped EDS or OI cases. Fibroblast cell lysates from 5 untyped EDS or 
OI patients were tested for ColGalT activity (A) and ColGlcT activity (B). Denatured bovine collagen type I 
was used as acceptor substrate in panel A and was galactosylated with GLT25D1 prior to serve as an 
acceptor for panel B assays. “w/o Acc” means the assay was performed without acceptor substrate.  n = 3 . 
Errorbars indicate mean ± SEM. 
Results 
 
 -106-  
 
Figure 16| Enzymatic activity of an untyped connective tissue disorder case. Fibroblast cell lysates from 
an untyped connective tissue disorder patient was tested for ColGalT activity (A) and ColGlcT activity (B). 
In both assays denatured bovine collagen type I was used as acceptor substrate or when indicated without 
substrate (w/o Acc). n = 2. Errorbars indicate mean ± maximal deviation from mean. 
 
Patient fibroblast cells were kindly provided by Prof. Dr. Matthias Baumgartner from the 
Kinderspital Zürich and by Dr. M. Rubio from the metabolic disease institute in Maastricht, 
Netherlands. 
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ABSTRACT 
Collagen is the most abundant protein in the human body and thereby a structural protein of 
considerable biotechnological interest. The complex maturation process of collagen, including 
essential post-translational modifications such as prolyl and lysyl hydroxylation, has precluded 
large-scale production of recombinant collagen featuring the biophysical properties of 
endogenous collagen. The characterization of new prolyl and lysyl hydroxylase genes encoded by 
the giant virus mimivirus reveals a method for production of hydroxylated collagen. The 
coexpression of a human collagen type III construct together with mimivirus prolyl- and lysyl 
hydroxylases in Escherichia coli yielded up to 90 mg of hydroxylated collagen per liter culture. The 
respective levels of prolyl and lysyl hydroxylation reaching 25% and 26% were similar to the 
hydroxylation levels of native human collagen type III. The distribution of hydroxyproline and 
hydroxylysine along recombinant collagen was also similar to that of native collagen as 
determined by mass spectrometric analysis of tryptic peptides. The triple helix signature of 
recombinant hydroxylated collagen was confirmed by circular dichroism, which also showed that 
hydroxylation increased the thermal stability of the recombinant collagen construct. Recombinant 
hydroxylated collagen produced in Escherichia coli supported the growth of human umbilical 
endothelial cells, underlining the biocompatibility of the recombinant protein as extracellular 
matrix. The high yield of recombinant protein expression and the extensive level of prolyl and 
lysyl hydroxylation achieved indicate that recombinant hydroxylated collagen can be produced at 
large scale for biomaterials engineering in the context of biomedical applications.   
 
Keywords: Protein engineering, post translational modification, hydroxylysine, hydroxyproline, 
virus  
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INTRODUCTION 
The structural and functional versatility of collagen in vertebrates makes it a coveted protein for 
tissue and biomaterials engineering. Yet, the considerable size of collagen polypeptides and the 
requirement for post-translational modifications have impeded the large-scale production of 
recombinant collagen featuring the biophysical properties of natural collagen. All types of collagen 
feature a triple helical conformation composed of repeats of the G-x-y motif, in which proline and 
lysine often occur at the x and y positions. During translation in the endoplasmic reticulum, 
selected proline and lysine residues are hydroxylated by dedicated hydroxylases, thereby yielding 
hydroxyproline (Hyp) and hydroxylysine (Hyl) (Myllyharju and Kivirikko 2004). The formation of 
Hyp is essential to stabilize the collagen triple helix and confer its thermal stability at body 
temperature (Shoulders and Raines 2009). Lysyl hydroxylation is involved in the formation of 
covalent intra- and inter-molecular crosslinks, contributing to condensation and fibril formation 
(Takaluoma et al. 2007). Hyl also serves as acceptor for the attachment of collagen-specific glycans 
(Schegg et al. 2009). Defects of lysyl hydroxylation lead to diseases such as Ehlers-Danlos type-VI 
(Hyland et al. 1992), Bruck syndrome (van der Slot et al. 2003), and skeletal dysplasia (Salo et al. 
2008), demonstrating the biological importance of this post-translational modification. 
The multimeric organization and limited stability of animal prolyl 4-hydroxylases and lysyl 
hydroxylases make them poor choices for the efficient production of recombinant collagen in 
conventional protein expression systems such as bacteria and yeasts, which lack endogenous 
prolyl and lysyl hydroxylases. Human collagen prolyl 4-hydroxylase has been expressed in 
Escherichia coli (Neubauer et al. 2005; Pinkas et al. 2011), although with limited activity towards 
short collagenous substrates. The coexpression of human prolyl 4-hydroxylase subunits and 
collagen constructs in the yeast Pichia pastoris has enabled the production of prolyl hydroxylated 
collagen up to 1.5 g per liter of culture (Nokelainen et al. 2001). Dual hydroxylation of proline and 
lysine has not yet been achieved in Pichia pastoris. Coexpression of human prolyl 4-hydroxylase 
subunits and the lysyl hydroxylase LH3 has been described in tobacco plants, in which 
recombinant human collagen type I was expressed at up to 200 mg per kg of fresh leaves (Stein et 
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al. 2009). The use of animal cells, such as Sf9 insect cells (Lamberg et al. 1996; Tomita et al. 1995) 
and HEK293 human cells (Fichard et al. 1997) that express prolyl and lysyl hydroxylase 
endogenously, yields recombinant collagen in the g to mg range per liter of culture, thereby 
precluding large-scale applications of the recovered collagen product. 
The description of several aquatic giant viruses belonging to Phycodnaviridae (Van Etten 2003) 
and Mimiviridae (Raoult et al. 2004) has shown that collagen-like genes are not restricted to 
metazoans and some prokaryotes. In addition to collagen genes, these viruses harbor genes 
encoding prolyl 4-hydroxylase (Eriksson et al. 1999) and lysyl hydroxylase enzymes (Luther et al. 
2011). These viral hydroxylases are soluble and active when expressed in E. coli, thus opening 
new possibilities for the production of recombinant hydroxylated collagen in bacterial expression 
systems. So far, human collagen type II has been produced at amounts exceeding 10 g per liter 
(Guo et al. 2010), although without post-translational modifications. To circumvent this 
limitation, we now exploit bacterially active prolyl and lysyl hydroxylase enzymes from the giant 
virus mimivirus (Luther et al. 2011) to produce recombinant hydroxylated collagen at high yield 
in E. coli.  
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MATERIALS AND METHODS 
Cloning of mimivirus hydroxylase expression vectors - The mimivirus lysyl hydroxylase L230 
(Luther et al. 2011) and prolyl 4-hydroxylase L593 open reading frames were amplified by PCR 
from mimivirus genomic DNA using primers including XhoI and BamHI sites. The primers were 
5’-TGACCTCGAGATTAGTAGAACTTATGTAATT-3’ and 5’-CAGGGATCCGTCCAATAAAGTGTAT-
CAAC-3’ for L230, 5’-TGACCTCGAGAAAACTGTGACTATCATTACAATA-3’ and 5’-CAGGGA-
TCCATTTTGTGTTAAAAAAATTTTAGG-3’ for L593. The resulting amplicons were ligated as XhoI-
BamHI fragments into the XhoI-BamHI linearized expression vector pET16b, yielding the pET16b-
L230 and pET16b-L593 vectors. Expression vectors lacking His-tags were prepared by first 
amplifying the L230 and L593 genes using the primers 5’GTCGACG-
AGCTCACCATGGGCATTAGTAGAAC-3’ and 5’-GTAATGACATATGCGCAAGCCCAG-3’ for L230, 5’-
ATACCATGGTATTGTCAAAATCTTGTGTGT-3’ and 5’-CAGGGATCCATTTTGTGTTAAAAA-
AATTTTAGG-3’ for L593. The corresponding amplicons were introduced into pET16b linearized 
with NcoI-NdeI for L230 and with NcoI-BamHI for L593, yielding pET16b-noH-L230 and pET16b-
noH-L593. The bicistronic vector pET16b-L593/L230 was prepared by inserting the expression 
cassette of the pET16b-L593 as a BglII-HindIII fragment into the BamHI-HindIII-linearized 
pET16b-L230 vector. The bicistronic vector pET16b-noH-L593/L230 featuring L230 and L593 
without His-tag was prepared in the same way. 
Cloning of collagen expression vectors - A fragment of human collagen type III COL3A1 cDNA 
encompassing 1206 bp and lacking propeptide-encoding regions was custom synthesized 
(GenScript, Piscataway, NJ, USA) using codons optimized for bacterial expression and including 
NcoI and BamHI sites at 5’- and 3’-ends (Fig. 1).  The pET28a expression vector was first digested 
with NcoI-BamHI, which eliminates the His-tag at the N-terminal site. The resulting hCOL3 
segment was inserted as a NcoI-BamHI fragment into pET28a, yielding pET28a-hCOL3-His. 
Protein expression in E. coli - The pET16b- and pET28a-based vectors were transformed into 
chemically competent E. coli BL21 (DE3) cells, which were plated on LB-agar plates containing 
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50 μg/ml kanamycin (Sigma-Aldrich) and 100 μg/ml ampicillin (Sigma–Aldrich) and incubated 
overnight at 37°C. Protein expression followed standard protocols (Tolia and Joshua-Tor 
2006). Briefly, bacteria were grown in liquid cultures at 37 °C under agitation at 220 rpm until 
reaching an OD600 value of 0.6. Isopropyl β-D-1-thiogalactopyranoside (Sigma-Aldrich) was 
added to 1 mM to induce expression and the cultures were incubated for a further 3 h at 34 
°C under agitation at 220 rpm.  
Protein purification - Cells were pelleted at 4,000 x g at 4 °C for 30 min, resuspended in 3 ml 
of 20 mM sodium phosphate, pH 7.4, 100 mM NaCl per gram of E. coli wet weight and lysed 
with 250 μg/ml lysozyme, 4 mg/ml deoxycholic acid under rotation at 4 °C for 20 min. DNAse 
I (Fluka, Buchs, Switzerland) was added to 20 μg/ml and incubation proceeded at room 
temperature for 30 min. Cell lysates were clarified by centrifugation at 12,000 x g for 30 min 
at 4 °C and filtered through 0.22 μm membrane filters (Milipore). Imidazole was added to a 
concentration of 20 mM and His-tagged proteins were purified by affinity chromatography on 
a 1 ml HisTrap FF Ni Sepharose 6 column (GE - Healthcare) using an Äkta FPLC system (GE - 
Healthcare). Elution of His-tagged proteins was performed with 500 mM imidazole, 20 mM 
sodium phosphate, pH 7.4, 100 mM NaCl. His-tagged proteins were detected after transfer to 
nitrocellulose (Highbound ECL, GE-Healthcare) using the anti-polyHis HIS-1 monoclonal anti-
body (Sigma-Aldrich).  
Prolyl and lysyl hydroxylase activity assays - Prolyl and lysyl hydroxylase activities were 
measured as described previously (Luther et al. 2011). Briefly, 5 g His-tag purified L230 lysyl 
hydroxylase or L593 prolyl hydroxylase were added to acceptor peptides at 0.5 mg/ml in 50 
mM Tris-HCl, pH 7.4, 100 μM FeSO4, 1 mM ascorbate, 100 μM DTT, 60 μM 2-oxoglutarate and 
100 nCi of 2-oxo[14C]glutarate (PerkinElmer Life Sciences) in a total volume of 100 μl and 
incubated at 37 °C for 45 min. Released [14C]O2 was captured in a filter paper soaked in NCS II 
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Tissue Solubilizer (GE Healthcare) suspended above the assay in a sealed 30 ml vial (VWR, 
Dietikon, Switzerland). Assays were stopped by addition of 100 μl ice-cold 1 M KH2PO4 and the 
filter papers were transferred to scintillation vials filled with 10 ml of IRGA-Safe Plus 
scintillation fluid (PerkinElmer Life Sciences). Radioactivity was measured in a Tri-Carb 2900TR 
scintillation counter (PerkinElmer Life Sciences). 
Amino acid analysis - Purified collagens (10 μg) were hydrolyzed in 500 μl of 6 M HCl for 12 h at 
105 °C.  Hydrolysates were dried down under nitrogen, then washed twice with 500 μl of H2O and 
dried down again. Samples were resuspended in 100 μl of H2O and derivatized using 9-
fluorenylmethoxycarbonyl chloride (FMOC) following the procedure of Bank et al. (Bank et al. 
1996). Derivatized amino acid samples were analyzed by reverse phase HPLC as described in 
Schegg et al. (Schegg et al. 2009). 
Mass spectrometry - Purified collagens (2 μg) were alkylated with iodoacetamide and digested 
with trypsin (Shevchenko et al. 2006). Briefly, after diluting the sample in 100 mM ammonium 
bicarbonate, 0.1 % (w/v) RapiGest (Waters, Saint-Quentin, France) and 5 mM dithiothreitol, the 
sample was heated for 30 min at 60 °C, cooled, and alkylated in 15 mM iodoacetamide for 30 min 
in the dark. Proteins were digested with trypsin overnight at 37 °C and acidified with 
trifluoroacetic acid to a final concentration of 0.5 % prior to desalting using a C18 ZipTip 
(Millipore). Tryptic digests were subjected to reverse phase LC-MS/MS analysis using a custom 
packed 150 mm x 0.075 mm Magic C18- AQ, 3 μm, 200 Å, column (Bischoff GmbH, Leonberg, 
Germany) and an Orbitrap Velos mass spectrometer (Thermo-scientific).  Peptides were 
separated with an 80 min gradient of 3% to 97% of a buffer containing 99.8 % acetonitrile and 0.2 
% formic acid. Spectra were recorded in the higher energy collisional dissociation mode acquiring 
10 MS/MS spectra per MS scan with a minimal signal threshold of 2000 counts.  Peptides were 
identified and assigned using Matrix Science Mascot version 2.4.1 and verified with the Scaffold 
version 4 software (Proteome Software, Inc.) using the X! Tandem search engine. Variable 
modifications included 16 Da on methionine, proline and lysine. 
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Circular Dichroism - Proteins were purified by gel filtration using a Superdex 200 10/300 GL 
Column (GE – Healthcare). Protein fractions were concentrated in a 10 kDa Spin-XR UF 500 
centrifugal concentrator (Corning) in PBS, pH 7.4, and kept at 4 °C at a concentration of 0.1 mg/ml 
prior to analysis. Human collagen type III was purchased from Sigma-Aldrich. Measurements were 
performed with a wavelength between 200 and 250 nm in a spectropolarimeter (J-810, Jasco) 
with a thermostated quartz cell of 1 mm length. Thermal stability was analyzed at 221.5 nm under 
heating at a rate of 0.5 °C/min from 4 °C to 70 °C. 
Trypsin digestion of collagen -  Recombinant hCOL3 (15 g) in PBS pH 7.4 was digested with 15 ng 
trypsin (Roche) for 2 h at temperatures ranging from 10°C to 35°C. Digestions were stopped by 
addition of 2X Laemmli sample buffer and proteins were separated in 10% SDS-PAGE under 
reducing conditions.  
Endothelial cell culture - Human umbilical vein endothelial cells (HUVEC) were cultured on 0.1% 
gelatin (Sigma-Aldrich), 0.1% recombinant hydroxylated hCOL3, 0.1% recombinant hCOL3 or 
0.25% poly-D-lysine in ECM endothelial cell medium (ScienCell, Carlsbad, CA) at 37 °C in 5 % CO2. 
For immunofluorescence, cells were seeded on glass cover slips at 1000 cells / cm2, 13.3 μg coating 
matrix / cm2 and cultured for 60 h. After washing twice with PBS, pH7.4, cells were fixed with 2 
% paraformaldehyde for 10 min at room temperature, washed twice with 20 mM glycine in PBS 
and permeabilized with 1 mg/ml saponin. Cells were incubated with mouse anti--tubulin 
SAP.4G5 monoclonal antibody (Sigma-Aldrich) diluted 1:200 and labeled with rabbit anti-mouse 
IgG Alexa-488 (Life Technology) diluted 1:500 for 30 min. Nuclei were stained with DAPI 
(Biotium, Hayward, CA). Viability was assayed by methylthiazolyldiphenyl tetrazolium reduction 
using standard protocols (Mosmann 1983). 
Sequence data - The L230 and L593 nucleotide sequences reported in this paper have the GenBank 
accession number NC_014649.1. The L230 and L593 protein sequences have the 
UniProtKB/Swiss-Prot accession numbers Q5UQC3 and Q5UP57, respectively. The nucleotide 
sequence of the human hCOL3 construct has the EMBL/EBI accession number HG779440.  
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RESULTS 
The genome of the giant virus mimivirus contains seven collagen-like genes and open reading 
frames annotated as putative lysyl and prolyl hydroxylases (Raoult et al. 2004). We have 
previously demonstrated that the open reading frame L230 encodes a bifunctional collagen lysyl 
hydroxylase and glucosyltransferase enzyme (Luther et al. 2011). To confirm the activity of the 
putative proyl-4-hydroxylase encoded by the open reading frame L593, we expressed a His-
tagged version of the protein in E. coli. The 669 bp open reading frame L593 yielded a 26 kDa 
protein, which could be enriched on Ni2+ beads (Fig. 2A). The prolyl hydroxylase activity of the 
purified L593 protein was assayed using acceptor peptides featuring proline in sequences derived 
from human collagen type I, type II, adiponectin and mannose-binding lectin. The L593 protein 
was active as prolyl hydroxylase on the artificial peptide sequence (GPP)7 and on the peptides 
GDRGETGPAGPPGAPGAPGAP and GLRGLQGPPGKLGPPGNPGPS derived respectively from 
collagen type I and mannose binding lectin, each featuring the GPP motif (Fig. 2B). By contrast, 
prolyl hydroxylase activity was minimal on the peptides GPMGPSGPAGARGIQGPQGPR and 
GIPGHPGHNGAPGRDGRDGTP derived respectively from collagen type II and adiponectin, which 
lack the GPP motif (Fig. 2B).  The L593 prolyl 4-hydroxylase was also active on the non-
collagenous peptide (SPAP)5 derived from proline-rich mimivirus proteins, thus indicating that 
L593 was not strictly specific towards G-x-y repeats (Fig. 2B). 
To assess the ability of mimivirus L230 lysyl hydroxylase and L593 prolyl 4-hydroxylase to modify 
collagen fragments produced in E. coli, we coexpressed the two mimivirus hydroxylases together 
with a 38 kDa fragment of human COL3A1 collagen type III. To this end, the mimivirus L230 and 
L593 open reading frames were expressed bicistronically under kanamycin selection and the 
human hCOL3 fragment on a separate plasmid under ampicillin selection. The hCOL3 protein 
included 119 G-x-y repeats flanked by the N- and C-telopeptide sequences but lacking the N- and 
C-propeptide sequences (Fig. 1). The co-transformation of E. coli with the hydroxylase-containing 
plasmid and the human hCOL3 construct yielded expression of the three His-tagged target 
proteins at the expected molecular masses of 101 kDa, 37 kDa, and 26 kDa corresponding to L230, 
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hCOL3, and L593, respectively (Fig. 3A). As a next step, the L230 and L593 hydroxylases were 
expressed without His-tags to enable the single enrichment of the hCOL3 protein from E. coli cell 
lysates. The expression of hCOL3 alone or together with L230 and L593 hydroxylases showed that 
the collagen fragment reached similar expression levels. After purification by Ni2+ affinity chroma-
tography, 90 mg of collagen protein per liter of bacterial culture were routinely obtained. Of note, 
the coexpression with L230 and L593 hydroxylases produced a smear above the expected hCOL3 
band, suggestive of a larger protein size or a decreased migration in polyacrylamide gels (Fig. 3B). 
This smear may also reflect heterogeneity at the level of prolyl- and lysyl hydroxylation of the 
recombinant protein. 
The level of prolyl- and lysyl hydroxylation of the hCOL3 protein achieved by co-expression with 
L230 and L593 hydroxylases was determined by amino acid analysis. Native human collagen type 
III and the recombinant His-tagged hCOL3 protein expressed with or without L230 and L593 
hydroxylases were hydrolyzed under acidic conditions, and derivatized with FMOC. The 
separation of FMOC-labeled amino acids by HPLC analysis showed that 54% of proline residues 
and 47% of lysine residues were hydroxylated in native human collagen type III (Fig. 4A). By 
comparison, the levels of prolyl and lysyl hydroxylation reached respectively 25% and 26% in the 
human hCOL3 protein coexpressed with the L593 and L230 hydroxylases (Fig. 4B). In the absence 
of L593 and L230 hydroxylases no prolyl and no lysyl hydroxylation were observed in the 
recombinant hCOL3 protein (Fig. 4C). The efficient hydroxylation of recombinant hCOL3 indicates 
that substrates and co-factors required by the L593 and L230 hydroxylases are present in 
sufficient amounts in E. coli cultured in standard LB medium. 
The distribution of Hyp and Hyl residues across the recombinant hCOL3 protein was investigated 
by mass spectrometry. The analysis of tryptic digested hCOL3 covered 92% of the sequence 
including 84 of 87 proline residues and all 12 lysine residues of the hCOL3 protein. The analysis 
of three different batches of recombinant hCOL3 protein revealed that between 66% and 83% of 
covered proline residues were hydroxylated (Table 1). For lysine residues, between 55% and 80% 
were detected as hydroxylated (Table 1). The assembly of tryptic peptides showed that 
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hydroxylation was evenly distributed across the hCOL3 protein (Fig. 5A). The mimivirus prolyl 4-
hydroxylase did not appear to prefer proline residues at either the x or y position of the G-x-y 
motif. Several G-P-P motifs even included Hyp residues at both x and y positions. The recombinant 
hCOL3 protein included 12 lysine residues, of which 6 to 8 were hydroxylated (Fig. 5A). As 
observed for Hyp, the positions of Hyl residues within the G-x-y motif indicated that the mimivirus 
lysyl hydroxylase enzyme efficiently hydroxylated residues at both x and y positions. We 
compared the pattern of proline and lysine hydroxylation between native human collagen type III 
and the recombinant hCOL3 protein expressed in E. coli. The analysis revealed a similar 
distribution of hydroxylated amino acids across both polypeptide sequences (Fig. 5B). Overall, 
more Hyp residues were identified in the recombinant hCOL3 protein than in native collagen type 
III, although differences were minimal across the sequence regions surveyed. These sequences 
included only three lysine residues, only one of which was found to be hydroxylated in native 
collagen type III. By contrast, these three lysine residues were hydroxylated in the recombinant 
hCOL3 protein (Fig. 5B). Hyl residues on recombinant hCOL3 were not further modified, for 
instance, by glycosylation. We recently showed that the L230 protein is a bifunctional enzyme 
including both lysyl hydroxylase and Hyl glucosyltransferase domains (Luther et al. 2011). 
Whereas L230 efficiently converted lysine to Hyl, the enzyme failed to glycosylate the resulting 
Hyl residues on recombinant collagen, suggesting that the substrate UDP-Glc was not accessible 
in amounts sufficient to enable the L230-mediated glycosylation of recombinant collagen in E. coli.  
The triple helical conformation and the thermal stability of the recombinant hCOL3 protein were 
investigated by circular dichroism. The ellipticity spectra obtained for non-hydroxylated and 
hydroxylated hCOL3 proteins showed the typical shape for triple helical collagen with a maximum 
peak around 221 nm and a negative peak below 200 nm (Fig. 6A). The changes in ellipticity at 
221.5 nm during heating were monitored for non-hydroxylated and hydroxylated hCOL3 proteins 
to assess the thermal stability of both constructs. The triple helical conformation of the non-
hydroxylated hCOL3 protein was unstable and showed an approximate 50% loss of ellipticity by 
19.5°C (Fig. 6B). Since non-hydroxylated hCOL3 did not yield constant ellipticity values at low 
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temperatures, 19.5°C however cannot be defined as true Tm value.  By contrast, the hydroxylated 
hCOL3 protein showed a 50% loss of ellipticity by 24.3°C, indicating that hydroxylation increased 
the thermal stability of the construct (Fig. 6B). We also compared the degree of triple helical 
conformation in non-hydroxylated and hydroxylated hCOL3 by digestion with trypsin, which 
cleaves denatured collagen but not triple helical collagen (Bruckner and Prockop 1981). 
Hydroxylated hCOL3 was resistant to trypsin up to 30°C whereas non-hydroxylated hCOL3 was 
mostly degraded by 30°C (Fig. 6C). Both forms of hCOL3 were completely degraded by 35°C, which 
confirmed their low thermal stability below 37°C. 
The biocompatibility of hydroxylated and non-hydroxylated recombinant hCOL3 produced in E. 
coli was assessed by using the protein as a matrix supporting the growth of HUVEC. These cells 
prefer to grow on extracellular matrix proteins such as fibronectin and collagen (Smeets et al. 
1992). The growth of HUVEC was compared between poly-D-lysine, bovine gelatin, recombinant 
non-hydroxylated hCOL3 and recombinant hydroxylated hCOL3 used as support. Cell morphology 
was examined by immunofluorescent staining of microtubules.  When cultured on recombinant 
hydroxylated and non hydroxylated hCOL3, cell viability after 60 h culture reached respectively 
64% and 49% of the viability observed when cells grew on 0.1% gelatin. As expected, viability was 
lowest when cells were cultured on poly-D-lysine (Fig. 7A). Cell morphology assessed by staining 
of microtubules showed that cells were evenly spread and tightly attached to the gelatin and 
hydroxylated hCOL3 matrices as indicated by the large number of processes (Fig. 7B). By contrast, 
the amount of rounded cells was elevated when non-hydroxylated hCOL3 was applied as matrix 
and few cells were visible when cultured on poly-D-lysine (Fig. 7B). The compatibility of 
hydroxylated hCOL3 as support for the growth of HUVEC demonstrated that the recombinant 
protein was suitable for biological applications such as matrix-assisted cell proliferation and 
adhesion. 
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DISCUSSION 
The production of recombinant collagen requires post-translational modifications which are 
lacking in bacterial and yeast expression systems. In the present study we show that the prolyl 
hydroxylase L593 and the lysyl hydroxylase L230 from the giant virus mimivirus can be expressed 
as active enzymes in E. coli without any toxicity for the host cells. The coexpression of these two 
mimivirus hydroxylases with human collagen constructs enabled the efficient hydroxylation of 
proline and lysine residues across collagen requiring neither supplementation of co-factors, nor 
increased oxygen partial pressure.  
To date, typical cost-effective and high-yield expression systems like yeasts and bacteria have not 
allowed the production of both prolyl and lysyl hydroxylated collagen because of the low activity 
of animal hydroxylases introduced in these hosts. The best results were obtained in the yeast 
Pichia pastoris expressing human prolyl 4-hydroxylase, which enabled 44% hydroxylation of 
proline residues on recombinant human collagen type III (Vuorela et al. 1997). However, efficient 
lysyl hydroxylation of collagen has not been achieved in Pichia pastoris so far. The degree of 
collagen hydroxylation is also a limiting factor for expression systems based on animal cells. 
Accordingly, the endogenous prolyl 4-hydroxylase and lysyl hydroxylase activities of insect cells 
did not yield efficient modification of recombinantly expressed collagen without co-transfection 
with human prolyl 4-hydroxylase subunits (Lamberg et al. 1996). 
The expression of prolyl and lysyl hydroxylase enzymes derived from the giant virus mimivirus 
yielded degrees of hydroxylation for recombinantly expressed collagen close to those of native 
collagen type III. The roles of the prolyl hydroxylase L593 and lysyl hydroxylase L230 in 
mimivirus biology are unknown but the presence of seven collagen genes in the mimivirus 
genome (Raoult et al. 2004) suggests that L593 and L230 are involved in the hydroxylation of 
mimivirus collagen. Indeed, we have previously shown that the mimivirus collagen-like protein 
L71 is hydroxylated and glycosylated in vitro by the L230 enzyme (17). Structurally related 
proteins are also found in related giant viruses, such as megavirus (Arslan et al. 2011) and mou-
mouvirus (Yoosuf et al. 2012), which also include collagen genes in their genome. Considering 
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their stability and activity when expressed in E. coli, proteins from giant viruses may represent a 
valuable source of enzymes for biotechnological applications, as shown here for the production of 
hydroxylated recombinant collagen.  
The distribution of Hyp and Hyl residues on recombinant hCOL3 showed that mimivirus 
hydroxylases were able to hydroxylate proline and lysine in various sequence contexts. The 
pattern of prolyl hydroxylation showed that proline at either position x or y of the motif G-x-y 
could be efficiently hydroxylated. Studies performed on synthetic peptides containing Hyp at 
positions x or y or both demonstrated that Hyp at position y strongly increases thermal stability 
(Jiravanichanun et al. 2006) whereas Hyp at position x destabilizes the triple helical conformation 
in Gly-Hyp-y repeats (Inouye et al. 1982). The presence of Hyp at both positions x and y by 
contrast, further stabilized the triple helical conformation of the peptides (Berisio et al. 2004). The 
detection of several Hyp residues at position x on various types of collagen makes it difficult to 
predict the positional impact of Hyp on the thermal stability of more complex polypeptides (Bann 
and Bachinger 2000; Buechter et al. 2003; Song and Mechref 2013). Although early work 
demonstrated that Hyp occurs exclusively at position y (Fietzek and Rauterberg 1975), recent 
studies showed that Hyp also occurs at position x in fibrillar collagens (Song and Mechref 2013; 
Weis et al. 2010).   
In animal cells the C-propeptide domain of collagen is important for the initiation of triple helix 
formation in the endoplasmic reticulum and contributes to the solubility of the molecules along 
the secretory pathway (Boudko et al. 2012). The addition of trimerization domains to short 
collagen constructs, such as the bacteriophage T4 foldon domain at the C-terminus of a [GPP]10 
sequence, was reported to dramatically increase the thermal stability of the collagen construct 
(Boudko et al. 2002). Although advantageous in accelerating triple helix formation, the addition 
of propeptides in recombinant collagen constructs expressed in E. coli or Pichia pastoris later 
requires their removal for formation of fibrillar structures. This procedure is usually performed 
by pepsin digestion, which leaves the triple helical domain intact but also removes the short 
telopeptides sequences required for the registration of collagen molecules in order to form fibrils 
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(Capaldi and Chapman 1982).  Therefore, we chose to produce an hCOL3 construct devoid of 
propeptides but including the telopeptides necessary for fibrillogenesis. The absence of 
propeptides did not affect the solubility of the recombinant hCOL3 protein and simplified down-
stream processing by avoiding protease digestion and removal from purified collagen.   
The simplicity of this mimivirus hydroxylase expression system enables the efficient post-
translational hydroxylation of proteins containing collagen domains. In addition to the family of 
true collagens, several collagenous proteins like adiponectin, mannose-binding lectin and the 
surfactant proteins A and D can now be produced as hydroxylated proteins in E. coli. The high 
yield of bacterial expression combined with a high degree of prolyl and lysyl hydroxylation 
provides the framework for the large-scale production of recombinant collagens for human 
applications, in which animal collagens represent significant risks for allergic reactions and 
zoonotic disease transmission. 
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FIGURE LEGENDS 
 
FIGURE 1. DNA and protein sequence of synthetic human hCOL3 construct. The top panel shows 
the codon optimized DNA sequence of the truncated human hCOL3 cDNA construct flanked by a 
5’ NcoI site and 3’ BamHI site (underlined). The ATG and TGA stop codon are bold and shaded. 
The sequence encoding the His-tag preceding the stop codon is dash-underlined. The bottom 
panel shows the amino acid sequence of the truncated human hCOL3 protein. The Gly-x-y collagen 
domain is shaded.  
 
FIGURE 2. Bacterial expression and characterization of mimivirus L593. A, SDS-PAGE of 
mimivirus L593 expressed in E. coli shown as cell lysate (L) and after Ni2+-affinity purification (P), 
either after staining with Coomassie blue R-250 or after Western blotting with anti-His6 antibody. 
B, Prolyl hydroxylase activity of purified mimivirus L593 assayed on the peptide acceptors 
[SPAP]5 (1), [GPP]7 (2), GDRGETGPAGPPGAPGAPGAP from human collagen type I (3), 
GPMGPSGPAGARGIQGPQGPR from human collagen type II (4), GLRGLQGPPGKLGPPGNPGPS from 
human mannose-binding lectin (5), GIPGHPGHNGAPGRDGRDGTP from human adiponectin (6). 
Open bars show prolyl hydroxylase activity measured without peptide acceptor and black bars 
with peptide acceptors. Stars above bars indicate statistically significant activity using two-tailed 
paired t-test (p<0.01).  
 
FIGURE 3. Coexpression of His-tagged mimivirus hydroxylases L593 and L230 with His-tagged 
human hCOL3 fragment. A, SDS-PAGE of mimivirus L593, mimivirus L230, and human hCOL3 
construct expressed in E. coli shown as cell lysate (L) and after Ni2+-affinity purification (P), either 
after staining with Coomassie blue R-250 or after Western blotting with anti-His6 antibody. B, 
SDS-PAGE of His-tagged human hCOL3 construct expressed alone (-) or with L593 and L230 
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hydroxylases (+), shown after staining with Coomassie blue R-250 or after Western blotting with 
anti-His6 antibody. 
 
FIGURE 4. Amino acid analysis of native and recombinant human hCOL3. Purified hCOL3 proteins 
were acid hydrolyzed and the resulting amino acids labeled with FMOC, and separated by HPLC. 
The positions of amino acids are indicated by the single letter code. The positions of 
hydroxyproline (Hyp) and hydroxylysine (Hyl) are marked by arrows. A, native human COL3A1; 
B, recombinant hCOL3 construct coexpressed with mimivirus L593 and L230 hydroxylases; C, 
recombinant hCOL3 construct expressed alone. 
 
FIGURE 5. Distribution of Hyp and Hyl on recombinant human hCOL3. A, The occurrence of 
hydroxylated residues was determined by mass spectrometric analysis of tryptic digests from 
recombinant human hCOL3 protein. Grayed sequences represent portions of the sequences not 
covered in the analysis. Proline (P) and lysine (K) residues identified as hydroxylated are shaded. 
B, Comparison of Hyp and Hyl distribution on stretches of native human COL3A1 (nat) and 
recombinant human hCOL3 (rec) produced in E. coli. Proline (P) and lysine (K) residues identified 
as hydroxylated are shaded. 
 
FIGURE 6. Circular dichroism of recombinant human hCOL3. A, Samples of purified hydroxylated 
(left panel) and non-hydroxylated recombinant hCOL3 protein (right panel) protein at 0.1 mg/ml 
were scanned between 200 and 250 nm in a spectropolarimeter. B, Thermal transitions of 
hydroxylated (left panel) and non-hydroxylated recombinant hCOL3 protein (right panel) in PBS, 
pH7.4 measured at 221.5 nm under a heating rate of 0.5 °C/min from 4 °C to 70 °C. The Tm values 
were determined at the midpoints of the sigmoid curves. C, Trypsin digestion of hydroxylated (left 
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panel) and non-hydroxylated recombinant hCOL3 protein (right panel); the arrowhead at the 
right shows the position of the hCOL3 protein.   
 
FIGURE 7. Growth of HUVEC on recombinant human hCOL3 matrix. A, The viability of HUVEC 
seeded at 1000 cells per cm2 was determined by reduction of methylthiazolyldiphenyl tetrazolium 
to formazan after 60 h incubation at 37 °C on the matrices: 0.1% gelatin, 0.1% hydroxylated 
recombinant human hCOL3 (hCOL3-OH), 0.1% non-hydroxylated recombinant human hCOL3 
(hCOL3), and 0.25% poly-D-lysine (PDL).  Cell viability is expressed relatively to the values 
obtained for the positive control, 0.1% gelatin. Data show the average and standard error of the 
mean of three experiments. B, Immunofluorescence microtubule (green) and DNA (blue) staining 
of HUVEC grown on 0.1% gelatin, 0.1% hydroxylated recombinant human hCOL3 (hCOL3-OH), 
0.1% non-hydroxylated recombinant human hCOL3 (hCOL3), and 0.25% poly-D-lysine (PDL).  
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Table 1. Hydroxylation efficiency of recombinant hCOL3 protein. Tryptic digests were analyzed 
for hydroxylation of proline (Pro) and lysine (Lys) by mass spectrometry. 
  
 AAa 
Coverage 
[%] 
Pro Hyp 
Hyp/Pro 
[%] 
Lys Hyl 
Hyl/Lys 
[%] 
hCOL3  401  87   12   
Batch 1 346 86 80 56 70 11 6 55 
Batch 2 343 86 80 53 66 11 6 55 
Batch 3 291 73 63 52 83 10 8 80 
Combinationb 368 92 84 59 70 12 9 75 
 
a covered amino acid length 
b combined assembly of tryptic peptides from batches 1 to 3 
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GENERAL DISCUSSION 
The association of heritable developmental disorders with defects in collagen modifying enzymes 
suggests that defects in glycosylating enzymes could be found in patients with connective tissue 
disorders. Should defects in genes for collagen glycosyltransferases prove to be the genetic cause 
of the patient’s disease, these enzymes would be molecular targets for the development of possible 
therapies. Even though EDS, OI, and Marfan syndrome are genetic conditions and no cure exists, 
an improved understanding of the molecular mechanism provides information for personalized 
medical treatments. Such treatments aim at increasing bone mass and strength to prevent 
progressive deformities and fractures. Apart from medical interest, the production of 
recombinant collagen for biotechnological applications in tissue engineering, tissue remodeling 
after transplantation, and wound healing is in high demand. In order to fabricate tissues with 
characteristics closely resembling physiological tissues requires complete characterization of the 
physiological processes resulting in such tissues in vivo. Together, these points illustrate why 
identification of the ColGlcT is of considerable importance and interest as these findings should 
benefit many other fields in biomedicine and biotechnology. 
Collagen glycans as diagnostic markers 
Many collagen fragments derived from biosynthesis or degradation are cleared from the ECM by 
blood or urine drain. The presence of these remnants in body fluids renders them a valuable 
molecular target for diagnostic purposes. N-terminal propeptides freed from collagen type I or 
type III, PINP or PIIINP, reflect collagen biosynthesis, which can be assessed by measuring PINP 
or PIIINP in the blood by different assays [1]. Serum PINP is mostly affected by changes in bone 
metabolism with higher PINP levels in children than adults. In adults, serum PINP is a useful 
indicator for Paget’s disease of bone [2], for early detection of metastasis to bone from breast, 
prostate, and lung cancer [3-5], and the degree and progression of osteoporosis [6]. Additional 
measures of bone formation are cross-linked N-telopeptidyl (NTx) and C-telopeptidyl (CTx) 
markers in urine and serum which are indicators of bone resorption and have slightly higher 
diagnostic sensitivity for bone metastasis than PINP. [7]. These cross-linked telopeptidyl markers 
can be liberated as peptide bound (NTx and CTx) or free forms. The free form exist as two different 
cross-linked structures, varying in the amount of Hyl forming the pyridinium cross-links. 
Pyridinolines (PYD or HP) are derived from three Hyl residues, whereas deoxypyridinolines (DPD 
or LP) originate from two Hyl and one Lys residue. Even though PYD and DPD are found in bone, 
cartilage, tendon, and dentin, urine PYD and DPD levels largely reflect the extent of bone 
resorption. In addition to providing information for diagnosing metabolic diseases, the PYD/DPD 
ratio is also used to address hydroxylation levels of collagen in hereditary diseases. In OI and EDS 
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under- or over- hydroxylation is reflected in the urine by the excretion of an abnormal PYD/DPD 
pattern, as observed in OI type IX and EDS type VIA. These markers are used mainly as a diagnostic 
tool to detect recessive OI types [8, 9]. 
Our screening of collagen glycosylation in cells from several untyped connective tissue disorder 
patients did not reveal defects in collagen glycosylating enzymes. Differences in the amount of 
glycosylation per α-chain are, however, associated with defective collagen biosynthesis as 
observed in OI and EDS patients [10]. Elevated glycosylation results from prolonged enzymatic 
activity during the slower assembly of defective collagen α-chains leading to more disaccharides 
but not to an increase in glycosylated sites [11]. Glycosylated PYD in urine has been associated 
with synovial tissue degradation in patients with joint diseases [12]. The distribution of 
glycosylated PYD among connective tissues is however, not clear and how glycosylated PYD 
changes during the course of a disease needs to be investigated. 
Evaluating the sole contribution of PLOD3 for ColGlcT activity 
Despite repeated identification of UGGT2 in ColGlcT active fractions, UGGT2 was not able to 
glucosylate Gal-based acceptor substrates such as denatured bovine type I collagen and pNP-Gal. 
In contrast, we could confirm the ability of human PLOD3 to glucosylate collagen type I and pNP-
Gal to a low extent. PLOD3 is ubiquitously expressed with high expression early in development 
when basement membrane synthesis is important for the growing organism [13, 14]. The high 
expression level of PLOD3 in basement membrane associated tissue goes in hand with the highly 
glucosylated collagen types predominantly found in basement membranes [15, 16]. One 
possibility could be that PLOD3 is mainly glucosylating mesh-like collagen types as found in 
basement membranes or in the cuticle of C.elegans. Thus, a second enzyme would exist that 
preferentially glucosylates fibrillar collagen types. Furthermore the association of PLOD3 with 
basement membrane type IV collagen [16, 17] might indicate that PLOD3 could be the specific 
glucosyltransferase for non-fibrillar type collagen glycosylation. Considering the fact that the 
main collagen types in C.elegans are non-fibrillar basement membrane and cuticle types, C.elegans 
PLOD3 and GLT25D might be sufficient for collagen hydroxylation and glycosylation in C.elegans. 
Support for the theory of fibrillar and non-fibrillar type specific modification is the finding that in 
fibrillar collagen types the Lys residues in the helical domain are hydroxylated by PLOD1 and at 
the more distal telopeptidyl regions by PLOD2, making the LH activity of PLOD3 redundant in 
fibrillar type collagens. 
The lack of PLOD3 in G. gallus is the strongest indicator for the existence of another enzyme with 
ColGlcT activity since the disaccharide structure is confirmed in G. gallus and the catalytic activity 
can be measured [18]. However, with the repeated identification of the gallus PLOD1 in ColGlcT 
active fractions, a possible contribution of PLOD1 to collagen glucosylation could be proposed. 
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Since G. gallus is the only animal that does not contain a PLOD3 or PLOD3-like protein, the 
question arises whether the avian PLOD3 isoform was evolutionarily lost or whether the chicken 
PLOD1 or PLOD2 retained a glycosyltransferase activity. Even though the gallus PLOD1 shares 
76% identity with the human PLOD1 and only 59% with the human PLOD3, some N-terminal 
amino acid positions appear to be conserved between the gallus PLOD1, the human PLOD3, and 
the nematode PLOD enzymes (Table 1). Adjacent to the DDD motif are two Lys residues which are 
only shared between PLOD3 and the gallus PLOD1 but not the human PLOD1 or PLOD2. In the 
same region, the Ser at position 204 is also conserved in PLOD3, gallus PLOD1, and the nematode 
PLOD. A single Cys residue at position 144 in human PLOD3 was shown to be essential for ColGlcT 
activity, however, might not be directly involved in the active site [19]. This Cys residue is not 
conserved in gallus PLOD1. Whether all these amino acids are crucial for ColGlcT activity is not 
known. Nevertheless, human PLOD1 and PLOD2 expressed in insect cells do not possess 
glycosylating activities [20]. With gallus PLOD1 being more closely related to mammalian PLOD1 
than PLOD3, a functional similarity shared only between gallus PLOD1 and human PLOD3 is highly 
doubtful. 
 
To this extent, the mimiviral enzyme L230 which contains an LH domain and a GT domain 
supports the existence of such multifunctional proteins and evokes the interesting question of 
how these enzymes evolved. Between the three domains of life mimivirus is most closely related 
to eukaryotes [21]. Whether PLOD3 is a remnant of a bifunctional ancestor gene which has been 
separated into the two distinct LH (PLOD) and GT (GLT25D) enzymes or has evolved differently 
from the viral enzyme is unknown.  
Glc-Gal-Hyl and ColGlcT as ligand and receptor in the ECM 
Since the pioneering works of the seventies, little progress has been made investigating the 
function of collagen glycosylation. Several studies in the recent past assigned the function of 
collagen glycosylation mainly to collagen’s own biosynthesis and regulation [22-24]. In my 
personal opinion, the potential for the glycan structure to serve as ligand for surrounding cells 
could be considered the most likely function for the collagen glycans. Glycosylation plays 
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important roles in cell-cell contacts, adhesion, migration, homing, virus binding, cancer biology 
and autoimmunity [25-27]. All these receptor-ligand functions arise from the fact that glycan 
structures decorate surfaces, inevitably causing them to be the first target recognized upon the 
initial contact of an interaction. Recently, Stawikowski and coworkers described a mechanism for 
how collagen might modulate integrin based adhesion of cells to the basement membrane. 
Glycosylated Hyl residues facilitate integrin-binding in a dose dependent manner [28]. The 
association of glycosylated Hyl residues with receptors recruiting cells to the basement 
membrane has been investigated as early as the late seventies. The identification of collagen 
modifying enzymes, in particular the ColGlcT, in platelets that lack collagen-like proteins in their 
membranes provoked the theory of ColGlcT mediated platelet-collagen interaction [29-31]. The 
platelet expressed membrane-bound ColGlcT has been thought to recognize Gal-Hyl structures on 
native triple helical collagen. Upon interaction, ColGlcT mediates platelet aggregation forming the 
collagen containing haemofibrotic plug. However, the ColGlcT mediated platelet interaction 
theory could not be confirmed but rather was dismissed since native triple helical collagen is not 
a substrate for ColGlcT [32, 33] and the ColGlcT activities have since been found to be located in 
the soluble platelet and plasma fractions [34-36]. Platelet activation and adhesion mediated by 
collagen is now thought to occur via GPVI receptor and integrin α2β1 [37]. Yet, the possible 
secretion of ColGlcT into blood plasma still remains puzzling. Differentially localized ColGlcT 
activities, namely ER-resident and secreted [36, 38] supports the possibility of more than one gene 
coding for ColGlcT activity. 
Prospective research targets for collagen glycosylation 
Since siRNA degradation of specific enzymatic activities are never 100%, the application of a new 
biochemical tool, the CRISPR/Cas-system to specifically disrupt a gene of interest might be 
effective in eliminating PLOD3 function in human fibroblasts. By eliminating PLOD3 function, a 
possible contribution of another enzyme to collagen glucosylation could be investigated. This 
could answer not only whether PLOD3 is sufficient for collagen glucosylation, but could address 
what impact the missing Glc has on proper collagen folding or secretion. The CRISPR/Cas-system 
could also be used to investigate the general contribution of collagen glycosylation towards 
collagen synthesis, folding, and secretion.  
Another biochemical approach to address the function of the collagen glycan could include 
production of recombinant hydroxylated collagen in glycosylated and un-glycosylated forms. The 
Mimivirus L230 enzyme has been found to add a Glc residue to the polypeptide Hyl producing a 
Glc-Hyl glycan structure rather than the animal Gal-Hyl or Glc-Gal-Hyl structures [39]. Since we 
have successfully introduced the mimiviral hydroxylases L593 and L230 into a bacterial 
expression system to produce hydroxylated collagen [40], the production of glycosylated collagen 
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would be the next step towards the production of physiological collagen. Site-directed 
mutagenesis studies in the GLT25D1 galactosyltransferase revealed two essential DXD motifs 
important for the catalytic function [41]. The region with these two motifs could serve as a guiding 
principle for site directed mutation of the glucosyltransferase domain of L230 to shift from a 
glucosyltransferase activity to a galactosyltransferase activity. As yet, the conversion of a 
glycosyltransferase’s donor specificity from a UDP-hexose to another UDP-hexose has not been 
reported, hence the exact sequence information determining the donor specificity is unknown and 
its description would be a pioneering work. Since the conversion of the donor specificity of a 
glycosyltransferase is an ambitious task to achieve, another possibility to produce glycosylated 
collagen in E.coli could be the coexpression of the C.elegans ColGalT with collagen and the 
mimiviral hydroxylases. The nematode enzyme is not glycosylated itself and is active in bacteria 
unlike the mammalian ColGalT (unpublished data). 
While the biochemical approaches to identify the ColGlcT did not provide clear answers, the 
bioinformatics approach revealed the candidate enzyme GTDC1 that should be considered a 
strong candidate for a collagen glucosyltransferase. GTDC1 is widespread among the animal 
kingdom, belongs to the retaining GT-families for α-glycosyltransferases, contains an ER-
retention signal sequence, and has no known function assigned to it. Additionally of interest, 
proteomic analysis of collagen mediated platelet aggregation revealed the existence of GTDC1 in 
platelets among other collagen modifying enzymes, including PLOD1 and PLOD3 [42]. 
Conclusively, GTDC1 should be considered to examine for collagen glucosyltransferase activity. 
 
References 
1. Koivula, M.K., L. Risteli, and J. Risteli, Measurement of aminoterminal propeptide of 
type I procollagen (PINP) in serum. Clin Biochem, 2012. 45(12): p. 920-7. 
2. Alvarez, L., et al., Components of biological variation of biochemical markers of bone 
turnover in Paget's bone disease. Bone, 2000. 26(6): p. 571-6. 
3. Haider, M.T., et al., Modifying the osteoblastic niche with zoledronic acid in vivo-
potential implications for breast cancer bone metastasis. Bone, 2014. 66: p. 240-50. 
4. Valencia, K., et al., miR-326 associates with biochemical markers of bone turnover in 
lung cancer bone metastasis. Bone, 2013. 52(1): p. 532-9. 
5. Koopmans, N., et al., Serum bone turnover markers (PINP and ICTP) for the early 
detection of bone metastases in patients with prostate cancer: a longitudinal 
approach. J Urol, 2007. 178(3 Pt 1): p. 849-53; discussion 853; quiz 1129. 
6. Ebeling, P.R., J.M. Peterson, and B.L. Riggs, Utility of type I procollagen propeptide 
assays for assessing abnormalities in metabolic bone diseases. J Bone Miner Res, 
1992. 7(11): p. 1243-50. 
7. Joerger, M. and J. Huober, Diagnostic and prognostic use of bone turnover markers. 
Recent Results Cancer Res, 2012. 192: p. 197-223. 
Discussion 
 
 -143-  
8. Kraenzlin, M.E., et al., Automated HPLC assay for urinary collagen cross-links: effect 
of age, menopause, and metabolic bone diseases. Clin Chem, 2008. 54(9): p. 1546-
53. 
9. Rohrbach, M. and C. Giunta, Recessive osteogenesis imperfecta: clinical, radiological, 
and molecular findings. Am J Med Genet C Semin Med Genet, 2012. 160C(3): p. 175-
89. 
10. Cabral, W.A., et al., Abnormal type I collagen post-translational modification and 
crosslinking in a cyclophilin B KO mouse model of recessive osteogenesis imperfecta. 
PLoS Genet, 2014. 10(6): p. e1004465. 
11. Taga, Y., et al., Site-specific quantitative analysis of overglycosylation of collagen in 
osteogenesis imperfecta using hydrazide chemistry and SILAC. J Proteome Res, 2013. 
12(5): p. 2225-32. 
12. Gineyts, E., P. Garnero, and P.D. Delmas, Urinary excretion of glucosyl-galactosyl 
pyridinoline: a specific biochemical marker of synovium degradation. Rheumatology 
(Oxford), 2001. 40(3): p. 315-23. 
13. Wang, C., M. Valtavaara, and R. Myllylä, Lack of collagen type specificity for lysyl 
hydroxylase isoforms. DNA Cell Biol, 2000. 19(2): p. 71-7. 
14. Salo, A.M., et al., The lysyl hydroxylase isoforms are widely expressed during mouse 
embryogenesis, but obtain tissue- and cell-specific patterns in the adult. Matrix Biol, 
2006. 25(8): p. 475-83. 
15. Myllylä, R., et al., Expanding the lysyl hydroxylase toolbox: new insights into the 
localization and activities of lysyl hydroxylase 3 (LH3). J Cell Physiol, 2007. 212(2): 
p. 323-9. 
16. Ruotsalainen, H., et al., Glycosylation catalyzed by lysyl hydroxylase 3 is essential for 
basement membranes. J Cell Sci, 2006. 119(Pt 4): p. 625-35. 
17. Rautavuoma, K., et al., Premature aggregation of type IV collagen and early lethality 
in lysyl hydroxylase 3 null mice. Proc Natl Acad Sci U S A, 2004. 101(39): p. 14120-
5. 
18. Myllyla, R., et al., Isolation of collagen glucosyltransferase as a homogeneous protein 
from chick embryos. Biochim Biophys Acta, 1977. 480(1): p. 113-21. 
19. Wang, C., et al., Identification of amino acids important for the catalytic activity of 
the collagen glucosyltransferase associated with the multifunctional lysyl 
hydroxylase 3 (LH3). J Biol Chem, 2002. 277(21): p. 18568-73. 
20. Heikkinen, J., et al., Lysyl hydroxylase 3 is a multifunctional protein possessing 
collagen glucosyltransferase activity. J Biol Chem, 2000. 275(46): p. 36158-63. 
21. Suzan-Monti, M., B. La Scola, and D. Raoult, Genomic and evolutionary aspects of 
Mimivirus. Virus Res, 2006. 117(1): p. 145-55. 
22. Terajima, M., et al., Glycosylation and cross-linking in bone type I collagen. J Biol 
Chem, 2014. 289(33): p. 22636-47. 
23. Parisuthiman, D., et al., Biglycan modulates osteoblast differentiation and matrix 
mineralization. J Bone Miner Res, 2005. 20(10): p. 1878-86. 
24. Pokidysheva, E., et al., Posttranslational modifications in type I collagen from 
different tissues extracted from wild type and prolyl 3-hydroxylase 1 null mice. J Biol 
Chem, 2013. 288(34): p. 24742-52. 
25. Ohtsubo, K. and J.D. Marth, Glycosylation in cellular mechanisms of health and 
disease. Cell, 2006. 126(5): p. 855-67. 
26. Moremen, K.W., M. Tiemeyer, and A.V. Nairn, Vertebrate protein glycosylation: 
diversity, synthesis and function. Nat Rev Mol Cell Biol, 2012. 13(7): p. 448-62. 
27. Maverakis, E., et al., Glycans in the immune system and The Altered Glycan Theory of 
Autoimmunity: a critical review. J Autoimmun, 2015. 57: p. 1-13. 
Discussion 
 
 -144-  
28. Stawikowski, M.J., et al., Glycosylation modulates melanoma cell alpha2beta1 and 
alpha3beta1 integrin interactions with type IV collagen. J Biol Chem, 2014. 289(31): 
p. 21591-604. 
29. Barber, A.J. and G.A. Jamieson, Platelet collagen adhesion characterization of 
collagen glucosyltransferase of plasma membranes of human blood platelets. 
Biochim Biophys Acta, 1971. 252(3): p. 533-45. 
30. Jamieson, G.A., C.L. Urban, and A.J. Barber, Enzymatic basis for platelet: collagen 
adhesion as the primary step in haemostasis. Nat New Biol, 1971. 234(44): p. 5-7. 
31. Katzman, R.L., A.H. Kang, and E.H. Beachey, Collagen-induced platelet aggregation: 
involement of an active glycopeptide fragment (alpha1-CB5). Science, 1973. 
181(4100): p. 670-2. 
32. Myllylä, R., L. Risteli, and K.I. Kivirikko, Glucosylation of galactosylhydroxylysyl 
residues in collagen in vitro by collagen glucosyltransferase. Inhibition by triple-
helical conformation of the substrate. Eur J Biochem, 1975. 58(2): p. 517-21. 
33. Anttinen, H., et al., Intracellular enzymes of collagen biosynthesis in human platelets. 
Blood, 1977. 50(1): p. 29-37. 
34. Menashi, S., R. Harwood, and M.E. Grant, Native collagen is not a substrate for the 
collagen glucosyltransferase of platelets. Nature, 1976. 264(5587): p. 670-2. 
35. Menashi, S. and M.E. Grant, Studies on the collagen glucosyltransferase activity 
present in platelets and plasma. Biochem J, 1979. 178(3): p. 777-84. 
36. Leunis, J.C., et al., The distribution of collagen:glucosyltransferase in human blood 
cells and plasma. Biochim Biophys Acta, 1980. 611(1): p. 79-86. 
37. Ruggeri, Z.M., Platelets in atherothrombosis. Nat Med, 2002. 8(11): p. 1227-34. 
38. Henkel, W. and E. Buddecke, Purification and properties of UDP-glucose 
galactosylhydroxylysine collagen glucosyltransferase (EC 2.4.1.?) from bovine 
arterial tissue. Hoppe Seylers Z Physiol Chem, 1975. 356(6): p. 921-8. 
39. Luther, K.B., et al., Mimivirus collagen is modified by bifunctional lysyl hydroxylase 
and glycosyltransferase enzyme. J Biol Chem, 2011. 286(51): p. 43701-9. 
40. Rutschmann, C., et al., Recombinant expression of hydroxylated human collagen in 
Escherichia coli. Appl Microbiol Biotechnol, 2014. 98(10): p. 4445-55. 
41. Perrin-Tricaud, C., C. Rutschmann, and T. Hennet, Identification of domains and 
amino acids essential to the collagen galactosyltransferase activity of GLT25D1. 
PLoS One, 2011. 6(12): p. e29390. 
42. Milioli, M., et al., Quantitative proteomics analysis of platelet-derived microparticles 
reveals distinct protein signatures when stimulated by different physiological 
agonists. J Proteomics, 2015. 121: p. 56-66. 
 
 
Acknowledgements 
 
 
 -145-  
ACKNOWLEDGEMENTS 
At the very beginning, I would like to thank all the people who contributed in various manners to the 
completion of my PhD thesis. I thank my supervisor Prof. Dr. Thierry Hennet for giving me the 
opportunity to accomplish my PhD studies in your research group. And in particular I am very thankful 
that you always had an open door, were constantly available to address scientific questions, and for 
your great deal of patience. 
I would like to express thanks to the members of the thesis committee PD Dr. Lubor Borsig, Prof. Dr. 
Arnold von Eckardstein, and Prof. Dr. Matthias Baumgartner for their time and effort to analyze and 
review the present research work and for helpful suggestions during the committee meetings. 
During my thesis I came sometimes to a point where I needed external assistance. I would like to thank 
Dr. Peter Gehrig and Dr. Simon Barkow from the Functional Genomic Center Zürich for your huge help 
to obtain and analyze masspectrometric data. 
Then, I would like to acknowledge all the excellent researchers I was working with in the lab: Christoph 
Rutschmann for teaching me a lot of labtechniques, for our awesome collaboration, and for all the 
mental support during the quick ristretto breaks. Anna Rommel for correcting my funny cowboy 
writing style, for your immense support at the finish line, and all your delicious cupcakes in the coffee 
breaks, omnom. Dr. Kelvin Luther, for having always an idea how to continue with my work and in the 
rare cases you did not, your sense of humor brought me back on track with a big smile, GoWingsGo. 
Dr. Andreas Hülsmeier for all the fruitful scientific discussions and for sharing your deep and profound 
biochemical knowledge with me, which also fed my fascination for masspectrometry technology. Dr. 
Nikunj Shah, the alltime bestest inder and ‘dear friend’ for being an awesome bench neighbor in the 
bestest cloning lab. Dr. Adrienne Weiss for the sweet side of life, no not glycans, cakes and happiness. 
Dr. Michael Welti, Yen-lin Eddie Huang, and Sacha Schneeberger for your Asian style I very much 
appreciated as in Jiu Jitsu lessons, Chinese lessons, and all kinds of peculiar foods you brought, mjamm. 
Giovanna Roth, for the early morning coffee chats and the awesome pasta dinners again and yet again 
at your place. Furthermore I would like to thank former and current lab members Dr. Andrea Fuhrer, 
Stephan Baumann, Marek Whitehead, Nina Hochhold, Luca Plan, and the Borsigs Dr. Irina Häuselmann, 
Marko Roblek, Jesus Glaus Garzón (for the many jesusito hugs ), Darya Protsyuk, and Esther 
Quinzano. 
Since I owe the accomplishment of this thesis not only to scientists, I wish to express my deep gratitude 
to my parents, Heidi and Andrin, my sister Dr. Katrin, my brother Urs, Stephi, my friends, and my 
girlfriend Anna for patient and tremendous mental support and encouragement in so many different 
ways. Thank you all!!! 
